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Harnessing the RNAi pathway with synthetic siRNA as a potent and selective mode of 
post-transcriptional gene silencing and has therapeutic potential in personalised medicine; 
however, the large size and negative charge of siRNA creates a hurdle for intracellular 
delivery that has thus far limited its development as a therapeutic. Cell penetrating peptides 
(CPPs), such as the Antennapedia homeodomain (AntpHD) and its third helix, Penetratin, 
are well characterised cationic motifs used previously to deliver covalently linked nucleic 
acid cargo, such as siRNA in vitro and in vivo, may offer a strategy to address this 
challenge. 
This thesis aimed to design, purify and characterize novel recombinant fusion proteins, that 
would have broad applicability as carrier molecules for non-covalent siRNA delivery. The 
fusion proteins were comprised of a cell penetrating peptide sequence (either AntpHD, 
Penetratin, HIV-Tat or EB1) fused to either the first dsRNA binding motif 1 (DRBM) or 
the tandem motifs (DRBMx2) from human PKR, which bind dsRNA with high avidity in a 
sequence independent manner.  A panel of constructs were cloned, expressed in a bacterial 
cell system, and purified by affinity chromatography under both native and denaturing 
conditions. Several of the constructs were either poorly expressed, insoluble or prone to 
precipitation during purification or dialysis; however, construct C5.1 was successfully 
purified and its identity confirmed by mass spectrometry.  Construct C5.1 bound  siRNA 
only at a high ratio of protein to siRNA due to the presence of co-purifying nucleic acid, 
whereas constructs C12.2 and C13.2 bound siRNA at low molar ratios. Both C12.2 and 
C5.1 were efficiently internalized in either live or fixed HEK293 and HepG2 cells; 
however, the proteins appeared to be sequestered in endosomes whether in the presence or 
absence of cargo. Cytotoxicity of the fusion proteins in HEK293 cells increased in the 
order of C12.2<C5.1<C13.2<C11.2 whereas in HepG2 cells, C11.2 was significantly more 
cytotoxic than C12.2; suggesting that the proteins exhibit cell type-specific cytotoxicity. 
Moreover, C11.2 and C12.2 altered HepG2 cell morphology in the presence of siRNA, 
compared to C5.1 and C13.2.  In a HEK293-dEGFP reporter cell line, a complex of C12.2 
and siRNA induced a significant decrease in dEGFP expression, which was not observed 
with C5.1-siRNA; however, unexpectedly similar effects were observed with C12.2-
scrambled siRNA suggesting non-specific siRNA effects. Effects on PTP1B expression 
were also examined with all purified proteins complexed with the optimum molar 
concentration of PTPN1 siRNA; none were able to exhibit PTP1B expression knockdown 
at the protein level.  
In this thesis, a comprehensive strategy for the design, purification and testing of novel 
siRNA carriers has been developed. A number of recombinant siRNA carriers have been 
successfully produced and characterised. The results highlight common issues encountered 
with the development CPP-based siRNA delivery vectors; nonetheless, the ability of C12.2 
to mediate RNAi-mediated knockdown demonstrates the potential of the development of 
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 The RNAi pathway 1.1
In 1970, following the discovery of the double stranded DNA helix, Francis Crick 
proposed a model describing how DNA governs protein synthesis through an RNA 
intermediate. This model went on to become the ‘Central Dogma of biology’(Crick, 1970), 
describing the linear flow of genetic information from the DNA level, to RNA and finally 
protein, in a hypothesis that is generally described as ‘one gene-one ribonucleic acid chain-
one protein’. Messenger RNA (mRNA) was subsequently discovered by Jacob and Monod 
(1961), as the intermediate following gene transcription; and Crick’s hypothesis that one 
gene encodes for one protein product was rejected when Leder and Nirenberg ‘cracked’ the 
genetic code in 1964 and assigned nucleotide triplets (‘codons’) to each of the 20 amino 
acids (Leder and Nirenberg, 1964). The RNAi pathway, was not elucidated until much 
later, following the work of plant biologists with, oddly enough, petunias. 
 In the early nineties, Napoli and Jorgensen were investigating how to increase the purple 
coloration in petunias by introducing chalcone synthase as a transgene, in an attempt to 
overexpress the protein in the rate-limiting step in flavonoid biosynthesis. The resulting 
petunias came out white (Napoli et al., 1990). This observation of gene co-suppression had 
never been reported before, although the mechanism was not elucidated until Fire et al. 
(1998) used double-stranded RNA (dsRNA) instead of single stranded RNA (ssRNA) in 
the nematode C. elegans to modify gene expression. 
In 2006, Craig Mello and Andrew Fire were subsequently awarded the Nobel Prize in 
Medicine for their seminal work with RNA interference (RNAi), which highlighted an 
endogenous, evolutionarily conserved mechanism, that involves sequence-specific post-
transcriptional gene silencing (PTGS) with dsRNA as a trigger, and not single-stranded 
21 
 
RNA (ssRNA) as had been previously reported by Guo and Kemphues (1995). According 
to their proposed model, double-stranded RNA (dsRNA) could interfere with gene 
expression by selectively binding to cognate mRNA and targeting it for degradation, 
thereby attenuating protein translation from the target mRNA.  
In plants and animals, RNAi via microRNA (miRNA) transcription play an important role 
in cellular processes such as gene regulation, proliferation, development, tumour formation 
and homeostasis (Ambros and Lee, 2004). RNAi is also an innate antiviral mechanism; 
viral dsRNAs are generally long and perfectly complementary, inducing RISC loading, 
cleavage into 21-25 bp fragments (siRNAs) and cleavage upon cellular infection, inhibiting 
viral replication (Umbach and Cullen, 2009). In nematodes and plants, the initial antiviral 
response is potentiated by RNA-dependent polymerases, increasing the overall number of 
siRNAs available for RISC loading (Aoki et al., 2007, Diaz-Pendon et al., 2007). In 
mammals, viral infection activates the interferon (IFN) response via recognition by pattern-
recognition receptors (PRRs). A systemic antiviral response is mounted via dissemination 
of the intercellular IFN response, which activates a positive feedback loop with the Janus 
kinase/Signal transducer and activator of transcription (JAK/STAT) pathway and the 
activation of RNAse-encoding genes and protein kinase R (PKR) (Cullen, 1986, Umbach 
and Cullen, 2009). In the context of drug discovery, the value of siRNA is based on the 
assertion that drug targets, such as overexpressed oncogenes in cancer, or indeed the 
aberrant expression of any gene, can be knocked-down before it is translated into a 
mutated, misfolded or overexpressed protein. It therefore shows great promise as a 
therapeutic approach to many diseases whose underlying causes are genetic aberrations. In 
addition to oncologic applications, an RNAi strategy has been investigated in infectious 
diseases, such as malaria, targeting plasmodium falciparum (Malhotra et al., 2002); HIV, 
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against the p24, Gag, and CCR5 proteins (Surabhi and Gaynor, 2002), amongst others, 
with promising results in vitro.  
RNAi in humans can be triggered by dsRNA sequences 21-25 nt in length, via two distinct 
pathways: the natural and the synthetic pathway. The latter occurs via the introduction of 
stabilized and often chemically modified short interfering (siRNA) molecules, whereas the 
canonical RNAi pathway is initiated by the ‘trimming’ of long primary-microRNA (pri-
miRNA) transcripts into a ~70 bp stem-loop or hairpin miRNA precursors (pre-miRNA) 
in the nucleus, by a protein complex comprised of the RNAseIII enzyme Drosha and Di-
George syndrome critical region 8 (DGCR8), which collectively make up the 
Microprocessor complex (Ha and Kim, 2014). Pre-mRNA is exported from the nucleus by 
exportin 5, a dsRNA binding protein, for further processing by Dicer in the cytoplasm.  
Once in the cytoplasm, pre-miRNA is cleaved into an miRNA duplex by Dicer, an 
RNaseIII endonuclease (Zhang et al., 2004) which works in partnership with HIV-TAR 
RNA-binding protein (TRBP), Drosha and the protein activator of protein kinase PKR 
(PACT) (Fig. 1.1). Dicer proceeds to remove any loop structures and cleave pre-miRNA 
into shorter, 19-22 bp dsRNA duplexes with 2 nucleotide (nt) 3’-hydroxyl overhangs.  
Similarly, Dicer processes endogenous, long dsRNA precursors into siRNA duplexes, 20-
25 bp in length. Endogenous siRNA precursors may arise from trans interactions between 
gene and pseudogene transcripts, or from hairpin transcripts (Czech and Hannon, 2011). In 
mammals, these precursors have so far been found only in embryonic stem (ES) cells and 
mouse oocytes (Babiarz and Blelloch, 2008, Babiarz et al., 2008, Tam et al., 2008, 
Watanabe et al., 2008). Exogenous siRNA, procured as synthetic 20-25 nt oligos are not 
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subject to Dicer’s RNAse III action and are this directly loaded onto the RNA-induced 
silencing complex (RISC).  
Once cleaved, small dsRNAs are sorted by Dicer based on the precursor molecule, the 
structure of miRNA and siRNA duplexes, terminal nucleotides, thermodynamic properties 
and the Argonaute (AGO) protein they are destined for.  
The Argonaute clade of mammals consists of eight members in the Ago (AGO1-AGO4), 
and Piwi (PIWIL) proteins (Ross and Kassir, 2014), although only AGO1-AGO4 have 
been shown to bind siRNA and miRNA indiscriminately (Burroughs et al., 2011, Czech 
and Hannon, 2011, Liu et al., 2004, Meister et al., 2004). These are expressed ubiquitously 
in humans, although in different, tissue-specific, proportions (Reviewed by Meister, 2013) 
Post-translational gene silencing is mediated by AGO2, the only member of the AGO clade 
that possesses mRNA cleavage activity in mammals. Studies have shown that the silencing 
action of siRNAs targeting the coding sequence of several endogenous genes is inhibited in 
the absence of AGO2 in mice livers (Ruda et al., 2014). Furthermore, studies by Gregory 
et al. (2005) and Maniataki and Mourelatos (2005) have shown that small dsRNA sorting 
by Dicer and AGO loading is a concerted effort, at least in animals, whereas Jinek and 
Doudna (2009) proposed that the structure of AGO proteins mediates dsRNA loading, 
unwinding and the formation of RNA induced silencing complex (RISC). AGO proteins 
are comprised of an amino-terminal (N), a PIWI-Argonaute-Zwille (PAZ), a middle (MID) 
and a PIWI domain. The N and PAZ domains collectively make up lobe 1, whereas the 
MID and PIWI domains make up lobe 2. Lobes1 and 2 are separated by a flexible hinge 
region that mediates the structural rearrangement of AGO proteins upon dsRNA binding. 
According to their model, the PAZ domain anchors the 3’ end of small dsRNA by bending 
it into a binding pocket, whereas the MID domain anchors the 5’end of dsRNA to a 
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conserved tyrosine residue by stacking interactions and hydrogen bonds. The N domain is 
required for loading and unwinding of the duplex during RISC assembly (Kwak and 
Tomari, 2012), whereas the PIWI domain in AGO proteins functions as an endonuclease to 
cleave target mRNA, following small dsRNA binding (Jinek and Doudna, 2009). 
Cleavage of the passenger strand and subsequent unwinding of the dsRNA duplex is 
governed by the ‘Asymmetry rule’ whereby Argonaute2 (AGO2) action is guided by the 
strength of base-pair binding on the 5’end of the duplex - its thermodynamic stability 
(Schwarz et al., 2003) - with the less stably paired 5’ end strand preferentially loaded onto 
AGO TRBP acts as an asymmetry sensor, and allows the guide strand to be loaded onto 
RISC following dicing (Noland et al., 2011). In order for the mature RISC to form, siRNA 
or miRNA transfer to AGO is mediated by heat shock protein 90 (HSP90). HSP90 allows 
AGO to remain in an open state to accommodate dsRNA by hydrolyzing Adenosine 
triphosphate (ATP) to Adenosine diphosphate (ADP) and phosphate (Pi) (Iki et al., 2010, 
Johnston et al., 2010). RISC is a multimeric protein complex, comprised of Dicer, TRBP 
and the ‘slicing’ enzyme AGO2 (Meister et al., 2004). Once RISC is assembled, the N-
domain of the Ago proteins unwind the complex, although reports by Meister et al. (2005) 
and Gu et al. (2011) support the action of RISC-associated helicases, such as RNA helicase 
A (RHA) when unwinding the dsRNA helix.  
In the endogenous miRNA pathway, the ‘seed’ sequence, comprised of nt 2-8 within a 
longer miRNA, is perfectly complementary to the cognate mRNA. Complementarity 
between at least 7 bp of siRNA-mRNA is required for efficient silencing, thus providing 
some specificity to this ubiquitous mechanism (Elbashir et al., 2001b). Where partial 
sequence complementarity occurs, i.e where the RNA duplex contains internal loops or 
bulges, translational repression occurs via RNAi. This occurs when miRNAs are loaded 
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onto RISC, rather than siRNAs; RISC in this case is guided to partially complementary 
sequences typically found in the 3’ untranslated region (3’ UTR) of target mRNA, leading 
to translational silencing or exonuclease degradation (Huntzinger and Izaurralde, 2011). In 
the case of siRNAs (either endogenously generated or exogenously introduced), where 
perfect Watson-Crick base pair complementarity exists, RISC is directed to induce the 
degradation of primary mRNA transcripts by AGO2-mediated cleavage (Kim et al., 2009b, 
Umbach and Cullen, 2009). Moreover, the greater the number of RISCs bound to a target 




 Mechanism of RNA interference in mammalian cells. RNA interference Figure 1.1
(RNAi) pathways are guided by small RNAs that include small interfering RNA (siRNA) 
and microRNAs (miRNAs). The siRNA pathway begins with cleavage of long double-
stranded RNA (dsRNA) by the Dicer enzyme complex into siRNA, which are then 
incorporated into Argonaute 2 (AGO2) and the RNAi-induced silencing complex (RISC). 
If the RNA duplex loaded onto RISC has perfect sequence complementarity, AGO2 
cleaves the passenger (sense) strand so that active RISC containing the guide (antisense) 
strand is produced. The siRNA guide strand recognizes target sites to direct mRNA 
cleavage. RNAi therapeutics typically involve the delivery of synthetic siRNA into the cell 
cytoplasm. The microRNA pathway begins with endogenously encoded primary 
microRNA transcripts (pri-miRNAs) that are transcribed by RNA polymerase II (Pol II) 
and are processed by the Drosha enzyme complex to yield precursor miRNAs (pre-
miRNAs). These precursors are then exported to the cytoplasm by exportin 5 and 
subsequently bind to the Dicer enzyme complex, which processes the pre-miRNA for 
loading onto the AGO2–RISC complex. When the RNA duplex loaded onto RISC has 
imperfect sequence complementarity, the passenger (sense) strand is unwound leaving a 
mature miRNA bound to active RISC. The mature miRNA recognizes target sites 
(typically in the 3′-UTR) in the mRNA, leading to direct translational inhibition. Binding 
of miRNA to target mRNA may also lead to mRNA target degradation in processing (P)-
bodies. Adapted from Kim and Rossi (2007). 
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 siRNA as a therapeutic drug: challenges and limitations 1.2
SiRNA’s high specificity for their target mRNA, potency and adaptability are favorable 
attributes. From the pharmaceutical industry’s perspective, they are easy to manufacture, 
relatively cost-effective, compared to small molecule inhibitors, with limited cytotoxicity, 
and can be designed in silico with various stabilizing modifications to complement a 
specific mRNA of interest (Vaishnaw et al., 2010), and avoid the elicitation of off-target 
effects. Since transfected synthetic siRNA sequences can be used to induce RISC (Elbashir 
et al., 2001a), the RNAi pathway can be potentially harnessed to downregulate the 
expression any disease-associated gene. Moreover, siRNA-mediated RNAi has become a 
routine tool for post-translational gene modification (Aagaard and Rossi, 2007, de 
Fougerolles et al., 2007), as sequences are amenable to chemical modifications and 
improved pharmacologic profiles. Their high specificity may also allow targeting of 
specific alleles that differ from wild-type ones only by a few mutations. They are also less 
likely to interfere with gene regulation by endogenous miRNAs, as they enter the RNAi 
pathway later and are not produced by cleavage of longer dsRNA precursors by RISC  
(Grimm et al., 2006, Rao et al., 2009). Such is the potential of siRNA that within three 
years since its use as a gene expression modulator in cultured human cells was confirmed 
(Elbashir et al., 2001a), antisense oligonucleotide-based therapeutics had entered clinical 
studies utilizing the endogenous RNA pathway as a therapeutic strategy. Many siRNA-
based formulations are still being tested at various clinical phases (Summarized in Table 
1.1). The only FDA-approved RNAi-based drugs as of 2014 are fomivirsen (marketed as 
Vitravene) for the treatment of cytomegalovirus retinitis (CMV) for HIV or 
immunocompromised patients via intraocular injection, and mipomersen (Kynamro) which 
targets mutated apolipoprotein B (apoB) in familial hypercholesterolemia. Both drugs were 
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developed by Isis Pharmaceuticals. It is interesting to observe that both FDA- approved 
drugs are composed of chemically stabilized single stranded antisense oligos; so far there 
have been no successful clinical trials with siRNA-based formulations. 
Indeed, the development of siRNA-based therapies has been met with many challenges. As 
a drug that exploits a natural pathway to mediate its action, there is always the risk of 
saturating the RNAi pathway and disturbing the intracellular equilibrium. In vivo studies 
by Grimm et al. (2006) and Yi et al. (2005) have reported elevated, dose-dependent 
lethality in mice tested with 49 different short hairpin RNAs (shRNAs), due to liver 
toxicity. Their results suggested that the rate-limiting step to efficient RNAi was nuclear 
export by exportin-5, as introduced shRNAs had blocked the canonical miRNA pathway. 
Seminal work byElbashir et al. (2001a), showed that transfection with oligonucleotide 
sequences shorter than 30 bp, did not induce any cytotoxicity.  However, the introduction 
of longer (≥30 bp) dsRNAs has been shown to activate the immune response by protein 
kinase R (PKR) - the first point of contact when viral dsRNA enters a mammalian cell. 
Similarly, transfection with GU-rich sequences such as the 5’-GUCCUUCAA-3’ ‘danger 
motif’ (Hornung et al., 2005), leads to the induction of the interferon response through 
activation of pattern recognition receptors (PRRs), such as Toll-like receptors 3 (TLR3) on 
the cell surface, and TLR7/8 upon siRNA entry. TLR3 are transmembrane receptors that 
are found on the cell surface of dendritic cells, in the epithelium and endothelium (Zimmer 
et al., 2011) and are able to ‘sense’ unmodified siRNA sequences ≥23-33 bp in length, in a 
sequence-independent, but cell-type dependent manner (Kariko et al., 2004, Reynolds et 
al., 2006). Upon internalization, endocytic TLR7 and TLR8 expressed within dendritic 
cells, macrophages, or regulatory T cells (Kokkinopoulos et al., 2005) can also sense 
internalized siRNA, in a sequence-dependent manner, favoring GU-rich or AU-rich 
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duplexes (Diebold et al., 2006).  Immune-mediated toxicity is thus elicited through the 
induction of interferon-α (IFNα), IFNγ and interleukin-12 (IL-12) (Robbins et al., 2009). 
Another significant drawback is the unwanted side effects caused by less-than-perfect 
siRNA complementarity to their target sequences. Although Elbashir et al. (2001b) had 
reported  a short, 7 bp  ‘seed’ sequence as a targeting feature on cognate mRNA sufficed 
for RNAi, microarray screening analysis by Jackson et al. (2003) showed that a sequence 
as short as 11 bp could induce off-target effects with toxic phenotypes. A ‘seed’ sequence 
is necessary for mRNA recognition, as it places the target’s scissile phosphate group 
directly within the slicer site of AGO2 (Parker et al., 2005)  
Other issues with unformulated siRNAs as a therapeutic platform include poor serum 
stability, degradation by RNase A- type nucleases, poor bioavailability, a short half-life 
(Moschos et al., 2007) or clotting effects (Bramsen and Kjems, 2012, Pecot et al., 2011). 
In addition, compared to small molecule inhibitors (SMocs), the large size of siRNA 
molecules necessitate the development of stabilizing formulations that will allow the 
siRNA molecules to enter cells, without activating patrolling macrophages or the 
intracellular innate immunity protein repertoire, escape from endosomes, and retain 
potency and activity after loading onto the RNAi machinery in vivo. These hurdles, as well 
as the pharmacokinetic properties of siRNA, make this molecule a ‘difficult’ bioactive 
drug. In addition, its small size (≤ 10 nm in diameter) poses serious challenges for systemic 
delivery, as it is rapidly cleared by the renal system; studies have shown that most of 
intravenously administered siRNA rapidly accumulates in the kidneys (Moschos et al., 
2007, van de Water et al., 2006). Endosomal entrapment and subsequent degradation of 
internalized siRNA formulations by lysozomal nucleases, necessitate the development of 
fusogenic vectors that will become protonated upon acidification and allow the siRNA to 
30 
 
escape unharmed from endosomes. It is still unknown whether siRNA will ever become a 
universal ‘Superdrug’ that will revolutionize personalized medicine, but both academia and 




 SiRNA-based therapeutics currently in clinical trials (2013). Local delivery refers to ocular, pulmonary, pancreatic and Table 1.1
colonic tissues; non-invasive patient administration. Targeted systemic delivery refers to intravenous (IV) uptake, or delivery by synthetic 
carriers. RSV, respiratory syncytial virus; TTR, transthyretin; VEGF, vascular endothelial growth factor; PLK1, polio-like kinase 1; PKN3, 
protein kinase N3, effector molecule in the phosphatidyl inositol 3 kinase (PI3K) metastatic pathway; miR-122, miRNA-122; HCV, Hepatitis C 
virus; SNALP, stable nucleic acid lipid particle; LNA, locked nucleic acid; AMD, age-related macular degeneration; DME, diabetic macular 
edema; TLR, Toll-like receptor. (Adapted from  Zhou et al. (2013). Confirmed status April 2014) 
Company Lead Drug(s) Target Disease Delivery Clinical Trial Number, Trial Phase 
Alnylam ALN-RSV01 Nucleocapsid 
‘N’ gene  
RSV infection  in lung transplant 




NCT01065935, IIb (abandoned) 
 
ALN-VSP02 VEGF  Liver cancer Local NCT01158079, I 
 
ALN-TTR02 TTR  Hereditary amyloidosis Systemic (SNALP) NCT01961921  III (ongoing) 
 
 
ALN-TTRsc TTR  Hereditary amyloidosis Systemic (SNALP) NCT01981837, II (ongoing) 
 
ALN-PCS PCSK9 Severe hyper-cholesterolemia Systemic (subcutaneous 
ESC-GalNAc conjugate) 
NCT01437059, I (completed) 
Tekmira  TKM-PLK1 PLK1  Solid cancer tumors Systemic (SNALP) NCT01437007, I/II (completed) 
 
TKM-EBOLA Ebola viral 
infection 
Ebola virus (biodefense); Fast-
tracked by the FDA, April 2014 
Systemic (subcutaneous 
LNA) 















AMD, DME Local 
(Intravitreal) 







AMD, DME Local 
(Intravitreal) 
NCT00363714, II (discontinued, off-
target effects) 
Quark / Pfizer PF-655 Proangiogenic 
factor RTP801  
AMD, DME Local NCT01445899, NCT00713518, I/II and 
II (terminated, TLR activation) 
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 Engineering stabilizing modifications for siRNA 1.3
In addition to the above challenges in the development of siRNA as a therapeutic 
molecule, the elicitation of off-target effects as a reflection of the common RNAi pathway 
between miRNA and siRNA (Doench et al., 2003) and the competition, and ultimate 
saturation, of the RNAi machinery by both cognate miRNAs and exogenously introduced 
siRNAs is still a major issue (Castanotto et al., 2007, Vickers et al., 2007). Chemical 
engineering of siRNA has overcome many of these limitations, either by modifying (i) the 
phosphodiester backbone, (ii) the ribose sugar, (iii) the nucleoside base, or (iv), the 
nucleotide structure itself, in order to maximize potency and minimize unwanted side-
effects. Common backbone modifications include the phosphorothioate (PS) (Detzer et al., 
2008) and boranophosphate modifications (Hall et al., 2006), which improve nuclease 
resistance, biodistribution and uptake by cells. Modifications in the furanose ring of the 
ribose involve substituting the 2’-OH group with either 2’-F or 2’-OMe structures that 
confer potency, specificity and a reduction in immunogenicity, with minimal effects on 
conformation and activity (Fig. 1.2). Finally, changes in the nucleoside base, most 
commonly Uracil, are used to increase base-pairing properties either alone or in 
conjunction with other stabilizing modifications (Bramsen and Kjems, 2012).  
The site of modification on the double helix is critical, as chemical manipulation of the 
siRNA structure bias affects strand loading onto Argonaute proteins. As a general rule, 
each backbone modification decreases the melting temperature (Tm) of siRNA duplexes, 
increasing their thermodynamic stability by 0.3-0.5°C per modification (Amarzguioui et 
al., 2006, Harborth et al., 2003). A difference in melting temperature (∆Tm) of 3-5°C has 
been observed in locked nucleic acid (LNA) monomers (Koshkin and Wengel, 1998), 
nucleic acid analogues with enhanced thermodynamic stabilities. By ‘locking’ the C4 and 
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2’-OH groups in a ribose monomer, molecule rotation is restricted, thereby forcing the 
monomer to adopt an A-RNA structure (Kierzek et al., 2009). Incorporation of LNA 
modifications into siRNA molecules has been shown to greatly siRNA delivery and 
specificity (Elmen et al., 2004) and therefore provide attractive alternatives to siRNA 
oligos. Previous work by Chiu and Rana (2003), Schwarz et al. (2003), and more recently 
by Bramsen et al. (2009), has identified that siRNA is amenable to moderate, but not 
extensive, modifications or conjugations on the 3’-terminus of the antisense strand, or both 
5’- and 3’- termini of the sense strand, with little influence on its activity-related 
properties. Many companies now offer custom-made siRNA sequences with proprietary 
modifications that can be used in gene-regulation studies, although the type and extent of 





 Common chemical siRNA modifications. A. Stabilising modifications in Figure 1.2
the ribose furanose ring (top panel) or in the phosphodiester backbone (lower panel).        





 siRNA Delivery Strategies 1.4
However elegant siRNA modifications have been in increasing target specificity and 
stabilization against degradation, the current challenge in siRNA biotherapeutics 
development is targeted, efficient and non-immunogenic delivery to tissues of interest. 
Indeed, preservation of bioactivity, biodistribution, selectivity and target specificity for any 
given drug is no small feat. The development of either systemic or tissue-specific drug 
delivery vectors has been the bottleneck for many biotechnology companies, and the 
tombstone for some of big pharma’s RNAi technology divisions (Novartis, for example, 
has decided to shut down its RNAi R&D operations, a decision ‘driven by ongoing 
challenges with formulation and delivery […]’ (FierceBiotech, 2014) following Merck, 
Roche, Abbott and Pfizer in 2011. 
 The incorporation of specificity-enhancing, stabilising modifications have, to a great 
extent, minimised issues such serum degradation and off-target effects encountered with 
naked siRNA. Utilisation of naked siRNA in formulations is also problematic due to its 
highly charged anionic nature, which hinders uptake via the hydrophobic cell membrane. 
Formulation attempts include non-viral vectors to increase bioavailability and specificity, 
and to overcome the electrostatic barrier posed by the cell membrane. Such vectors involve 
lipid-based formulations, including neutral liposomes, cationic lipids and lipoplexes; stable 
nucleic acids (SNALPs), which are PEGylated lipid nanoparticles for systemic delivery, 
various polymers (chitosan nanoparticles, polyethyleneimine (PEI), cyclodextrin and 
dendrimers), each with its own advantages and limitations with respect to efficacy and 
toxicity. Lipid-based delivery strategies, especially cationic liposomes, have been used to 
deliver siRNA into mammalian cell cultures in vitro (Taetz et al., 2009), but are of limited 
use in an in vivo setting as they fail to release cargo and elicit dose-dependent 
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inflammation (Spagnou et al., 2004). Similarly, chitosan nanoparticles, derived from 
natural polysaccharides, lack endosomolytic escape properties, which limits their 
bioavailability even in an in vitro setting (Wu et al., 2012). These findings further highlight 
the need of effective siRNA carriers that will: (i) be able to protect its cargo from 
nucleophilic/lysozomal degradation, (ii) be effectively internalized either specifically in 
tissues of interest, or be stable for systemic delivery, (iii) promote the cytoplasmic release 
of nucleotide cargo, (iv) exhibit high biological activity at low concentrations and finally 




 Cell Penetrating Peptides 1.5
Cell penetrating peptides (CPPs); represent a class of therapeutically interesting vectors for 
targeted drug delivery. The classical definition of CPPs, or protein transduction domains 
(PTDs) is that of short cationic sequences (less than 30 amino acids long), rich in arginine 
(Arg, R), histidine (His, H), and lysine (Lys, K) residues. Their highly polar amino acid 
sequence allows them to cross the negatively charged lipid bilayer of the cell membrane, a 
key hurdle in the delivery of macromolecules into cells. Moreover, they have a low 
molecular weight (<500 Da) (Kerkis et al., 2006). Their internalisation efficiency depends 
on the number of arginine (R) residues in the peptide backbone, with R6 and R8 synthetic 
repeats showing the highest, compared to other CPPs (Futaki et al., 2001). Interactions 
with the cell membrane involve binding  interactions between key polyanions on the 
external face of the cell membrane, such as heparan sulfate, heparin, polysialic acid, as 
well as nucleic acids, and CPP (Poon and Gariepy, 2007). 
 The classification criteria for CPPs have greatly expanded in the past 10 years, and now 
involve different classes of molecules, that can span the cell membrane, including 
hydrophobic protein sequences, and tissue specific proteins identified by phage display 
(Milletti, 2012). Most cell penetrating peptides do not obey Lipinski’s rule of five1 
(Lipinski et al., 2001), and must therefore be examined on a case-by-case basis for 
efficacy.  
CPPs can be categorised based on their origin or their classification (Table 1.2). Classical 
CPPs, such as the HIV transactivator of transcription (TAT), the Herpes simplex virus 
                                                 
1
 Lipinski’s rule of 5: In a study of ≥2000 pharmacological agents, Lipinski concluded that a drug is more 
likely to be cell-permeant if MW≤500, lipophilicity (LogP)≤5, number of H-bond donors ≤5 and number of 
H-bond acceptors ≥10. 
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protein VP22, and the Antennapedia homeodomain from Drosophila melanogaster, are 
considered classical CPPs. These are naturally derived proteins, which obey the structural 
rules of amphipathicity or cationic charge and adopt an α-helical structure upon interaction 
with the phospholipid membrane (Oehlke et al., 1997, Scheller et al., 2000). For example, 
HIV-Tat’s ability to translocate through the cell membrane is conferred by its arginine 
residues whereas, Penetratin’s ability (the third helix of the Antennapedia homeodomain), 
is based on its hydrophobic core (W6, F7) (Christiaens et al., 2002, Derossi et al., 1996, 
Magzoub et al., 2001).  
Two strategies have been used so far to conjugate siRNA cargo to CPPs; one is covalent, 
and the other non-covalent, via electrostatic interactions between protein and cargo. These 
are sufficient to hold the complexed siRNA-protein together and deliver it intracellularly 
(Eguchi et al., 2009, Lundberg et al., 2007).  
Futaki et al. (2001) first demonstrated that poly-arginine sequences were able to transduce 
cargo intracellularly by virtue of bidentate hydrogen bonding between the guanidinium 
group in arginine and the phosphate backbone. Translocation efficiency was thus found to 
be directly proportional to the number of arginine residues within a cationic sequence 
(Tunnemann et al., 2008). A number of either natural or synthetic sequences have since 
been designed, containing transducing motifs in tandem, or combinations thereof (Abes et 
al., 2007, Meade and Dowdy, 2007) and tested in vitro with various cargoes, which have 
been either covalently or non-covalently conjugated to the peptides.  
Covalent conjugation strategies include disulfide, amide, hydrazine and thiazolidine bonds 
between the 3’ end of the sense strand and the C’ or N’ terminus of the protein (Chiu et al., 
2004, Davidson et al., 2004, Detzer et al., 2009, Moschos et al., 2007, Muratovska and 
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Eccles, 2004) and have been used mostly in the delivery of oligonucleotide cargoes, such 
as morpholinos, peptide nucleic acids (PNA) (Fabani and Gait, 2008), steric block 
oligonucleotides (Abes et al., 2008) or full-length proteins (Snyder and Dowdy, 2005), 
amongst others (Dietz and Bahr, 2004). Non-covalent strategies, which rely on 
amphipathic or cationic proteins with a polar and a non-polar domain, arranged either 
sequentially (i.e. within the primary sequence), or by conformation (once the protein has 
adopted its three-dimensional structure in solution) (Deshayes et al., 2008), have become 
increasingly popular. Electrostatic interactions between the positively charged carrier and 
its anionic cargo suffice for efficient delivery, without necessitating the incorporation of 
chemical, and often structurally-modifying, conjugations. Simeoni et al. (2003), first 
illustrated the transduction of siRNA by MPGα via non-covalent conjugation in vitro, 
followed by reports with polyarginine (Kim et al., 2006), HIV-Tat (Eguchi et al., 2009) 
and the endosomolytic analogue of Penetratin, EB1 (Lundberg et al., 2007). 
Interest in CPP development as a drug delivery vector stems from their abilities to enter 
most, if not all, cell types non-specifically, including primary and difficult to transfect cell 
lines (Eguchi et al., 2009). They also show rapid cellular uptake and do not rely on nucleic 
acid integration into the host cell genome (El-Andaloussi et al., 2011, Sugita et al., 2008), 
compared to viral vectors. The most commonly used CPPs are summarized in Table 1.2. 
Another class of CPPs are the stapled peptide CPPs. These were developed in an attempt to 
circumvent issues such as proteolytic degradations and renal clearance (Jenssen and 
Aspmo, 2008) and to provide enhanced conformation stability via α,α-disubstitution and 
macrocyclic bridge formation (Henchey et al., 2008). By adopting such a hydrocarbon 
staple, proteins are induced to form α-helices, with an increase in target affinity, thereby 
providing an alternative solution to inherently unstable CPPs (Verdine and Hilinski, 2012) 
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 Examples of cell penetrating peptides that have shown efficient cargo Table 1.2
transduction in vitro. εNHα represents four trifluoromethylquinoline-based derivatives via 
a succinilated lysine tree. Polar amino acids Arginine (R), red; Lysine (K), blue. (Laufer 












Joliot et al. (1991a) 
Penetratin Classical RQIKIWFQNRRMKWK
KEN 




 Elliott and O'Hare (1997) 
HIV-Tat Classical GRKKRRQRRRQC Dyson et al. (2004), 
Frankel and Pabo (1988) 
MPGα Classical GALFLAFLAAALSLMG
LWSQPKKKRKV 



















Kelemen et al. (2002) 
Mastoparan Rhegnylogic 
bioportide 
INLKALAALAKKILa Higashijima et al. (1988), 
Pooga et al. (1998) 
CADY Synthetic GLWRALWRLLRSLWR
LLWRA 





Lundberg et al. (2007) 
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 HIV-Tat - a (brief) timeline 1.6
HIV’s transactivator of transcription (Tat) was the first CPP to be discovered. Frankel and 
Pabo (1988), observed that exogenously added transcription-transactivating (Tat) protein 
from HIV-1 could enter HeLa cells unaided and localise in the nucleus. Mutational 
analyses by site-directed mutagenesis of polar amino acids with non-polar substitutions 
showed that the conserved basic domain (GRKKR), which acts as a nuclear localisation 
signal, was indispensable for its intracellular localisation (Hauber et al., 1989). The full-
length protein is 86 amino acids long, with a highly conserved cysteine region, which acts 
as the regulatory region, and a basic region (Tat47-58), rich in lysine and arginine residues 
(Arya et al., 1985).  Its function is to trans-activate transcription of the viral genome from 
the HIV long terminal repeat (LTR), one of the structural landmarks of the HIV ssRNA 
genome (Sodroski et al., 1985). It does this by associating with the trans-acting response 
element (TAR) RNA, as well as improving translational efficiency (Marciniak et al., 
1990). Calnan et al. (1991) showed that the arginine-rich RNA-binding domain only 
adopts a helical structure upon binding dsRNA, and that this property is dependent on the 
overall charge density of Tat47-58, rather than sequence specificity. This makes Tat an RNA 
binding protein (Dingwall et al., 1990), and it is this characteristic which has been 
exploited to effectively deliver covalently linked macromolecular cargoes such as full-
length proteins (Schwarze et al., 1999) and non-covalently linked nucleic acids with 
efficiency (Eguchi et al., 2009).  
The exact mechanism of how Tat enters cells was investigated by various groups at the 
time. Mann and Frankel (1991), reported a non-specific, endocytic-dependent mechanism 
of Rho-Tat internalisation in HeLa cells, by performing binding-kinetic time-course 
experiments at 37°C and 4°C. The latter abolished binding to the cell membrane, indicating 
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that an energy-dependent process may be involved in uptake. Interestingly, they reported 
that another, temperature-independent mechanism was involved in binding in a cutaneous 
T lymphocyte (H9) cell line, as treatment with trypsin, a serine protease which digests cell 
receptors, did not affect uptake. Dextran sulfate and heparin, polyanionic moieties on the 
cell surface, were identified as interacting molecules prior to internalisation (Mann and 
Frankel, 1991). Studies by Wadia et al. (2004) and Kaplan et al. (2005), described a 
macropinocytic method of Tat uptake in a number of cell lines, confirmed later by studies 
with fluorescein-labelled peptide (Fonseca et al., 2009). Macropinocytosis is a non-
endocytic type of bulk-transport, triggered when Tat interacts with HSPGs (Heparan 
sulfate proteoglycans) on the cell surface (Console et al., 2003). Internalization occurs 
though large vesicles that pinch off the phospholipid membrane and form heterogeneous 
vesicles, which accumulate within the cell (Wadia et al., 2004). The uptake, however of 
conjugated cargo, points towards an endocytic mode of uptake, depending on the 
molecular weight and transduced cell type, and typically resulting in endosomal 
sequestration (Fonseca et al., 2009).  More recently, the Dowdy group have developed a 
non-covalent, Tat-based siRNA delivery vector, which utilizes three Tat domains separated 
by a fusogenic heamgglutinin (HA) tag recombinantly expressed with a dsRNA binding 
motif (DRBM) from human PKR (Eguchi et al., 2009). This recombinant protein, PTD-
DRBD, was able to carry siRNA into a range of cell lines, including primary HUVEC 




  The Antennapedia homeodomain and Penetratin 1.7
 Another classical CPP is the homeotic protein Antennapedia from Drosophila 
melanogaster. The Antennapedia (Antp) gene, a member of the Antennapedia Complex 
(ANTP-C) is a homeotic gene that encodes for DNA-binding Transcription Factors, which 
regulate segmental identity in the thorax (Lewis, 1978, Lewis et al., 1980). Dominant 
mutations in the Antp gene result in the transformation of antennae into legs (Wakimoto 
and Kaufman, 1981).  Highest levels of gene transcription occur in the mesothorax, but not 
in the head during various stages of embryogenesis. Two promoters, P1 and P2, control the 
major protein coding region, composed of exons A, B, D & E (1512 nucleotides long) and 
C, D & E (1727 nucleotides long), respectively. Multiple AUG (start/Met) codons are 
present in exons A, B and C.  
The Antennapedia homeoprotein is a proline and glutamine-rich, 378 amino acid (aa) 
protein (43 kDa). Its evolutionarily conserved homeodomain (AntpHD), 60 aa long, is 
found near the C-terminus and has been shown to bind DNA in vitro and in vivo (Desplan 
et al., 1985). In 1988, Otting et al resolved the nuclear magnetic resonance (NMR) 
structure of the DNA-binding homeodomain as a helix-turn-helix motif (Otting et al., 
1988), akin to the structure of other prokaryotic regulatory proteins (Ohlendorf et al., 
1982). The seminal work by Alain Prochiantz’s group identified that the Antennapedia 
homeodomain (AntpHD) adopts a tertiary structure comprised of 3 α-helices with a β-turn 
between the last two, which allows it to bind to cognate dsDNA sequence in target 
promoters (Joliot et al., 1991a) (Fig. 1.3). Moreover, the group observed in 1991 that the 
evolutionarily conserved, 60 aa AntpHD could effectively translocate into nuclei and 
between neuronal cells thereby inducing differentiation and morphological changes. (Joliot 
et al., 1991b). Through site-directed mutagenesis studies, the third helix of the protein (16 
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aa) was identified as the minimal sequence required for translocation, and was duly named 
‘Penetratin’ (Pen) (Derossi et al., 1994).  
 
 Secondary structure of the Antennapedia homeodomain protein Figure 1.3
(AntpHD). The AntpHD exhibits a helix-turn-helix motif, common in cell penetrating 
proteins. Key amino acids responsible for its highly polar charge are shown in blue. 
Histidine residues, green; Methionine residues, grey. The sequence for the third helix, 
Penetratin, responsible for translocation, is shown in bold. Helical structures are underlined 
(Modelled with RSCB PDB Protein).  
The 16 amino acid sequence –RQIKIWFQNRRMKKWKK- and its ability to translocate 
through biological membranes has been widely studied as a vector for the delivery of 
various cargoes, from chemical drugs, to proteins, and nucleic acids (Dietz and Bahr, 
2004). A comparative study between Penetratin, Tat, transportan and polyarginine has 
demonstrated that unconjugated, rhodamine-labelled Penetratin exhibits negligible, cell 
type-independent cytotoxicity at concentrations of up to 100 M and a higher magnitude of 
uptake compared to Tat (Sugita et al., 2008). Moreover, Penetratin failed to co-localize 
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with transferrin, a clathrin marker, but co-localized with cholera toxin, a lipid raft marker, 
indicating a lipid raft-dependent, but clathrin-independent mode of translocation (Jones et 
al., 2005). Conversely, fluorescein-labelled Penetratin was found to be highly cytotoxic in 
HeLa and Jurkat cells, with a dose-dependent, cell type-independent mode of 
internalization, which was higher compared to Tat (Sugita et al., 2008). 
Thus far, only a handful of studies have investigated Penetratin as a siRNA carrier. The 
AntpHD has as yet, not been investigated for its potential siRNA transducing abilities, 
possibly due to its large molecular weight and dsDNA binding abilities. Penetratin was 
first covalently linked to siRNA, and applied to mammalian neurons, where it induced a 
gene knockdown effect (Davidson et al., 2004). In addition, covalently linked siRNA 
against GFP induced a reduction in the expression of both stable and transient-expressing 
cells (Muratovska and Eccles, 2004). In in vivo lung studies, Pen-siRNA targeted against 
p38 MAPK was found to induce the innate immunity response (Moschos et al., 2007).  
More recently, a folate-penetratin nanocomplex separated by a PEGylated linker has been 
used to deliver luciferase-specific siRNA, greatly decreasing its expression (Cheng and 
Saltzman, 2011). Some examples of cargoes successfully transduced by Penetratin are 
summarized in Table 1.3. Other CPPs have been covalently complexed with various forms 
of chemically stabilized dsRNAs, such as PNA or morpholinos (Abes et al., 2008, Ivanova 
et al., 2008), 2’-O-methyl phosphorothioate dsRNA (Hassane et al., 2011), with uncharged 
oligonucleotide molecules covalently linked to a CPP moiety proving to be more potent 
and specific than direct conjugation to highly charged siRNA (Juliano et al., 2008). It has 
been suggested that linking siRNA directly to amphipathic CPPs leads to charge 
neutralization, due to steric hindrance aggregation and loss of transducing abilities, which 
has consequently induced a shift to non-covalent conjugation approaches. This strategy for  
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siRNA conjugation includes delivery into a range of cell lines by the synthetic peptide 
MPG (Nguyen et al., 2006, Simeoni et al., 2003), successfully targeting Oct-4 (Zeineddine 
et al., 2006) and cyclin B1 (Crombez et al., 2007) in vivo. Moreover, Polyarginine (Kumar 
et al., 2007), Penetratin (Lundberg et al., 2007) and Tat (Meade and Dowdy, 2007) have 
also been utilized as siRNA carriers, successfully downregulating the expression of various 




 Notable examples of cargo successfully transduced by Penetratin. Table 1.3
Adapted from Dietz and Bahr (2004). 
Cargo Target/disease Effect Reference 
doxorubicin anti-neoplastic 
drug delivery  
6-fold increase in 
uptake through the 
BBB through in situ 
perfusion in rats 
Rousselle et al. 







in p16-/- cells 
G1 arrest in p16-
negative AsPC1 and 
BxPC3 pancreatic cell 
lines, human diploid 
fibroblasts 
Bonfanti et al. 
(1997), Fahraeus et 
al. (1998), Fujimoto 
et al. (2000), Kato et 
al. (1998) 
p21 anti-cancer 
treatment in p53 
mutated cancers 
growth inhibition in 
ovarian SKOV-3 and 
IGROV-1 cells; acute 
cytotoxicity in p53-
mutated cells but not 
healthy ones in a 
SKOV-3 nude mouse 
model 
Bonfanti et al. 





p38 mRNA  Reduction of p38 
mRNA levels in a L929 
cell line; Induction of 
innate immunity in vivo 












Hansen et al. (2012) 




upregulation of the 
luciferase gene in 
HeLa-pLuc cells 
Lundin et al. (2008) 
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 Overcoming endosomal entrapment  1.8
Early studies on the uptake of CPPs on fixed cells in vitro had proposed a receptor and 
energy-independent mechanism of translocation, since uptake was observed at both 37°C 
and 4°C (Derossi et al., 1996). Further studies in live cells, had attributed those 
observations to fixation artefacts (Lundberg et al., 2003, Richard et al., 2003), and 
proposed that CPPs enter cells by two distinct mechanisms, endocytosis (clathrin-
mediated, caveolae-mediated and macropinocytosis) and direct translocation.The 
mechanism of uptake was found to depend on the presence or absence and type of cargo 
(Lundin et al., 2008), temperature, primary protein sequence (Guterstam et al., 2009, Jiao 
et al., 2009) and concentration. Although the exact mechanisms of uptake are still elusive, 
most studies point towards initial bidentate interaction of the guanidinium group in 
arginine with sulfate atoms of heparin (Sakai and Matile, 2003) a member of the heparan 
sulfate proteoglycan family (HSPGs), and endocytosis-mediated uptake (Fuchs and Raines, 
2004). The mode of uptake that follows varies with concentration and the attachment of 
cargo, with lower concentrations and macromolecules favoring an endocytic mechanism, 
whereas at concentrations above a membrane density-specific threshold, a shift to direct 
translocation is observed for a number of CPPs (Duchardt et al., 2007, Kosuge et al., 2008, 
Rydstrom et al., 2011, Tunnemann et al., 2008). For example, Penetratin has been found to 
favor direct translocation only at concentrations below 2 M (Guterstam et al., 2009). 
Lundin et al. (2008) compared the uptake mechanism of various cationic and amphipathic 
CPP-peptide nucleic acid (PNA) complexes, concluding that amphipathic CPPs were 
endocytosed in clathrin-coated vesicles, whereas cationic ones favored macropinocytosis. 
Once endocytosed, CPP-cargo complexes become trapped in endosomes and are 
eventually degraded; indeed, CPP concentrations necessary to elicit a biological effect are 
49 
 
usually ≥ 10 M, which may be too high for therapeutic formulations (Milletti, 2012). 
Attempts to bypass endosomal sequestration of CPPs coupled to macromolecular cargos 
have incorporated reagents such as chloroquine in a co-incubation step, as a buffer that 
stops  the decrease in intra-endosomal pH, which may be relevant in an in vitro setting, but 
not in vivo, as cytotoxicity is elicited in a cell-type specific, and therefore tissue-specific, 
manner (Wadia et al., 2004). Incorporation of the HA2 subunit of the influenza 
hemagglutinin (HA) tag at the amino terminus of CPPs has been reported to aid 
fusogenicity (Eguchi et al., 2009, Wadia et al., 2004). HA2 adopts an alpha-helical 
structure upon acidification in the endosome and proceeds to fuse with the endosomal 
membrane, allowing the release of viral nucleocapsid into the cytoplasm (Bullough et al., 
1994). CPP-HA2 fusion proteins, when co-incubated with CPP-cargo in a stoichiometric 
ratio, have been reported to greatly enhance the delivery of nucleic acid/peptide cargo 
linked with Penetratin, Tat and transportan (El-Andaloussi et al., 2005, El-Andaloussi et 
al., 2006, Kaplan et al., 2005, Wadia et al., 2004). Another strategy involves the 
incorporation of histidine residues, which have been shown to disrupt endosomal 
membranes upon acidification via protonation of its imidazole ring (Midoux and 
Monsigny, 1999). A seminal study by Lundberg et al (2007), compared the efficiency of 
endosomal escape between EB1, a Penetratin analogue with Histidine insertions 
(LIRLWSHLIHIWFQN-RRLKWKKK), its parent peptide, Penetratin, as well as 
Penetratin fused to an HA2 tag non-covalently linked to siRNA (Table 1.2). EB1 yielded a 
substantial decrease in luciferase activity compared to the latter two, demonstrating that 
unmodified penetratin-siRNA were effectively trapped within endosomes and could not 
mediate RNAi.  
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  Double stranded RNA binding domains  1.9
Double stranded RNA (dsRNA) is ubiquitously involved in a myriad of pathogenic and 
non-pathogenic cellular processes. Viral genetic information is often in the form of dsRNA 
or ssRNA which, upon replication, form these double helical complexes. Moreover, there 
are cellular dsRNAs in the form of mRNA untranslated regions (UTRs), ribosomal RNAs 
(rRNAs), transfer RNAs (tRNAs), as well as smaller precursors, such as those of short 
interfering RNAs (siRNA) and microRNAs (miRNA) (Masliah et al., 2013). The diverse 
group of RNAs is recognized by a large superfamily of dsRNA binding proteins (DRBPs), 
which contain 1-5 dsRNA binding domains/motifs (DRBDs/DRBMs), zinc fingers, and 
sterile α-motif (SAM) domains, amongst others (Masliah et al., 2013). The double 
stranded RNA (dsRNA) binding domains represent conserved viral, eukaryotic and 
prokaryotic motifs within a large family of proteins that interact specifically with dsRNA. 
They are usually 65-70 amino acids in length (St Johnston et al., 1992) and provide a vital 
means of regulating gene expression. Eukaryotic dsRNA binding proteins (DRBPs) 
include adenosine deaminase acting on RNA 1 (ADAR1) (Wang et al., 2000), spermatid 
perinuclear RNA binding protein (SPNR) (Pires-daSilva et al., 2001), DICER, nuclear 
factors associated with dsRNA 1 and 2 (NFAR 1 and 2) (Saunders et al., 2001) and reside 
either in the nucleus or in the cytoplasm. The biological role of nuclear DRBPs is to 
regulate post-transcriptional control processes, such as RNA interference (RNAi), splicing, 
stability, transport as well as mRNA elongation and translation. They do so by binding the 
5’- and/or 3’- UTR of mRNA molecules (Lee and Schedl, 2006). Cytoplasmic DRBPs 
include PKR, TAR RNA binding protein (TRBP), Protein activator of PKR (PACT) and 
the Staufen protein from Drosophila melanogaster (Table 1.4).  
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DRBDs are able to interact with dsRNA in a sequence independent manner, binding RNA 
sequences as short as 11 bp (Manche et al., 1992). DRBD-containing proteins thereby 
interact primarily with A-form helical dsRNAs, since their minor groove is shallow and 
broad, allowing the formation of hydrogen bonds between the bridging oxygen atom in the 
ribose residue and the protein, but not ssRNAs, ssDNA or dsDNA (Fierro-Monti and 
Mathews, 2000, St Johnston et al., 1992). Non-specific interactions between dsRNA and 
DRBDs occurs by binding the 2’-OH groups and the phosphodiester backbone of the 
double stranded helix, rather than specific nucleotides, pointing towards a shape-
dependent, rather than sequence-dependent mechanism; crystallographic studies have 
shown that 11-16 base pair sequences are enough for protein-dsRNA binding (Ryter and 
Schultz, 1998). Although the DRBP family contains more than 500 members, the reason 
why some DRBPs have more than one DRBD has only been elucidated in the last 20 years; 
it has been suggested that different DRBDs within the same proteins bind dsRNA with 
different avidities, thereby stabilizing dsRNA-protein complex formation and mediating 
interactions with other DRBPs (Krovat and Jantsch, 1996). Indeed, several such protein-
protein interactions have been identified, leading to heterodimerisation, 
autophosphorylation and activation, such as the interactions between human Protein 
Kinase R (PKR) and TRBP (Peters et al., 2001), NFAR (Saunders et al., 2001), SPNR 







 Examples and cellular functions of the members of the dsRNA binding protein family (DRBPs). DRBMs, dsRNA binding Table 1.4




Localization Organism Molecular 
weight 
(kDa) 
Cellular Function Reference 
PKR 2 Cytoplasmic, 
20%  Nuclear 
Human, rat 68 Antiviral defense,  
inhibition of protein synthesis 
Galabru and Hovanessian (1987), 
Meurs et al. (1990) Levin and 
London (1978) 
NFAR 1, 2 2 Nuclear Human 90, 110 mRNA processing, PKR 
interaction 
Saunders et al. (2001) 




40-50 Interaction with HIV 
transactivating region (TAR) 
RNA, PKR modulation  









viral and brain mRNA editing 
(A→I) in the liver 
O'Connell et al. (1995), Patterson et 
al. (1995), Chen et al. (2000) 





60, 65 Localization and mRNA 
translation 
Ramos et al. (2000), Ferrandon et al. 
(1994) 
PACT 3 Cytoplasmic Human,  
mouse 
35 Stress-induced PKR activation 
by autophosphorylation 




1, 2 Nuclear E. coli, 
Human, 
Drosophila 
160, 153 pre-mRNA processing, 
endoribonuclease activity 
Nicholson (1996), Filippov et al. 
(2000) 





Endoribonuclease and helicase  
activity in RNAi  
Bernstein et al. (2001) 
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 Human Protein Kinase R 1.10
The human isoform of Protein Kinase R (PKR) is encoded by a single gene on 
chromosome 2p21 and is a prominent member of the DRBPs. It has recently been 
evaluated in various reports for its dsRNA binding abilities, as part of engineered 
recombinant proteins for the delivery of therapeutically relevant siRNA (Eguchi et al., 
2009, Geoghegan et al., 2012, Kim et al., 2009a).  It is a 551 aa long interferon-induced, 
dsRNA activated serine/threonine (Ser/Thr) kinase that plays a key role in the immune 
response against viral infections (Rice et al., 1985, Samuel et al., 1984), as well as in the 
regulation of signal transduction, apoptosis, cell proliferation and differentiation (Donze et 
al., 1995, Wu and Kaufman, 1996). It therefore plays a critical function in allowing the cell 
to rapidly respond to external stimuli by shutting down its translational machinery 
(Merrick, 1992, Pain, 1996). In the case of viral infection, PKR recognizes and directly 
bind viral dsRNA via its two N-terminal tandem dsRNA binding motifs (DRBMs) in a 
sequential manner and induce the interferon response. This in turn allows the trans-
phosphorylation of various Ser/Thr and Tyrosine residues (Ser83, Ser242, Thr88-90, 
Thr255, Thr258, Thr446 and Thr451) in its C-terminal kinase domain and subsequent 
homodimerization of the protein (Taylor et al., 2001, Zhang et al., 2001).  Once the 
dsRNA substrate has been correctly inserted between the two DRBDs, activated PKR 
proceeds to phosphorylate the α-subunit of eukaryotic translation initiation factor 2 
(elF2α), a rate limiting component of translation, which is docked within the catalytic 
domain. elF2α phosphorylation induces a dramatic arrest of protein translation and the 
induction of autophagy and ultimately the self-destruction of the infected host cell (Dabo 
and Meurs, 2012). PKR is able to bind most forms of dsRNA, including aptamers with 
bulges, internal and hairpin loops, and multistem junctions (Bevilacqua et al., 1998), as 
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well as various viral dsRNAs, with imperfect Watson-Crick complementariy, as its two 
DRBMs adopt a dumb-bell shape with a canonical α-β-β-β-α topology (Dzananovic et al., 
2013) (Fig. 1.4). 
 
 Structure of the two dsRNA binding motifs in human PKR that Figure 1.4
compose its dsRNA binding domain (DRBD). DRBM1 is shown on the left and DRBM2 
on the right, linked by 22 amino acid loop. Adapted from Nanduri et al. (1998). 
 
Mutational analysis studies by Nanduri et al. (1998) identified conserved binding sites 
within each DRBM, which were also confirmed by structural studies on the Xlrbpa DRBM 
from Xenopus laevis (Ryter and Schultz, 1998). These critical residues correspond to three 
regions on each DRBM; namely regions α1 (N15-T16), β1-β2 loop (P36-R39) and β3-α2 
loop (R58-K64) in DRBM1, and regions α3 (N106-R107), β4-β5 (H125-G130) and β6-α4 
(S148-K154) in DRBM2 (Nanduri et al., 2000). 
Although PKR can non-specifically interact with as few as 15 base pairs (Bevilacqua and 
Cech, 1996, Schmedt et al., 1995, Ucci et al., 2007), a minimum of 30 bp is required for 
activation, homodimerization and the subsequent induction of immune signals, in response 
to exogenous dsRNA introduction into the cell (Lemaire et al., 2008). 
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DRBM19-77 was found to be less conformationally restricted than DRBM2100-167, although 
similar in length (Nanduri et al., 2000). This allows dsRNA binding with high affinity 
(dissociation constant, Kd = 3.8x10-7) (Schmedt et al., 1995). The binding affinity for 
dsRNA is increased 100-fold by the cooperative action of both tandem motifs (Kd= 4x10-9) 
(Geoghegan et al., 2012, Schmedt et al., 1995).  
A seminal report by Eguchi et al. (2009), expressed the DRBM1 from human PKR as a 
fusion protein with the HIV Tat protein (PTD; Tat-Tat-HA-Tat), creating an engineered 
PTD-DRBD siRNA delivery vector. They claimed that the DRBM1 (DRBD) from human 
PKR was sufficient in binding 21-23nt siRNA sequences at a 4:1 molar ratio, at 90° to the 
phosphate backbone and with a high enough avidity for intracellular transduction and post-
translational gene silencing in a reporter cell line. 
In another study Kim et al. (2009a) engineered a recombinant protein comprised of the 
entire DRBD1-177 (DRBM1 and 2) with the fusogenic peptide KALA, and was able to 
downregulate the expression of GFP by delivering GFP-specific siRNA without 
endonuclease or serum degradation. A third study, by Geoghegan et al. (2012), evaluated 
the DRBD as a protein platform for siRNA delivery, and observed that the use of DRBM1 
only was insufficient for stable binding of siRNA when fused to various different cell 
penetrating moieties (Penetratin, B2, Tat). The use of the entire DRBD, consisting of both 
DRBM1 and 2, however, yielded specific and stable dsRNA binding at low molar ratios. 
Intracellular delivery however was hindered due to the endosomal entrapment of the fusion 




 PTP1B in Type 2 Diabetes: a potential target for siRNA-based 1.11
intervention  
Type 2 Diabetes (T2DM) is a metabolic disorder that has reached epidemic proportions 
due to an increased prevalence of obesity and sedentary lifestyles. It accounts for 90% of 
all diabetes cases that affect 3 million people in the UK alone (DiabetesUK, 2013). Its core 
pathophysiological features include insulin resistance and insufficient β-cell insulin 
production, hyperglycemia and hyperinsulinemia, adipocytic lipolysis and increased 
glucose resorption in the kidneys (Defronzo, 2009). Long-term complications include heart 
attacks, renal failure, stroke and retinopathy. Current monotherapies have various 
limitations, highlighting a need for the development of new pharmacologic agents (Carpino 
and Goodwin, 2010). Current therapies include various anti-hyperglycemic agents such as 
metformin, which lowers liver glucose output, but which elicits adverse side-effects such 
as lactic acidosis and renal damage, sulfylureas, which increase insulin secretion, but 
whose adverse effects include hypoglycemia, glinides, α-glucosidase inhibitors, which 
reduce the rate of polysaccharide breakdown, thiazolidinediones, that increase sensitivity 
to existing systemic glucose levels and insulin, which is still the ‘golden standard’ when it 
comes to lowering glucose levels (Mazzola, 2012). Other monotherapies include insulin 
secretagogues such as meglitinide, pioglitazone, or a dipeptidyl peptidase 4 (DPP-4) 
inhibitor (Irons and Minze, 2014).  All monotherapies aim to by-pass diminished signaling 
by the Insulin Receptor (IR), characterized by aberrations in molecular pathways 
downstream of the IR which attenuate the signals mediated by the activation of the 
receptor upon ligand binding. These are caused by the de-phosphorylating action of a class 
of Protein Tyrosine Phosphatases (PTPs). This family of receptor-like tyrosine kinases 
plays an important role in the regulation of various signal transduction pathways. 
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Signaling through the insulin receptor (IR) is activated when endogenous insulin, secreted 
by pancreatic β cells, binds to the two α-chains of the extracellular domain of the receptor, 
triggering the activation of the intrinsic tyrosine kinase activity of its intracellular β-
subunit tyrosine residues (Taniguchi et al., 2006). Auto-phosphorylation of key tyrosine 
residues (Y1146, Y1150, Y1151), results in the recruitment and phosphorylation of insulin 
receptor substrates 1 and 2 (IRS1 and 2), allowing the regulatory subunit of phosphatidyl 
inositol 3 kinase (PI3K) to dock. As PI3K is activated, the membrane phospholipid 
phosphatidyl-inositol 3,4,5-triphosphate (PIP3) is recruited and in turn, activates the 
second messengers 3-phosphoinositide-dependent protein kinase 1 and 2 (PDK1 and 2), 
ultimately activating protein kinase B (PKB)/Akt, a key mediator of the metabolic effects 
of insulin (Guo, 2014). Akt activation leads to glucose uptake by GLUT4, protein and 
glucose synthesis and gluconeogenesis (Taniguchi et al., 2006). Growth and differentiation 
via the ras-MAPK pathway is also regulated by insulin, which elicits the GTP-dependent 
activation of p-21ras, stimulated by Grb-SOS (White, 2003).  Ras-GTPase-activating 
protein (rasGAP) keeps ras in an inactive state by interacting with phosphorylated p62-
Dok. The protein tyrosine phosphatase 1B (PTP1B) plays a key role in the feedback loop 
that dephosphorylates both the IR and p62 Dok, attenuating both PKB-mediated signaling 
and ras inactivation, thereby leading to a prolonged MAPK activation. PTP1B also 
attenuates Leptin signaling by dephosphorylating recruited Janus-2-kinase (JAK2) on the 
leptin receptor. Active JAK2 phosphorylates Signal Transducer and Activator of 
Transcription 3 (STAT3), which dimerizes and translocates to the nucleus to regulate gene 
expression. Abolishing signaling via JAK2 inhibits leptin feedback to the hypothalamus, 
which would normally elicit satiation and energy usage (Koren and Fantus, 2007). Insulin 
resistance occurs through perturbations in the phosphorylation status of signaling 
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molecules or increased degradation and decreased synthesis (Biddinger et al., 2008), 
leading to a chronic elevated state of blood insulin and glucose levels.   
PTP1B is encoded by the protein tyrosine phosphatase non-receptor type 1 gene (PTPN1) 
on chromosome 20q13 in humans – a region linked with insulin resistance, T2DM and 
obesity in human populations (Tsou and Bence, 2012). Although a ubiquitously expressed 
protein (Haj et al., 2003), hepatic PTP1B has been implicated in the negative regulation of 
insulin signaling (Ahmad et al., 1995). As a member of the large family of protein tyrosine 
phosphatases, it is involved in dephosphorylating key tyrosine residues on the IR and IRS 
proteins (Agouni et al., 2011). As a member of the protein tyrosine phosphatase 
superfamily, it contains the highly conserved (I/V)HCXXGXXR(S/T) active site motif, 
and is regulated by phosphorylation within key residues in its catalytic site (Barford et al., 
1994) (Fig. 1.5). 
Early studies in PTP1B knockout (PTP1B-/- KO) mice showed insulin hypersensitization 
with increased insulin receptor phosphorylation in liver and muscle tissue, compared to 
PTP1B+/+ mice (Elchebly et al., 1999). This was confirmed by later studies with KO mice 
that showed improved glucose homeostasis in muscle (Delibegovic et al., 2007) and liver 
(Delibegovic et al., 2009), and protection from diet-induced obesity (Klaman et al., 2000). 
Moreover, studies in diabetic (db/db) and insulin-resistant (ob/ob) mice with PTP1B-
targeting antisense oligonucleotides (ASOs) have shown a downregulation in the 
expression of genes normally associated with lipogenesis in adipose tissue and liver, 
improving glucose homeostasis (Waring et al., 2003) and increasing insulin-stimulated 
PKB activation as well as reducing hyperinsulinemia (Zinker et al., 2002). PTP1B-specific 
antisense oligonucleotide therapy in ob/ob hyperglycemic mice decreased mRNA levels by 
up to 50% in liver and adipose tissues (Rondinone et al., 2002, Waring et al., 2003, Zinker 
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et al., 2002).  In addition, Isis Pharmaceuticals are in Phase II studies with ISIS-PTP1BRx, 
an antisense formulation that selectively targets PTP1B, for T2DM patients that are 
currently on metformin and show poor control of glucose levels (clinicaltrials.gov 
identifier: NCT01918865). No data has as yet been published by Isis, therefore the 
outcome of this work is still unclear. The development of potent, orally bioavailable 
inhibitors for PTP1B has so far been hindered by the 94% active site identity it shares with 
its closely related phosphatase T-cell PTP (TCPTP), encoded by the closely related 
tyrosine-protein phosphatase non-receptor type 2 gene (PTPN2) (Tiganis, 2013). Whereas 
PTP1B knockout improves insulin sensitivity, TCPTP knockout mice die within eight 
weeks after birth from anemia and systemic inflammation (Barr, 2010). The highly 
charged, conserved nature of its active site also poses a barrier to the development of small 
molecule inhibitors (Barr et al., 2009). Taken together, evidence from antisense studies 
point towards a PTPN1 gene knockdown approach, since the high specificity of ASOs or 
siRNAs can be used to selectively target PTP1B, but not TCPTP in T2DM patients, as a 




 Structural domains and PTP1B regulation. Human PTP1B comprises of an N-terminal catalytic domain separated from the C-Figure 1.5
terminal endoplasmic reticulum (ER)-targeting domain by a proline (Pro)- rich domain. PTP1B is regulated via phosphorylation of tyrosine 
residues (Y152,Y153) by the insulin receptor (IR) kinase. Proline residues (P309-P310) interact with Src, Grb2, Crk and p130Cas. Sumoylation 
at lysine 335 (K335) inhibits its activity, whilst phosphorylation at serine 352 (S352) is cell-cycle dependent. Adapted from Yip et al. (2010). 
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 Aims and Objectives 1.12
The cell penetrating properties of the CPP Penetratin in a non-cytotoxic or cell-specific 
manner has been well documented. The abilities of its parent protein, the AntpHD, have 
been less well studied, although its ability to carry cargo in the form of p21 DNA into p53-
mutated tumors in vivo has been reported (Kousparou et al., 2012). Utilizing the non-
cytotoxic, cell penetrating AntpHD penetratin, as well as the endosomolytic analogue EB1 
previously developed by Lundberg et al. (2007), fused to the dsRNA binding domain(s) 
from human PKR, as in the studies by Eguchi et al. (2009) and Geoghegan et al. (2012) 
this project aims to clone, purify and characterize various recombinant proteins and 
investigate whether they can provide an efficient, non-cytotoxic platform for the delivery 
of therapeutically relevant siRNA in vitro.  
The first part of this project specifically aimed to: 
1. Clone, express and purify several AntpHD-DRBM1 and Pen-DRBM1 fusion 
proteins. These would be produced from a synthetic template comprised of the 
cDNA sequence for the Antennapedia homeodomain and the dsRNA binding motif 
1 from human PKR separated by a flexible glycine/serine linker.. Purified proteins 
were characterized by proteomic and mass-spectrometry analyses. 
2. Determine whether purified proteins retained their transducing properties, and their 
potential intracellular localization in a HEK293 and HepG2 cell lines by 
fluorescence studies in both live and fixed cells.  
3. Determine whether purified proteins retained their dsRNA binding potentials and 
subsequently assess their complex formation efficiencies. 
62 
 
4. Assess whether proteins can transduce the cell membrane when non-covalently 
complexed with cargo siRNA and induce GFP-specific gene knockdown in a 
HEK293-dEGFP reporter cell line.   
 
The primary sequence of Penetratin and the AntpHD indicated that the fusion proteins may 
have lacked endosomolytic abilities and were likely to be sequestered into endosomes 
should uptake involve endocytosis. Moreover, the affinity of the entire DRBD (DRBMx2) 
compared to the DRBM1 only was expected to yield stronger siRNA binding.   
The second part of this project therefore aimed to: 
1. Clone and purify several EB1-DRBMx2 and DRBMx2-EB1 constructs 
2. Purify the constructs Tat-DRBMx2, Penetratin-DRBMx2 and DRBMx2 used in a 
report by Geoghegan et al. (2012) and compare siRNA transduction between 
HEK293 and HepG2 cells. 
3. Assess the efficiency of siRNA-induced knockdown in a HEK293-dEGFP reporter 
cell and compare any differences in knockdown efficiency to the work done by 
Geoghegan et al. (2012) in an HPRT-expressing reporter cell line.  
4.  Attempt to assess PTP1B knockdown at the protein level in HepG2 cells following 





 Characterisation of Chapter 2.
recombinant proteins comprised of the 
AntpHD or Penetratin and DRBM1 





In order to generate a recombinant protein that can deliver therapeutically relevant siRNA 
in vitro, several constructs were designed to incorporate two different functional domains 
separated by a flexible linker. The cell-penetrating moiety was comprised of the entire 
Antennapedia homeodomain (AntpHD) from Drosophila melanogaster or its third helix, 
Penetratin (Pen), whilst its dsRNA binding moiety comprised of the dsRNA Binding Motif 
1 (DRBM1) from the human Protein Kinase R (PKR) (Appendix I). The Antennapedia 
homeodomain has been found to effectively translocate through the plasma membrane of 
eukaryotic cells and is able to mediate transduction of cargo molecules ranging from small 
proteins to antisense oligonucleotides (Derossi et al., 1996, Duchardt et al., 2007). 
Penetratin, the third helix in the homeodomain protein is the minimal sequence required for 
translocation (Joliot et al., 1991a). 
PKR is a human protein involved in the immune response by recognizing foreign dsRNA 
that has been introduced by a virus into the cell via its double-stranded RNA binding 
domain (DRBD) (Rice et al., 1985, Samuel et al., 1984). This domain is made up of two 
distinct motifs (Ryter and Schultz, 1998), DRBM1 and 2. Previous research by Heinicke et 
al. (2009) has shown that the first motif (DRBM1) binds dsRNA with higher avidity than 
the second motif (DRBM2). A study by Eguchi et al. (2009) has utilised  a recombinant 
protein (PTD-DRBD), comprised of the first DRBM fused to an HIV Tat peptide, to 
effectively mask the large negative charge of siRNA and prevent PTD inactivation, thereby 
enhancing the cellular uptake of attached siRNA. The potential of DRBM1 fused to a 
different CPP sequence (in this case the Antennapedia homeodomain and Penetratin) for 
siRNA delivery, is investigated here.   
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For this project’s purposes, the cDNA sequence corresponding to the AntpHD Isoform 1 
(canonical sequence) or Penetratin, was identified in GenBank (accession number 
M14496.1), and corresponded to the amino acid sequence of the homeobox (UniProt ID: 
P02833-1 [amino acids 297-356]). Sequence specific primers were designed for the 
specific amplification of its third helix, Penetratin, during subcloning by PCR. The cDNA 
sequence for the DRBM1 from human PKR was obtained from Genbank (accession 
number M35663.1), corresponding to amino acids 9-77 (Uniprot ID: P19525-1). These two 
domains were separated by a small, flexible linker (-GGGGSGGGGS-; [G4S]2) which was 
comprised of solubility-promoting, small amino acids (Arai et al., 2001, Trinh et al., 2004) 
to yield several constructs encoding for bifunctional proteins with the hypothetical 
properties of efficient siRNA binding and translocation through plasma membranes. A 
synthetic cDNA template corresponding to the AntpHD-linker-DRBM1 sequence supplied 
in a pBluescriptII vector was synthesized commercially (Epoch Biosciences, Missouri 
City, TX, USA). 
In order to facilitate expression and purification of fusion proteins, oligonucleotide primers 
were designed such that constructs could be PCR amplified and inserted by restriction 
enzyme cloning into a modified pET32-a, or pGEX-6P-2 vector (Appendix II). This 
approach enabled the generation of several constructs with either an N-terminal or C-
terminal affinity tags and different protease cleavage sites (as shown in Fig. 2.1), and was 
used in order to maximise the likelihood of identity of highly expressed, soluble fusion 
proteins. This was done in order to provide a 5’-His10 tag from the vector with a Factor Xα 
protease cleavage tag, or a 3’-end His6 tag with a TEV protease cleavage tag to each 
construct. Poly(His) and GST affinity tags were introduced to the in silico design of 
proteins in anticipation of increased solubility, efficiency of refolding, improved yield, and 
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minimisation of proteolytic degradation upon purification (Waugh, 2005). The terminus at 
which the affinity tag is attached is critical to the aforementioned parameters, however, the 
effects of each solubility tag at each of the two protein termini can only be assessed case-
by-case (Arnau et al., 2006a, Arnau et al., 2006b).  Subcloning the synthetic template into 
a pGEX-6P-2 vector plasmid provides a 5’-end GST tag with a downstream human 
Rhinovirus 3C Protease tag (commercially sold as Prescission Protease (PP), GE 
Healthcare) for its removal following purification (Fig. 2.1). The poly(His) tags allows 
purification by Immobilised Metal Affinity Chromatography (IMAC) over a Nickel 
nitroloacetic (Ni-NTA) column, whereas the GST tag allows purification by affinity 
chromatography over a Glutathione Sepharose 4b (GS4B) column. All sequences were 
assembled using Vector NTI Advance v11.5.2 software (Invitrogen, Paisley, UK) to 
construct six novel recombinant proteins:  
 C1.1: His10 – AntpHD-DRBM1 with a Factor Xα cleavage site 
 C2.1: His10 – Pen-DRBM1 with a Factor Xα cleavage site 
 C3.1: AntpHD-DRBM1 –His6 with a TEV protease cleavage site 
 C4.1: Pen-DRBM1 – His6 with a TEV protease cleavage site  
 C5.1: GST – AntpHD-DRBM1 with a Prescission protease cleavage site 
 C6.1: GST – Pen-DRBM1 with a Prescission protease cleavage site 
A c-myc epitope tag (as a sequence corresponding to the amino acid sequence (-
EQKLISEEDLN) was also added to the C-terminus of C5.1 and C6.1 by insert-specific 







 Schematic of the fusion protein constructs in a modified pET32-a Figure 2.1
vector (C1.1-C4.1) or a pGEX-6P-2 vector (C5.1-C6.1). They are comprised of either: 
the Antennapedia homeodomain (AntpHD); Penetratin; the dsRNA binding motif 1 of 
human protein kinase R (DRBM1) and either  an N-terminal 10xHistidine tag (His10), a C-
terminal 6xHistidine tag (His6) or an N-terminal  Glutathione-S-transferase (GST) tag. 
Protease cleavage sites for removal of affinity tags are indicated   (   ). TEV: Tobacco Etch 
virus protease; Prescission Protease: Rhinovirus 3C protease. Construct domains are 














 Schematic of the myc-tagged recombinant proteins with an N-terminus Figure 2.2
Glutathione S-transferase (GST) tag in a pGEX-6P-2 vector. They are comprised of 
either: the Antennapedia homeodomain (AntpHD); Penetratin; the dsRNA binding motif 1 
of human protein kinase R (DRBM1); a GST affinity tag  and a c-myc epitope tag with a 
Prescission protease cleavage site (indicated as     ). Construct domains are separated by a 










2.2.1 Subcloning the recombinant constructs into expression vectors 
Constructs were amplified by PCR with a Platinum pfx polymerase (Invitrogen, Paisley, 
UK), ligated into their corresponding plasmid vectors. Purified insert/vector DNA was 
used to transform the propagation strain XL1-Blue.Three colonies from each plate were 
screened directly for correct insert sizes by colony PCR. C1.1-C4.1 were analysed using 
insert-specific forward and reverse primers, while C5.1 and C6.1 were amplified with a 
vector-specific forward primer and an insert-specific reverse primer (Appendix I) and 
analysed by agarose gel electrophoresis. Expected sizes for inserts were 495 bp (C.1), 369 
bp (C2.1), 480 bp (C3.1), 351 bp (C4.1), 408 bp (C5.1) and 339 bp (C6.1) and 
corresponded to the bands on the gels (Fig 2.3). Sequences were confirmed by sequencing 
(GATC Biotech, London, UK) and analysed with Sequence Scanner v1.0 (Applied 
Biosystems) and Expasy Translate (Swiss Institute of Bioinformatics, Switzerland). C5.1 
was used as a template for the PCR amplification of the c-myc epitope tag at the 3’-end of 
pGEX-6P-2.C5.1/C6.1 with insert-specific reverse primers. Amplified fragments were 
used to transform XL1-Blue cells and band sizes were confirmed by colony PCR, agarose 









 Insert screening by colony PCR following ligation of insert in pET32-a Figure 2.3
(C1.1-C4.1) or pGEX-6P-2 (C5.1-C6.1). Expected size of bands for His10-AntpHD-
DRBM1 (C1.1), 0.49 kb; His10-Pen-DRBM1 (C2.1), 0.37 kb. AntpHD-DRBM1-His6 
(C3.1), 0.48 kb; and Pen-DRBM1-His6 (C4.1), 0.35 kb.  Bands at 0.4 kb and 0.34 kb 
correspond to AntpHD-DRBM1 (C5.1) and Pen-DRBM1 (C6.1) in pGEX-6P-2, 
respectively. M: 1 kb Marker. Gels were visualized under a UVP transilluminator. 
 
 
 PCR amplification of GST - tagged C5.1 and C6.1 with a c-myc epitope Figure 2.4
tag. A. PCR amplification of C5.1, C6.1, C5.1-myc and C6.1-myc. B. Colony screening by 
PCR of XL1-blue colonies following transformation with pGEX-6P-2-ligated inserts. C: 





2.2.2 Recombinant protein expression on a 50ml scale and purification by affinity 
chromatography 
Sequenced constructs generated in section 2.2.1 were used to transform 
BL21(DE3)pRARE cells in LB broth containing 100 µg/ml ampicillin and 34µg/ml 
chloramphenicol. Protein production was induced with Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and His-tagged proteins were purified by Immobilised Metal 
Affinity Chromatography (IMAC) on Nickel-Nitriloacetic acid (Ni-NTA) columns charged 
with 0.1M Ni2+ under native conditions. GST-tagged proteins were purified over a 
Glutathione sepharose 4B (GS4B) column. The total, flowthrough, wash and eluted 
fractions were collected and analysed by polyacrylamide gel electrophoresis (SDS-PAGE).  
His10-tagged C1.1 (His10-AntpHD-DRBM1) was found to be mostly insoluble and 
expressed at low levels by the expression host, as shown by the weak bands in the total (T) 
and flowthrough (FT) fractions, especially when compared to C2.1 (His10-Pen-DRBM1) 
(Fig. 2.5). C-terminally His6–tagged C3.1 was also insoluble, compared to C4.1, although 
similarly expressed at low levels (Fig. 2.6). The presence of protein in the eluted fractions 
of C2.1 and C4.1 (E1-E3) warranted further investigation by upscaling to purifications 
from 0.5L culture purifications.  
In contrast, GST-tagged proteins were expressed at higher levels compared to the His-
tagged proteins, as indicated by the difference in band intensities in the total fractions 
during SDS-PAGE analysis. In this instance, GST-AntpHD-DRBM1 (C5.1) is efficiently 
eluted form the Glutathione sepharose 4B (GS4B) column, compared to GST-Pen-DRBM1 
(C6.1) (Fig. 2.7 samples E1-E2). Isolation of the protein in the eluted fractions by 
competitive displacement with 10 mM reduced glutathione provided the foundations for 
further expression studies and the use of C5.1 as the template for the PCR amplification of 
72 
 
the c-myc epitope tag at the C-terminus  of these proteins. Myc-tagged GST-AntpHD-
DRBM1 (C5.1-myc) and GST-Pen-DRBM1-myc (C6.1-myc) were expressed at high 
levels (Fig. 2.8), although  faint bands by SDS-PAGE analysis in the eluted fractions of 
C6.1-myc indicated that the protein was isolated at very low levels and that it is mostly 
expressed as an insoluble protein. 
The presence of Pen-DRBM1 constructs (C2.1 and C4.1) mostly in the flowthrough 
fractions during purification over Ni-NTA or GS4B columns indicates that it is not 
sufficiently binding to the column and that methods for purification need further 
optimisation. To investigate whether increased yields of eluted C2.1 and C4.1 could be 
obtained from larger scale cultures under the same conditions, there proteins were purified 








 Small-scale expression analysis of His10 constructs C1.1 and C2.1 by Figure 2.5
SDS-PAGE. A. Construct C1.1; B. Construct C2.1. 20 l samples were analysed by SDS-
PAGE on a 12% w/v acrylamide gel. Fractions from the Ni-NTA purification are shown: 
T, Total fraction (in 6 M Urea); FT, Flowthrough; W, Wash, E1-E3, Eluates 1-3. M, 
molecular weight marker. Arrows indicate the expected molecular weight of fusion 
proteins in kDa. 15 l sample loaded  per well.The gel was stained with Coomassie blue 










 Small-scale expression analysis of His6 constructs C3.1 and C4.1 by Figure 2.6
SDS-PAGE. A. Construct C3.1; B. Construct C4.1. 20 l samples were analysed by SDS-
PAGE on a 12% w/v acrylamide gel. Fractions from the Ni-NTA purification are shown: 
T, Total fraction (in 6 M Urea); FT, Flowthrough; W, Wash, E1-E3, Eluates 1-3. M, 
molecular weight marker. Arrows indicate the expected molecular weight of fusion 
proteins in kDa. 15 l sample loaded  per well The gel was stained with Coomassie blue 










 Small-scale expression analysis of GST-fusion constructs C5.1 and C6.1 Figure 2.7
by SDS-PAGE. A. Construct C5.1; B. Construct C6.1. 20 l samples were analysed by 
12% SDS-PAGE on a 12% w/v acrylamide gel. Fractions from the Ni-NTA purification 
are shown; T, Total fraction (in 6 M urea); FT, flowthrough; W, Wash, E1-E2, Eluates 1-2. 
M, molecular weight marker (kDa). 20l sample loaded  per well The gel was stained with 



















 Small-scale expression analysis of GST-fusion constructs C5.1-myc and Figure 2.8
C6.1-myc by SDS-PAGE. A. Construct C5.1-myc; B. Construct C6.1-myc. 20 l samples 
were analysed by 12% SDS-PAGE on a 12% w/v acrylamide gel. Fractions from the Ni-
NTA purification are shown; T, Total fraction (in 6 M urea); FT, flowthrough; W, Wash, 
E1-E2, Eluates 1-2. M, molecular weight marker (kDa). 20 l sample loaded  per well The 






2.2.3 Poly(His)- tagged protein purifications from 500 ml E.coli cultures under 
native conditions 
Following small scale expression tests on 50ml cultures, expression testing on a 500ml 
scale aimed to estimate His-tagged protein concentrations at each step of the purification 
process and to provide some insight as to the role of each tag with regards to solubility or 
expression enhancement. Prior His-tagged protein analysis had indicated that
 
AntpHD-
DRBM1 (C1.1 and C3.1) was both insoluble and expressed at low levels, an observation 
supported by purifications on 50 ml and 500 ml scales under the same conditions for C1.1 
(Fig. 2.9 A). Larger scale cultures for C3.1 were not pursued due to the presence of 
contaminating nucleic acids in the flowthrough fractions.  
Although SDS-PAGE gel band intensities signified that C1.1 was well expressed, it was 
mostly found in the Total (crude lysate) and the Flowthrough (cleared lysate) fractions and 
did not bind to the Ni-NTA column efficiently. Conversely, His10-Pen-DRBM1 (C2.1), 
which was expressed as a soluble fraction on a 50ml scale, was expressed at low levels and 
at low purities under native conditions. There was little protein isolated in the eluted 
fractions (Fig. 2.9 B).  
C-terminus His6-tagged Pen-DRBM1 (C4.1) was expressed at higher levels that its N-
terminally-tagged counterpart and was successfully eluted from the column. However, the 
banding pattern with vertical streaking in the eluted fraction lanes (E1-E3) pointed towards 
nucleic acid contamination during purification (Fig. 2.9 C) and therefore necessitated the 






 Expression analysis of C1.1, C2.1 and C4.1 from 0.5L cultures by SDS-Figure 2.9
PAGE. A. Construct C1.1; B. Construct C2.1; C. Construct C4.1. Samples were analysed 
by SDS-PAGE on as 12% w/v polyacrylamide gel. Fractions from the Ni-NTA purification 
are shown; T, Total fraction (in 6 M urea); FT, flowthrough; W, Wash, E1-E3, Eluates 1-3. 
M, molecular weight marker (kDa). 15 l sample loaded  per well The gel was stained with 







2.2.4 GST-tagged protein purifications from 500 ml E.coli cultures 
Having successfully purified GST-tagged C5.1, C5.1-myc, C6.1 and C6.1-myc, from 50ml 
E.coli cultures, protein purification was scaled to 500 ml. Both C5.1 and C5.1-myc were 
isolated with 80% purities following batch binding and gravity flow affinity purification 
over a GS4B column (Fig. 2.10). The induction of protein expression from 
BL21(DE3)pRARE with 0.5 mM IPTG was evident in the induced (I) fraction lanes (Fig. 
2.10 and 2.11, Lane I) compared to the uninduced fraction lanes (U). In the case of C5.1 
and C5.1-myc, there was little protein lost in the flowthrough (FT) and wash (W) fractions. 
Both proteins were successfully eluted from the GS4B column (E1-E3) by competitive 
displacement with 10 mM reduced glutathione in GST elution buffer (containing 500 mM 
NaCl and 10 mM DTT). Pooled eluate concentration was analysed by Nanodrop at A280 
using each protein’s predicted extinction coefficient (ε) and molecular weight (MW) 
(Appendix I). As a method, measuring the spectrophotometric absorbance of protein at 
A280 by Nanodrop provides reliable results with 98% accuracy, provided that samples are 
purified. Measurements are done based on the number of tryptophan and tyrosine residues 
and disulphide (cysteine-cycteine) bonds. Absorptivity is calculated based on Beer’s Law 
(List of formulae, p18). In the case of uncharacterised proteins, however, concentration 
assessment by Nanodrop may not be as accurate as the Bicinchoninic acid (BCA) assay, 
although it eliminates the necessity for standard curve interpolation. 
Pooled eluate concentrations for C5.1 and C5.1-myc were 3.98 mg/ml (with a final yield of 
11.7 mg) and 3.53 mg/ml (with a final yield of 10.2 mg), respectively (Table 2.1). In 
contrast, most GST-tagged C6.1 and C6.1-myc, were lost in the FT fractions (Fig. 2.11 A 
and B). Soluble C6.1 and C6.1-myc protein bound to the GS4B column were eluted, 
although with lower purities and yields in comparison to C5.1 and C5.1-myc. Pooled eluate 
80 
 
concentrations for C6.1 and C6.1-myc were 0.90 and 0.95 mg/ml, respectively. In order to 
cleave the GST tag with PP at a 1:5 molar ratio to total protein, according to the protocol 
developed by Barr et al. (2009), pooled eluates were buffer exchanged first into 
equilibration buffer (containing 200 mM NaCl and 2 mM DTT) to remove glutathione ions 
and decrease the molar concentrations of DTT and salt. This was done as they were 
incompatible with enzymatic activity at 4°C. The subsequent decrease in the ionic strength 
of the buffer resulted in a marked decrease in protein yields: C5.1 decreased by 19.4 %, 
C5.1-myc by 24.8%, C6.1 by 57.4% and C6.1-myc by 62.6% (Table 2.1).  
Further yield losses were observed upon tag cleavage by PP at a 1:5 ratio to protein in GST 
equilibration buffer. Protein desalting into 1xPBS resulted in further yield losses;  C5.1 
decreased by 51.8%, C5.1-myc by 14.9%, C6.1 by 46.6% and C6.1-myc by 57.4%, 
compared to yields in equilibration buffer before tag cleavage (Fig. 2.12 and 2.13).  
Our multi-step purification strategy (purification, buffer exchange, protease cleavage and 
desalting) resulted in overall losses of 61.1%, 36.0%, 77.2% and 84.1% for C5.1, C5.1-
myc, C6.1 and C6.1-myc, respectively (Table 2.1). Final yields for C5.1, C5.1-myc, C6.1 





 Expression analysis of GST-tagged constructs C5.1 and C5.1-myc from Figure 2.10
0.5L cultures by SDS-PAGE.  A. Construct C5.1; B. Construct C5.1-myc. Samples were 
analysed by SDS-PAGE on a 12% w/v acrylamide gel. Fractions from the GS4B 
purification are shown: U, Uninduced fraction; I, Induced fraction T, Total fraction (in 6 M 
Urea); FT, Flowthrough; W, Wash, E1-E3, Eluates 1-3. M, molecular weight marker. 
Arrows indicate the expected molecular weight of fusion proteins in kDa. 20 l sample 
loaded  per well. The gel was stained with Coomassie blue (0.5% w/v) and visualized on a 







 Expression analysis of GST-tagged constructs C6.1 and C6.1-myc from Figure 2.11
0.5L cultures by SDS-PAGE. A. Construct C6.1; B. Construct C6.1-myc. Samples were 
analysed by SDS-PAGE on a 12% w/v acrylamide gel. Fractions from the GS4B 
purification are shown: U, Uninduced fraction; I, Induced fraction T, Total fraction (in 6M 
Urea); FT, Flowthrough; W, Wash, E1-E3, Eluates 1-3. M, molecular weight marker. 
Arrows indicate the expected molecular weight of fusion proteins in kDa. 15 l sample 
loaded  per well. The gel was stained with Coomassie blue (0.5% w/v) and visualized on a 







 0.5L expression analysis of C5.1 and C5.1-myc in 1xPBS following Figure 2.12
GST-tag cleavage, by SDS-PAGE. A. Construct C5.1; B. Construct C5.1-myc.  Samples 
were analysed by SDS-PAGE on a 12% w/v acrylamide gel. Fractions from the GS4B 
purification and tag cleavage by Prescission protease are shown: FT, Flowthrough; E1-E4, 
Eluates 1-4, E5, Eluate 5. M, molecular weight marker. Arrows indicate proteins present in 
each fraction. PP, Prescission protease. 20 l sample loaded  per well.  Gels were stained 








 0.5L expression analysis of C6.1 and C6.1-myc in 1xPBS following Figure 2.13
GST-tag cleavage, by SDS-PAGE. A. Construct C6.1; B. Construct C6.1-myc. Samples 
were analysed by SDS-PAGE on a 12% w/v acrylamide gel. Fractions from the GS4B 
purification and tag cleavage by Prescission protease are shown: FT, Flowthrough; E1-E4, 
Eluates 1-4, E5, Eluate 5. M, molecular weight marker. Arrows indicate proteins present in 
each fraction. PP, Prescission protease. 20 l sample loaded  per well. The gel was stained 







Table 2.1 Yield analysis of GST- tagged fusion proteins obtained during purification from 0.5L E. coli cultures.  Yield represents 
the total protein found in eluted samples at each step of the purification process. % change represents change in yield between each 
purification step. Overall % change represents the change in yield from the point of elution to the point of buffer-exchange into 1xPBS after 
GST tag removal by Prescission protease. n=1. 





exchange into  in 
equilibration buffer  (mg) 
Change in yield 
(%) 
Yield in 1xPBS following 




Overall % change  
(Step 1      3) 
C5.1 11.7 9.4 -19.4 6.6 -51.8 -61.1 
C5.1-myc 10.2 7.7 -24.8 4.6 -14.9 -36.0 
C6.1 1.8 0.8 -57.4 0.4 -46.6 -77.2 
C6.1-myc 2.5 1.0 -62.6 0.4 -57.4 -84.1 
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2.2.5  Large scale purifications of GST-tagged C5.1, C6.1-myc, C6.1 and C6.1-myc  
Loss of protein yields from 500 ml purifications indicated that the process of purifying 
GST-tagged proteins needed optimization. The long purification protocol adopted with 
0.5L cultures, comprised of a sequential buffer exchange to achieve GST tag cleavage and 
desalting, had proved detrimental to protein yields. C5.1 and C5.1-myc, which had 
exhibited fewer % losses, were up-scaled to 4L cultures and purified, while C6.1 and C6.1-
myc from 3L cultures. The purification strategy was adjusted to reflect changes in volumes 
and the slow kinetics between the GST tag and the resin. To minimise yield losses, a batch-
binding strategy with PP and on-column cleavage was adopted. Cleared lysates and resin 
were batch-bound for at least one hour at 4°C before they were applied to the column; the 
sepharose matrix with bound protein was incubated with PP at a 5:1 ratio of enzyme to 
estimated protein yield. Following GST tag removal, proteins were eluted from the column 
by gravity flow affinity chromatography into GST binding buffer. A final elution step with 
glutathione-containing elution buffer released the protease, cleaved tag and any uncleaved 
protein that remained on the column (Fig. 2.14 and 2.15, Lane E5). Fractions containing 
purified protein (FT2, E1-E4) were pooled and buffer exchanged into 1xPBS. SDS-PAGE 
analysis indicated that C5.1 was isolated mostly in fractions E1-E4, with very little protein 
being lost from the column in the FT2 fraction, while C5.1-myc, C6.1 and C6.1-myc were 
isolated mostly in the FT2-E2 fractions. Uncleaved C5.1 and C6.1 are also visible in the E5 
fraction. SDS-PAGE results are representative of 2 independent experiments (n=2). Final 
yields in 1xPBS for C5.1, C5.1-myc from 4L cultures were 35.5 mg and 64.35 mg, 
respectively, while final yields for C6.1 and C6.1myc from 3L cultures were 5.3 mg and 




 4L expression analysis of C5.1 and C5.1-myc following GST-tag Figure 2.14
cleavage, by SDS-PAGE. A. Construct C5.1; B. Construct C5.1-myc.  Samples were 
analysed by SDS-PAGE on a 12% w/v acrylamide gel. Fractions from the GS4B 
purification and tag cleavage by Prescission protease are shown: FT2, Flowthrough 2; E1-
E4, Eluates 1-4, E5, Eluate 5. M, molecular weight marker. Arrows indicate proteins 
present in each fraction. PP, Prescission protease. 20 l sample loaded  per well. The gel 








 3L expression analysis of C6.1 and C6.1-myc following GST-tag Figure 2.15
cleavage, by SDS-PAGE.  A. Construct C6.1; B. Construct C6.1-myc.  Samples were 
analysed by SDS-PAGE on a 12% w/v acrylamide gel. Fractions from the GS4B 
purification are shown: FT2, Flowthrough 2; E1-E4, Eluates 1-4, E5, Eluate 5. M, 
molecular weight marker. Arrows indicate proteins in the E5 fraction. PP, Prescission 
protease. 20 l sample loaded  per well. The gel was stained with Coomassie blue (0.5% 





Table 2.2  Large-scale protein purification yields for C5.1, C5.1-myc, C6.1 and C6.1-myc. The GST tag was cleaved by Prescission 
protease and eluates were concentrated in an Amicon Ultra-15 column before buffer exchange into 1xPBS/10% (v/v) glycerol. Results are 
representative of 2 independent experiments (n=2). 
Protein Protein yields (mg) or concentrations (mg/ml) after each purification step 
Eluates after GST 




Concentration in GST 
binding buffer 
(mg) 













C5.1 45.1 36.4 -19.30% 35.5 -2.6% -21.3% 
C5.1-myc 118.6 97.4 -17.89% 64.4 -33.9% -45.7% 
C6.1 5.0 7.5 +51.21% 5.3 -29.7% +6.3% 
C6.1-myc 8.8 3.0 -65.90% 3.9 +22.1% -65.9% 
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2.2.6  C5.1 and C5.1-myc stability assessment and detection by western blotting 
In order to assess the stability of proteins prior to further in vitro studies, purified C5.1 and 
C5.1-myc in PBS were characterised by SDS-PAGE before and after thawing. Stability 
was assessed by centrifugation at 16,100 x g and by immunoblot with an anti-myc 
antibody (Fig 2.16). The difference in band intensity before and after centrifugation 
indicated that at least some C5.1 and C5.1-myc protein had precipitated, even when equal 
amounts of protein were loaded on an SDS-PAGE gel (20 µg).  
 C6.1 and C6.1-myc were also assessed by SDS-PAGE following purification, but 
appeared to have precipitated following buffer exchange into PBS/10% (v/v) glycerol (Fig 
2.16 A). SDS-PAGE and western blot analysis (Fig. 2.16 C) of C5.1 and C5.1-myc with an 
anti-myc antibody was done to confirm expression and integrity of the myc-epitope tag, as 
well as to validate the anti-myc antibody prior to subsequent immunofluorescence studies 
with C5.1-myc. Final yields were 33.8 mg, 36.6 mg, 0.3 mg and 0.7 mg for C5.1, C5.1-








 Stability analysis by centrifugation and immunoblot of purified C5.1, Figure 2.16
C5.1-myc, C6.1 and C6.1-myc in 1xPBS. A. Proteins C5.1 (Lane 1) and C5.1-myc (Lane 
2) remain soluble in 1xPBS whilst C6.1 (Lane 3) and C6.1-myc (Lane 4) precipitate 
following buffer exchange. B. C5.1 and C5.1-myc (Lanes 1-2) centrifuged at 16,100 x g 
for 30 minutes at 4°C remain stable with little loss of protein. 20 µg protein were analysed 
on a 12% w/v SDS-PAGE gel. M; Marker. C. Immunoblot analysis on 10 µg C5.1 (Lane 
1) and C5.1-myc (Lane 2) with an anti-myc primary antibody and an HRP-conjugated 
secondary antibody. 20 µg total protein loaded. Bands were detected by 
chemilluminescence on a UVP Auto Chemi Darkroom Imaging system. 
 
Table 2.3 Final concentrations and yields of cleaved proteins. Yields were obtained 
following purification of proteins from large scale cultures in 1xPBS, following 
centrifugation at 4°C and 16,100 x g.  
 
Protein Concentration (mg/ml) Final yield (mg) 
C5.1 1.13 33.8 
C5.1-myc 1.22 36.6 
C6.1 0.075 0.30 
C6.1-myc 0.175 0.70 
A. B. C. 
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2.2.7  Mass and purity determination for C5.1 and C5.1-myc by Mass Spectroscopy 
Knowledge of the exact molecular mass and biochemical parameters of a potential 
therapeutic molecule is crucial for pre-clinical evaluations in vitro. Before proceeding with 
localisation experiments in HEK293 cells, Matrix-Assisted Laser Desorption/Ionization 
Time-Of-Flight Mass Spectrometry (MALDI-TOF) analysis was performed after positive 
ionization of the 10 g C5.1 in formic acid. The mass to charge ratio (m/z) spectrum 
showed a dominant peak at 17,391 atomic mass units (amu) (Fig. 2.17), in good 
accordance to the 17,401 Da value predicted by bioinformatic analysis carried out by the 
Expasy ProtParam online tool (Gasteiger E., 2005). A larger peak at m/z 17,620 indicated 
the formation of a protein species that was approximately 229 Da larger than the 
predominant species. It is not known whether this species the result of post-translational 
modifications or nucleic acid contamination. 
The intact protein mass of C5.1 and C5.1-myc was further assessed by Electrospray 
Ionisation-Time-of-Flight Mass Spectrometry (ESI-QTOF MS). Electrospray ionisation is 
known as a "soft" ionisation method as the sample is ionised by the addition (or removal) 
of a proton, with very little extra energy remaining to cause fragmentation of the sample 
ions and has a mass accuracy of 99.9%. Each peak represents the intact protein molecule 
carrying a different number of charges (in this case, H+). The deconvoluted spectrum of 
C5.1 in positive ionisation mode produced a dominant peak at 17,402.75 amu, consistent 
with our predicted MW of 17,401 Da with few, larger impurities (Fig. 2.18 A). 
Consistent with a predicted MW of 18,701 Da, the m/z spectrum for C5.1-myc produced a 
dominant peak at 18,702.31 amu with smaller impurities, which could be attributed to 
phosphate groups in the buffer (Fig. 2.18 B). 
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MALDI-TOF was performed at the Proteomics facility, UCL, while ESI-QTOF was 
performed at the Structural Genomics Consortium (SGC), University of Oxford. 
 
 Intact C5.1 molecular weight assessed by MALDI-TOF. The dominant Figure 2.17
ion peak shows the actual mass of C5.1 to be 17,391 Da, in good accordance with the 
expected molecular mass of 17,401 Da. The m/z ratio is the mass-to-charge ratio measured 






 Deconvoluted ESI-QTOF spectra for C5.1 (A) and C5.1-myc (B). Figure 2.18
Purified proteins were positively ionised in formic acid and assessed for molecular weight 
and purity. A. The dominant ion peak at 17,402.75 Da represents the actual mass of C5.1 
(expected molecular mass,17,401 Da). B. C5.1-myc shows a dominant peak at 18,702.31 
Da (expected molecular mass of 18,701 Da).The m/z ratio is the mass-to-charge ratio 






2.2.8 C5.1-myc shows a dose-dependent intracellular localisation in HEK293 and 
HepG2 cells 
Following protein characterisation, it was important to ascertain whether C5.1-myc  has the 
potential for intracellular transduction. Localisation studies by indirect immuno-
fluorescence with an anti-myc antibody were therefore performed. These subsequently 
allowed the determination of the protein’s intracellular localisation upon internalisation. 
For this purpose, human embryonic kidney 293 (HEK293) cells were used; their size (20-
30 µm), division time (70% confluency within 48 hours of passaging), robust morphology, 
as well as ease of manipulation as a transfection host, make them an excellent mammalian 
cell vector for translocation/transduction experiments (Thomas and Smart, 2005). The 
human hepatocellular carcinoma (HepG2) cell line on the other hand, is an epithelial cell 
line which endogenously expresses protein tyrosine phosphatase 1B (PTP1B). PTP1B 
dephosphorylates the insulin receptor (IR), thereby negatively regulating IR signalling and 
is a potential target for T2D (Asante-Appiah and Kennedy, 2003, Cheng et al., 2002, 
Drake and Posner, 1998, Goldstein et al., 1998). This cell line has also been successfully 
used in other cell penetrating peptide studies (El-Andaloussi et al., 2011).   
Purified C5.1-myc was incubated with seeded, adherent cells for either 2 or 24 hours at 3 
different concentrations. The protein’s c-myc epitope tag was detected with an anti-myc 
antibody (clone 4A6, Millipore) and a fluorescein thiocyanate (FITC) - labelled secondary 
antibody following fixation/permeabilisation with 4% Paraformaldehyde/0.2% Triton-X. 
Nuclei were stained with ToPro3. Finally, cells were visualized with a Leica SP2 confocal 
microscope. Indirect immunofluorescence of C5.1-myc in HEK293 cells showed a dose-
dependent and time-dependent translocation at both timepoints (Fig 2.19, enlarged version 
in Appendix I.4).  
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Poor translocation was observed after 2-hour incubation even at the lowest molar 
concentration assayed (0.1 µM) (Fig. 2.19 A), as the protein at this point was localized 
primarily on the exterior face of the plasma membrane. At 1.0 µM, the protein was seen to 
translocate into cells more efficiently without altering cell morphology, with a mixture of 
diffuse and punctate distributions (Fig. 2.19 B). Similar distribution patterns were observed 
at 10.0 µM concentrations, with cell morphology remaining unaffected following 
treatment, compared to the mock control (Fig. 2.19 C). Conversely, there was little 
evidence of translocation at the 0.1 µM concentration after 24-hour incubation (Fig. 2.19 
D), possibly due to the low protein concentration. Protein internalization at this time-point 
appeared to be dose-dependent, with translocation and increased extra-cellular aggregation 
of the protein increasing between 1.0 µM and 10.0 µM (Fig. 2.19 E-F). Entrapment into 
endosomal vesicles upon transduction was also observed, which appeared to be dose-
dependent at both time-points.  
Qualitative observations from indirect immunofluorescence experiments with C5.1-myc at 
0.1 and 1.0 µM concentrations in fixed HepG2 cells after 2 and 24-hour incubations also 
pointed towards a dose-dependent and time-dependent uptake mechanism. After a 2-hour 
incubation, C5.1-myc at 0.1 µM concentration localized primarily on the outer membrane 
fold (Fig. 2.20 A). Internalized protein distribution was mostly diffuse at both 0.1 and 1.0 
µM concentrations, with some evidence of endosomal entrapment (Fig. 2.20 A-B). At 24 
hours, the protein was effectively translocating into cells at both 0.1 µM and 1.0 µM 
concentrations with evidence of perinuclear endosomal entrapment, typical of late 




 Intracellular localisation of C5.1-myc in fixed HEK293 cells is time-dependent and dose-dependent. Cells were incubated Figure 2.19
with 0.1 µM, 1.0 µM or 10.0 µM protein for either 2 or 24 hours, permeabilised, and fixed. Protein was detected with an anti-myc primary 
antibody and a FITC-labelled secondary antibody. Cells were visualized with a TCS SP2 Leica confocal microscope under a 63x objective. 
Nuclei were counterstained with Topro3.  A. 0.1 µM, 2 hours; B. 1.0 µM, 2 hours; C. 10.0 µM, 2 hours. D. 0.1 µM, 24 hours; E. 1.0 µM, 24 




 Intracellular localization of C5.1-myc in fixed HepG2 cells is time-Figure 2.20
dependent and dose-dependent. Cells were incubated with 0.1 µM, 1.0 µM or 10.0 µM 
protein for either 2 or 24 hours, permeabilized, and fixed. Protein was detected with an 
anti-myc primary antibody and a FITC-labelled secondary antibody. Cells were visualized 
with a TCS SP2 Leica confocal microscope under a 63x objective. Nuclei were 
counterstained with Topro3.  A. 0.1 µM, 2 hours; B. 1.0 µM, 2 hours; C. Mock control 
(PBS),  2 hours. D. 0.1 µM, 24 hours; E. 1.0 µM, 24 hours; F. Mock control (PBS), 24 
hours. Scale bar: 15 µm (upper panels) and 47.6 µm (lower panels) . Insets show magnified 





2.2.9 Assessing the potential of C5.1to deliver siRNA in live HepG2 cells with a 
lectin counterstain  
In order to address the issue of potential artefacts in fixed HepG2 cells and the potential of 
C5.1 to effectively complex with and deliver siRNA intracellularly, a non-specific siRNA 
oligomer fluorescently labelled with fluorescein (FITC) (Block-iT Fluorescent oligo, Life 
Technologies) was complexed at a 1:50 molar ratio with C5.1. Cells were incubated with 
complexes for one hour in the absence of a membrane counterstain (Fig. 2.21) and for two 
hours with a wheat germ agglutinin (WGA)-dsRed counterstain. WGA-dsRed is a 38 kDa 
cationic lectin which selectively binds sialic acids and N-acetylglucosaminyl residues on 
the cell membrane and can therefore be used counterstaining live cell localisation assays 
(Wright et al., 1984a, Wright et al., 1984b). Assuming 98% siRNA encapsulation (van 
Asbeck et al., 2013), C5.1 localized intracellularly following a one hour incubation with 
HepG2 cells (Fig. 2.21 A), compared to the siRNA control (Fig. 2.21 B). The somewhat 
aggregated distribution around the cell membrane necessitated the use of a membrane-
specific stain. 
The lack of a membrane counterstain was addressed using WGA-dsRed at a final 
concentration of 1mg/ml for 30 minutes (Fig. 2.22). Confocal analysis of live HepG2 cells 
indicated that WGA-dsRed localization was not limited to the membrane and that instead, 
intracellular localisation occurred within distinct vesicular structures, possibly endosomes. 
Complexed C5.1-siRNA-FITC was observed in the cytoplasmic compartment with a 
mostly diffuse distribution interspersed with vesicles, thereby demonstrating C5.1-
mediated siRNA transduction. Some overlap in the FITC-dsRed signals within cells 
pointed towards a common uptake pathway.  
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When cells were counterstained with 2.5 mg/ml WGA-dsRed for 10 minutes, the lectin 
localized primarily in the perinuclear region and in distinct punctae within the cytoplasm 
(Fig. 2.23). Conversely, C5.1-siRNA uptake resulted in a diffuse cytoplasmic distribution 
characterised by the absence of endosomal structures, which pointed towards a non-
endocytic mechanism of uptake (Fig. 2.23). 
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 C5.1-siRNA localization in live HepG2 cells in the absence of a membrane counterstain. C5.1 was co-incubated with 30 Figure 2.21
pmol siRNA-fluorescein (FITC) at a 50:1 molar ratio for one hour and applied to HepG2 cells to a final siRNA concentration of 50 nM. A. C5.1-
siRNA-FITC, B. siRNA only. Scale bar, 22 M (upper panels) and 11.7 M (lower panels). 
A. 
B. 








 Intracellular localization of C5.1-siRNA in live HepG2 cells Figure 2.22
counterstained with 1 mg/ml wheat germ agglutinin (WGA)-dsRed for 30 minutes. 
C5.1-siRNA complexes were allowed to form by co-incubation and incubated with HepG2 
cells for one hour at 37°C. WGA-dsRed, used as a counterstain localizes within distinct 
vesicular structures. Cells were visualized with a TCS SP2 Leica confocal microscope. 






 Intracellular localization of C5.1-siRNA-FITC in live HepG2 counter-Figure 2.23
stained with 2.5 mg/ml wheat germ agglutinin (WGA)-dsRed for 10 minutes. C5.1-
siRNA complexes were allowed to form by co-incubation and incubated with HepG2 cells 
for two hours at 37°C. WGA-dsRed, used as a counterstain, localizes mainly around the 





2.2.10 C5.1 shows diminished siRNA binding through the DRBM1 
The transducing abilities of C5.1-myc were assessed in vitro, with the protein exhibiting a 
time-dependent and dose-dependent translocation into HEK293 and HepG2 cells. It 
seemed essential to also assess the dsRNA binding abilities conferred to the fusion protein 
by the C-terminal DRBM1 moiety. The Electrophoretic Mobility Shift Assay (EMSA) is a 
sensitive method to assess protein-nucleic acid interaction by observing a gel shift on 
either a highly concentrated agarose gel (typically 3-5% w/v) or a dilute native PAGE gel 
(typically 5-6% w/v polyacrylamide). It is based on the premise that the electrophoretic 
mobility shift of protein-bound nucleic acid is less than that of free nucleic acid (Hellman 
and Fried, 2007). Eguchi et al. (2009), was able to show that the DRBM1 domain from 
human PKR in the PTD-DRBD fusion protein could bind 21-23nt dsRNA sequences in a 
sequence independent manner, with high avidity at a 4:1 ratio. To test whether these results 
could be replicated with C5.1, excess protein was allowed to form a complex with 1 µM 
siRNA (Stealth siRNA, Invitrogen, Paisley, UK) at various molar ratios, for 30 minutes at 
4°C and assessed by EMSA on a 6% native PAGE gel. The gel was stained with Ethidium 
bromide (EtBr) and analysed under UV light. At a 2:1 and 4:1 and 8:1 molar ratios, only a 
partial gel shift was observed, indicative of insufficient binding by the DRBM1. The 
protein-siRNA complexes aggregated at the top of the wells and failed to migrate towards 
the anode. Fluorescence under UV light was expected only for Ethidium bromide-stained 
nucleic acid; instead, the negative control protein (C5.1 only) was seen to fluoresce (Fig. 
2.24). Coupled with electrophoretic mobility results by Geoghegan et al. (2012) and 
recombinant proteins comprised of the DRBM1 coupled to various CPPs, new constructs, 





 Electrophoretic mobility shift assay with C5.1 and siRNA at various Figure 2.24
molar ratios. Complexes were allowed to form in PBS at 4°C and analysed by 





Utilization of the endogenous RNAi pathway as a post-translational gene modification 
strategy has been greatly investigated as a routine tool to regulate gene expression. In vivo, 
RNAi has the potential as a therapeutic intervention in genetic diseases, where single 
nucleotide polymorphisms in mutant allele transcripts exist (Whitehead et al., 2009, Wen 
and Meng, 2014). Moreover, RNAi has therapeutic potential in viral diseases, such as 
Hepatitis C, whose single stranded RNA genome that encodes for a polyprotein is an 
attractive target (Aagaard and Rossi, 2007). The major hurdle in the utilization of RNAi is 
systemic and targeted delivery, as siRNA’s intrinsic physicochemical properties (large 
anionic charge, susceptibility to degradation) prevent it from crossing the cellular 
membrane readily, and thus render it a poor pharmaceutical candidate. Viral siRNA 
vectors are unsuitable for siRNA delivery, due to concerns over immunogenicity and 
insertional mutagenesis whereas lipid-based strategies in vivo have shown rapid liver 
clearance and lack of tissue specificity. Cell penetrating peptides, such as the 
Antennapedia homeodomain (AntpHD) and penetratin, represent a class of protein-based 
delivery vectors, whose low cytotoxicities and versatile cargo-transduction have the 
potential to be suitable delivery vector alternatives. Although the AntpHD has been 
investigated as a dsDNA vector to restore p21 expression in p53-mutated cancers, with 
encouraging results in vivo (Kousparou et al., 2012), its potential as a siRNA vector has 
not been investigated. Penetratin, on the other hand, has been covalently linked to siRNA 
(Davidson et al., 2004, Muratovska and Eccles, 2004) inducing potent gene knockdown. 
Prior to this study, non-covalent siRNA conjugation strategies with the AntpHD have not 
been investigated, whereas this strategy with Penetratin has only been reported by 
Lundberg et al. (2007) and Geoghegan et al. (2012) while a seminal study by Eguchi et al. 
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(2009) had induced potent gene knockdown in a variety of adherent and primary cell lines 
using a recombinant construct comprised of the Tat domain fused to the DRBM1 (PTD-
DRBD; Tat-Tat-HA-Tat). 
This chapter therefore aimed to investigate whether the AntpHD and Penetratin, expressed 
as recombinant proteins with the DRBM1 from human PKR, could be used as siRNA 
vectors, and whether the non-covalent strategy of complex formation would produce 
similar results to the study by Eguchi et al. (2009) in a HEK293 and HepG2 cell lines.  
We have chosen to express these vectors as recombinant proteins from a bacterial cell 
system following heterologous protein induction by IPTG, similar to the methodology 
adopted by Eguchi et al. (2009). In this case, it was important to obtain soluble protein 
under native conditions by recombinant methods and affinity chromatography, as refolding 
insoluble structures back to their precise, three-dimensional shape is often a lengthy 
process and often leads to decreased yields (Arakawa et al., 2007). Affinity tags, such as 
the GST or poly(His) tags often enhance the solubility of recombinant proteins and aid 
purification under native or denaturing conditions (Waugh, 2005). Although His6-tags have 
been used to purify proteins at high yields and purities, longer (His10) tags have also been 
used successfully (Grisshammer and Tucker, 1997). Constructs obtained either an N-
terminal or C-terminal Poly(His) tag (~1 kDa) (Bornhorst and Falke, 2000)  by insertion in 
a modified pET32a vector, or Glutathione S-transferase (GST) tag (26 kDa) (Smith and 
Johnson, 1988) by insertion into a pGEX-6P-2 vector,  for affinity chromatography 
purification. The purification methodology adopted allowed the assessment of a) the 
expression state of proteins when purified under native conditions from 50 ml E. coli 
cultures and b) the relative yield when cultures were upscaled to 500 ml.  
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Expression tests on 50ml BL21DE3pRARE cultures transformed with pET32-a/insert 
plasmids indicated that the terminus at which the tag was attached, did not increase the 
solubility of expressed proteins. Although N-terminal poly(His) tags have been reported to 
enhance soluble protein expression compared to C-terminal ones (Busso et al., 2005, 
Dyson et al., 2004), in this case, both His10-AntpHD-DRBM1 (C1.1) and AntpHD-
DRBM1-His6 (C3.1) were expressed as insoluble fractions (as seen in the total fractions, 
and not in the eluates).  The low levels of expression may signify that these proteins are 
toxic to the host cell, as expression of heterologous genes rich in codons for arginine (R), 
isoleucine (I), leucine (L) and proline (P), such as C1.1-C4.1, have been implicated in 
translational stalling, causing protein expression to either fail or proceed at very low levels 
(Francis and Page, 2001). 
 Similarly, His10-Pen-DRBM1 (C2.1) and Pen-DRBM1-His6 (C4.1) were mostly present in 
the flowthrough and total fractions, with minimal amounts of protein successfully eluted 
from the columns, although higher expression levels may signify a lesser degree of 
toxicity. 
Considering that recombinant proteins ≤60 kDa are usually expressed as soluble fractions 
by BL21 E.coli strains (Graslund et al., 2008a, Graslund et al., 2008b), construct size may 
not be the cause of insoluble expression. Francis and Page (2001), brought forward the 
hypothesis that the proportion of a protein that forms α-helices has positive effects on 
refolding and soluble expression. The lack of soluble expression, then, could be explained 
by bioinformatic analysis of the secondary sequence. Consistent with Francis and Paige’s 
observations, the AntpHD-based proteins (C1.1 and C3.1), adopt mostly a coiled 
conformation (67.7% and 76.1%, respectively), with only 28% and 20% of each protein in 
an α-helical conformation.  The presence of disordered coils, may have promoted 
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aggregation (Francis and Page, 2001). Conversely, C2.1 and C4.1 conformations were 
predominantly helical (~42%), which may explain the higher levels of protein found in the 
cleared lysate (flowthrough) fraction. Further studies with C1.1 on a 0.5L scale confirmed 
that this protein was expressed as an insoluble fraction. On the same scale, C2.1 and C4.1 
were successfully purified; however, vertical streaking following analysis by SDS-PAGE 
signified nucleic acid contamination. This could be attributed to the absence of DNaseI in 
the lysis buffer, which would have digested any unsheared DNA following cell lysis by 
sonication. The incorporation of a DE52 anion exchange step to remove endogenous 
nucleic acid would have therefore been beneficial, and was incorporated as a final 
purification step following GST-tagged protein purification. Furthermore, these results 
indicated that poly(His)-tagged proteins were expressed as insoluble aggregates and 
needed to be purified under denaturing conditions. It would be interesting to investigate 
whether the conformation adopted in solution by these proteins, would have an effect on 
their uptake efficiency by cells in vitro.  
The GST-tag (Smith and Johnson, 1988) was added to the N-terminus of both constructs 
by ligation into a pGEX-6P-2 plasmid to yield C5.1 and C6.1. The incorporation of a c-
myc epitope tag at the C-terminus to yield C5.1-myc and C6.1-myc was done for 
downstream immunofluorescence studies. Small scale expression testing showed that the 
GST-tag enhanced soluble expression of C5.1 and C6.1, compared to their His-tagged 
counterparts, consistent with previous observations by Hammarstrom et al. (2002). 
The higher expression levels for all GST-tagged constructs also signified that the GST-tag 
enhanced the expression of fusion proteins and not just their solubility. In 0.5L 
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purifications, C5.1 was successfully eluted with 80% purity, confirming that in this case, 
the GST tag promoted solubility and effective purification of these fusion proteins.  
The GST-tag was cleaved from pooled eluates by the proteolytic action of Prescission 
protease (PP). PP is a human rhinovirus 3C protease-GST chimera, which recognizes the – 
LEVLFQ/GP- internal sequence downstream of the tag and cleaves between the glutamate 
and glycine residues. Tag removal was facilitated while the enzyme was immobilized on 
the GS4B column in a buffer formulation that lacked reduced glutathione. This 
necessitated the buffer exchange of purified proteins into an equilibration buffer that did 
not include reduced glutathione.  This process resulted in a step-wise decrease of protein 
yields, which signified that they were unstable in equilibration buffer. C6.1 and C6.1-myc 
decreased by 77.2% and 84.1%, respectively, with 0.40 mg as a final yield in PBS/10% 
glycerol. Step-wise yield calculations indicated that the lengthy process of batch-binding, 
purification, buffer exchange, proteolytic tag cleavage and a final exchange into PBS 
caused both proteins to precipitate, possibly as a result of changes in ionic strength, buffer 
composition and increased handling.  
Their lower levels of expression and instability during manipulation, meant that an 
alternative strategy, such as solid-phase synthesis, would have been advantageous for these 
proteins at this stage. Indeed, most studies in the last 10 years have used chemically 
synthesized proteins, and most commonly proteins prepared by solid-phase synthesis, via 
an Fmoc (9H-fluoren-9-ylmethoxycarbonyl) (El-Andaloussi et al., 2011) or Tboc (tert-
butoxycarbonyl) protection strategy (El-Andaloussi et al., 2007b, Jones et al., 2005). This 
strategy, whereby the peptide chain is sequentially coupled step-wise on a solid support, 
allows the high-grade purification of proteins without loss of stability or degradation (Hu, 
2009) and the covalent conjugation of cargo  (Jarver et al., 2012, Coursindel et al., 2012). 
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It is however, very costly, and synthesis is limited to an average amino acid length of 36 
amino acids. This strategy would therefore be beneficial only in the development of 
constructs based on the shorter, 16 amino acid Penetratin constructs, rather than the longer 
AntpHD. Another alternative, would have been to purify these constructs by IMAC 
followed by fast protein liquid chromatography (FPLC) (GE Healthcare) on an Akta 
purification system, utilizing a linear gradient during buffer exchange, rather than a manual 
buffer exchange process, similar to the successful methodology adopted by Eguchi et al. 
(2009). 
In order to obtain sufficient amounts of all GST-tagged proteins for downstream assays, 
bacterial cultures were scaled up to 4L for C5.1 and C5.1-myc, and 3L for C6.1 and C6.1-
myc. To minimize the steps involved, a batch-binding strategy with Prescission protease 
was adopted, prior to purification by affinity chromatography. Subsequent concentration 
resulted in C5.1, C5.1-myc and C6.1-myc precipitating to various extents; only the 
concentration of C6.1 increased by 51% during this step. Yields decreased in the order of 
C6.1-myc˃C5.1˃C6.1˃C5.1-myc. Overall, C5.1 decreased by 21.3%, compared to 61.1% 
previously. C6.1 showed increased stability , whereas C6.1 increased by 6.3%  and finally, 
yields for C6.1-myc also showed improvement, with less protein precipitating. These data 
suggest that a streamlined purification strategy involving batch-binding and on-column 
cleavage helps minimize protein losses due to precipitation duting extended handling, and 
that the addition of glycerol can aid protein solubility by preventing aggregation.  
The presence of the myc epitope was confirmed by immunoblotting with an anti-myc 
primary antibody. Assessment of protein stability by centrifugation at 16,100 x g and 4°C 
indicated that C5.1 was relatively stable, with little loss in yield, whilst C5.1-myc yield 
was almost halved. C6.1 and C6.1-myc on the other hand completely precipitated, which 
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confirmed that they were unstable in PBS/10% (v/v) glycerol. The intact molecular 
weights of C5.1 and C5.1-myc were assessed by MALDI-TOF and ESI-QTOF mass 
spectroscopy, and confirmed that expected molecular weights were in good accordance 
with actual molecular weights, with small contaminating ions attributed to phosphate 
groups in the buffer or nucleic acids. As ESI is a ‘soft’ ionization method, it allows the 
precise interrogation of con-covalent complexes (Akashi et al., 2005, Sundqvist et al., 
2005), such as the ones between Tat and TAR RNA and Tat-TAR RNA complexes and the 
antibiotic neomycin (Sannes-Lowery et al., 1997). It would therefore have allowed the 
interrogation of both the protein, and non-covalent protein-nucleic acid complexes with 
respect to the stoichiometry and the dissociation constants between the protein and 
endogenous nucleic acid.  
Localization studies in fixed HEK293 and HepG2 cells by indirect immunofluorescence 
utilized the C-terminal c-myc tag of C5.1. Indirect immunofluorescence experiments in 
fixed HEK293 and HepG2 cells with C5.1-myc, indicated a dose-dependent and time-
dependent mechanism of uptake, as well as periplasmic membrane aggregation at high 
concentrations (10 M). Even though a large AntpHD-Rab3 (93 aa) chimera has been 
successfully used in transduction studies in chick embryo myoblasts (Perez et al., 1992), 
the distribution of C5.1-myc (161 aa) pointed towards extra-cellular aggregation, 
indicative of auto-association on the outer leaflet of the cell membrane in HEK293 cells 
(Eiriksdottir et al., 2010). This observation could be attributed a size-specific molecular 
weight cut-off point for CPP entry through cell membranes, and may have further 
implications for the delivery of macromolecular cargo by the homeodomain. The punctate 
distribution of internalized protein at 0.1 M and 1.0 M concentrations support uptake by 
an endocytic mechanism at both timepoints, consistent with observations by Jiao et al. 
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(2009) whereas at 10 M, the diffuse distribution throughout the cytoplasm support 
endocytosis and direct translocation after two hours in HEK293 cells, consistent with 
MALDI-TOF analysis of penetratin at the same molar concentration in CHO cells (Alves 
et al., 2011). Diminished uptake after 24 hours indicated that uptake was time-dependent, 
consistent with findings in other studies with Penetratin by Dom et al. (2003), possibly due 
to protein degradation outside of the protective cellular environment, or sequestration into 
endosomes and subsequent degradation.   
Conversely, in HepG2 cells, C5.1-myc was internalized more efficiently after 24 hours, 
rather than after two hours. This difference further reinforces the notion that uptake is both 
time-dependent and cell-type dependent, with endosomal entrapment and aggregation 
occurring at higher micromolar concentrations. Formation of early endosomes (EE) occurs 
when molecules span the cell membrane and enter the cytosol, by a primarily endocytic 
pathway; trapped molecules are then degraded as the endosome matures to form late 
endosomes (LE), 250-1000 nm in diameter and an intra-lumen pH range of 4.9-6.0 
(Huotari and Helenius, 2011), which ultimately leads to degradation.  
 Although other groups have provided conflicting reports with regards to the molecular 
mechanisms of cell entry with Penetratin, (Alves et al., 2011, Drin et al., 2003, Duchardt et 
al., 2007), it is clear that differences in time-dependent transduction efficiencies between 
cell lines are caused by differences with regards to binding ligands on the cell surface, such 
as the proportion of sialic acid and proteoglycans present. It would be interesting to 
quantitate the amounts of C5.1 or C5.1-myc by spectroscopy, as this would provide new 
insight as to its cell penetrating efficiency and variations between different time-points, 
concentrations and cell lines, with potential implications as to its use as a transduction 
vector in different tissues. 
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Protein detection with a primary antibody against the c-myc epitope and a FITC-labeled 
secondary antibody has been widely used in the past, producing results with enhanced 
resolution by laser scanning confocal microscopy. However, indirect immunofluorescence, 
involving cell fixation with paraformaldehyde and permeabilization with a non-ionic 
surfactant such as Triton X-100, is a process that has been widely implicated in artefactual 
redistribution of protein around the plasma membrane as a result of membrane 
perturbations (Green et al., 2003, Richard et al., 2003) 
Subsequently, most current methods of protein detection in living cells involve the 
covalent linking of fluorescent probes in the form of organic dyes (fluorescein 
isothiocyanate (FITC, 389 Da), rhodamine (tetramethyl rhodamine isothiocyanate (TRITC, 
479 Da) or biological fluorophores, such as GFP (~27 kDa), amongst others (Cazes, 2001, 
Chalfie et al., 1994).  A major drawback of covalently linked probes for fluorimetry lies in 
their large molecular weight or possible alteration of biochemical characteristics, 
especially when used in conjunction with bifunctional fusion proteins such as C5.1. The 
methodology developed in this study therefore attempted to circumvent these issues whilst 
assessing the siRNA-binding efficiency of the DRBM1 moiety via non-covalent 
interactions. Complexes were allowed to form by co-incubation at a 50:1 ratio of protein to 
siRNA-fluorescein (FITC) (Eguchi et al., 2009, Geoghegan et al., 2012) in Optimem and 
applied to adhered HepG2 cells. This molar ratio has been previously identified as the 
optimal ratio of ~98% siRNA encapsulation by any CPP, irrespective of charge or peptide 
mass (van Asbeck et al., 2013). Moreover, HepG2 cells have been reported to express N-
linked sialic acid on their cell surface, which makes this cell line suitable for live 
localization assays (Wu et al., 2006) as previous reports have identified this α-2, 8-
polysialic acid as the membrane ligand for AntpHD (Bloch-Gallego et al., 1993, Joliot et 
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al., 1991b). Similarly, wheat germ agglutinin (WGA)-dsRed, a cationic lectin labeled with 
red fluorescent Alexa Fluor 594, selectively binds N-acetylneuraminic and poly-sialic acids 
on the cell surface and is routinely used as a cell membrane marker. Initially, we wanted to 
investigate whether WGA-dsRed could be used as a live cell membrane counterstain.  
Unexpectedly, incubating cells with WGA at 37°C for 30 minutes following C5.1-siRNA 
treatment for two hours, resulted in cellular uptake into peripheral endosomes, consistent 
with observations by Raub et al. (1990). We were curious then, to assess whether WGA-
dsRed uptake following C5.1-siRNA treatment was inhibited, or whether WGA-dsRed 
competed with C5.1 for the same plasma membrane binding sites, and by consequence, 
whether this would result in diminished uptake of WGA-dsRed. Similar intracellular 
localization within endosomal structures were observed, which indicated that a common 
endocytic uptake mechanism may occur, although the majority of C5.1-siRNA appeared to 
translocate directly into the cells.  Finally, this observation confirmed that C5.1 could 
effectively bind and transduce siRNA cargo intracellularly at a 50:1 molar excess, although 
results are only preliminary. Again, this observation would have to be repeated using 
quantitative methods such as flow cytometry to assess the amounts of internalized protein-
siRNA complexes in the absence or presence of WGA-dsRed, or by MALDI-TOF 
spectrometry, as previously shown by Alves et al. (2011). Geoghegan et al. (2012) 
reported that the DRBM1 from human PKR did not bind siRNA  and thus did not induce a 
complete gel shift at 4:1 molar ratios to siRNA, as previously reported by Eguchi et al. 
(2009).  His group had achieved complete encapsulation of siRNA with DRBM1 at 4:1 
ratios, which in fact had been the result of non-specific interactions of the Tat-Tat-HA-Tat 
penetrating moiety of PTD-DRBD.  
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Results obtained using C5.1-siRNA in EMSA assays (n=3) are in agreement to those of 
Geoghegan et al, as siRNA binding by the DRBM1 was incomplete even at 8:1 molar 
ratios. In this case, aggregate formation at the top of the wells in the presence of EtBr 
without any nucleic acid bound to the siRNA and failure of C5.1 to induce a gel shift when 
complexed with siRNA was observed. This finding may be a consequence of the native 
purification strategy employed, which, in the absence of a DNase treatment, resulted in co-
purification of endogenous nucleic acid. Consequently, nucleic acid contamination may 
have saturated the protein and inhibited efficient dsRNA binding, but illustrates how C5.1 
can efficiently bind nucleic acid. This observation was not surprising considering that the 
biological function of the homeoprotein as part of the Drosophila homeobox is to bind 
DNA.  
In conclusion, increased aggregation and decreased siRNA binding affinity at low molar 
ratios render the C5.1 protein an inefficient siRNA delivery vector, at least in this study. In 
addition to binding siRNA, a vector protein suitable for delivering cargo to the cytoplasm 
must also facilitate its release from endosomal vesicles that target it for degradation. The 
fact that C5.1, in lieu of a fusogenic tag, becomes sequestered in endosomes upon uptake, 
affects the efficient cytoplasmic delivery of siRNA. In light of Geoghegan’s findings with 
Penetratin-DRBM1, proteins comprised of the DRBM1 were deemed insufficient siRNA 
vectors and new constructs were designed and purified, comprising of the endosomolytic 
EB1 penetratin analogue, fused to both tandem domains from human PKR. However, the 
fact that C5.1 localized intracellularly even in the presence of contaminating nucleic acid, 
leaves open the possibility that C5.1 may be used as dsRNA delivery vector, provided that 
a streamlined purification strategy is further developed to incorporate a fusogenic tag, 
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allow the efficient purification from contaminating nucleic acid, and efficiently refold or 
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  Introduction 3.1
Endosomal entrapment is an intracellular process triggered when uptake favours an 
endocytic mechanism, rather than direct translocation (Duchardt et al., 2007, Duchardt et 
al., 2009, Kosuge et al., 2008, Tunnemann et al., 2006, Tunnemann et al., 2008). Cell-
penetrating protein uptake via endocytosis has been reported to occur at low micromolar 
concentrations as a membrane composition-dependent mechanism. Endosomal entrapment 
and subsequent concomitant degradation in lysosomes, seems to be a limiting step in the 
delivery of cell penetrating proteins and their attached cargo. Various strategies have been 
employed to promote endosomal escape, such as the use of sucrose, calcium and 
chloroquine, or the incorporation of a fusogenic hemagglutinin (HA) tag within the protein 
sequence (Eguchi et al., 2009); their use however, is severely limited in an in vivo setting. 
Another strategy is the use of the ‘proton sponge’ effect, whereby histidine residues, with 
an imidazole group and protonatable secondary amine groups with a pKa ∼6.0, are 
incorporated in the primary amino acid sequence to act as a proton sponge in acidic 
endosomes (Midoux et al., 2009). As the endosomes mature, membrane-bound ATPase 
pumps recruit cytosolic protons, leading to a decrease in pH. Incorporated histidines resist 
this acidification. As proton influx increases, so does the influx of water, leading to a 
buildup of osmotic pressure, subsequent rupture of endosomes and cargo release (Boussif 
et al., 1995, Pack et al., 2005). Moreover, a protein’s secondary structure is critical for 
endosomolysis, with an alpha helical structure adopted by primary amphipathic and 
arginine rich proteins, such as Penetratin, promoting protonation (Biggin and Sansom, 
1999, Varkouhi et al., 2011).   
An elegant study by Lundberg et al. (2007) modified the amino acid sequence of 
Penetratin, incorporating a short N-terminal amino acid sequence that promoted an alpha 
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helix upon protonation in the endosome and histidine residues to assist in the formation of 
a proton sponge. This Penetratin analogue, EB1, was then used to non-covalently bind 
siRNA and induce luciferase gene silencing in vitro. It displayed high binding efficiency at 
low molar ratios, and increased knockdown effects compared to its parent peptide.  
In another seminal study by Geoghegan et al, recombinant proteins were comprised of a 
cell penetrating peptide moiety (Penetratin, HIV Tat) fused to the tandem dsRNA binding 
domains (DRBMx2). These fusion proteins exhibited efficient siRNA binding and gene-
specific knockdown in vitro. The DRBD (herein DRBMx2) binds siRNA with high avidity 
(Kd= 4x10-9 mol/L) (Chapter 4 Introduction), compared to DRBM1 or DRBM2 alone 
(Manche et al., 1992, Patel and Sen, 1992, Schmedt et al., 1995, Tian and Mathews, 2001). 
In this chapter, a set of siRNA carrier proteins were designed with the aim of incorporating 
domains capable of binding siRNA with high affinity, traversing the cell membrane and 
releasing siRNA cargo from endosomes. The endosomolytic EB1 Penetratin analogue 
developed by Lundberg et al. (2007) was therefore expressed as a recombinant protein 
with the tandem dsRNA binding domain from human PKR (DRBMx2) with either GST or 
His6 affinity tags, and purified under either native or denaturing conditions to obtain 
refolded protein (Fig. 3.1). To assess any effects on binding efficiency or endosomolysis, 
the EB1 sequence was placed at both the N-terminal position of the resulting protein, and 

















 Schematic of the EB1-based fusion proteins cloned into a modified Figure 3.1
pET32-a or pGEX-6P-2 vector. They are comprised of  either: EB1, the endosomolytic 
analogue of Penetratin; the entire DRBD of human PKR comprised of dsRNA binding 
motifs 1 and 2 (DRBM1-DRBM2); a C-terminal 6xHistidine tag (His6) or an N-terminal 











3.2.1 Subcloning EB1-DRBMx2 constructs into plasmid vectors 
Sequences for EB1-DRBMx2 and DRBMx2-EB1 were obtained by reverse translating the 
amino acid sequence of EB1 fused to the nucleotide sequence of the entire DRBD, 
separated by the original linker sequence (G4S)2 in a synthetic plasmid with a pUC 
backbone (636 bp) (Epoch Biosciences). PCR-amplified fragments were digested with 
BamHI/XhoI and subcloned into pGEX-6P-2 (C9.2 and C10.2); similarly, to obtain a C-
terminal His6 tag, constructs digested with NdeI/XhoI were subcloned into a modified 
pET32-a plasmid vector (C7.2 and C8.2) (Fig. 3.1).  
The XL1-Blue E.coli strain was transformed and colonies were screened directly for 
inserts by colony PCR. Constructs ligated into pGEX-6P-2 were analysedanalysed by 
colony PCR with insert-specific forward and reverse primers (Fig. 3.2 A) and vector-
specific forward and reverse primers, which produced fragments at 794 bp, as expected 
(Fig. 3.2 B). The slightly larger amplicon size corresponded to the PCR amplification of 
pGEX-6P-2 vector sequences. Colonies corresponding to the ‘insert + vector’ bands (794 
bp) were sequenced with a pGEX-5’ forward primer at GATC Biotech (London) and 
sequences were analysed with Sequence Scanner v1.0 (Applied Biosystems) and Expasy 
Translate (Gasteiger E., 2005). C9.2 and C10.2 sequences that did not contain any 
mutations were used as templates to replace the BamHI site with an NdeI site by PCR.  
NdeI/XhoI digested fragments, ligated into a modified pET32-a plasmid vector were used 
to transform XL1-Blue cells.  His-tagged proteins were purified by denaturing 
Immobilised Metal Affinity Chromatography (IMAC) on a Cobalt chloride (CoCl2) 
123 
 
nitriloacetic (Co-NTA) column, whereas GST-tagged proteins were purified by affinity 
chromatography on a Glutathione Sepharose 4B (GS4B) matrix.  
Direct colony screening by PCR using a T7 (vector-specific) forward primer and a gene-
specific reverse primer yielded ~660 bp bands when analysed by agarose gel 
electrophoresis, which were attributed to primer amplification of a short vector sequence 
by the forward primer (Fig. 3.3). Screened colonies were sequenced with a T7 minus1 





 Insert screening by colony PCR following ligation in pGEX-6P-2. A. Figure 3.2
Colony PCR with gene-specific primers. B. Colony PCR with vector specific primers. 
EB1-DRBMx2, C7.2; DRBMx2:EB1, C8.2. Expected size of bands; ~0.8 kb. M, 1 kb 
marker. 
 
 Insert screening by colony PCR following ligation in pET32-a, by a Figure 3.3
vector-specific forward primer and a gene-specific reverse primer. EB1-DRBMx2, 





3.2.2 Small-scale expression optimization of His-tagged C7.2 and C8.2  
Since GST-tagged endosomolytic fusion proteins were expressed as insoluble fractions, 
their His-tagged counterparts were expressed from 50 ml bacterial cultures and purified 
under native conditions by IMAC on a Cobalt nitriloacetic sepharose matrix (Co-NTA). 
This provided an estimate of both levels of expression and associated protein solubility, 
before upscaling to 1 L cultures.  Protein expression was induced with 0.5 mM IPTG for 
15 hours at either 18°C or 37°C; cultures were pelleted, lysed by sonication, purified and 
fractions were analysed by SDS-PAGE electrophoresis. Incubation of cultures at 18°C 
upon induction resulted in low expression of both His6-C7.2 and His6-C8.2 (Fig. 3.4 A and 
C, Total fractions), compared to protein levels expressed at 37°C (Fig. 3.4 B and D). 
Protein was lost in the flowthrough fraction, with no protein eluted from the column after 
incubations at either temperature, indicating that most of the protein was insoluble. 
Moreover, vertical streaking in bands from flowthrough fractions (Fig. 3.4 B and D) 
indicated nucleic acid contamination or degradation. This necessitated purification by 













 Optimization of His6-tagged C7.2 and C8.2 protein expression following Figure 3.4
incubation at 18°C and 37°C. Proteins were purified from 50ml cultures by affinity 
chromatography by immobilized metal ion chromatography over a Co-NTA matrix and 
analysed on a 12% w/v SDS-PAGE gel. A. His6-C7.2 incubated at 18°C, B. His6-C7.2; 
37°C, C. His6-C8.2; 18°C, D. His6-C8.2; 37°C. Expected molecular weights (MW): His6-
C7.2, 24 kDa; His6-C8.2, 24.1 kDa. T, Total (crude) lysate; FT, Flowthrough (soluble) 
fraction; W, Wash; E1-E3, Eluates 1-3. M, Marker. Gels were stained with 0.5% 








3.2.3 Small-scale expression optimization of GST-tagged C9.2 and C10.2  
Plasmid DNA from sequence-verified constructs C9.2 and C10.2 in the pGEX-6P-2 vector 
were used to transform the expression strain BL21(DE3)pRARE. In order to optimise 
soluble expression from bacterial cultures, two critical conditions for recombinant protein 
expression were assessed: temperature and Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
concentration. Induction of heterologous protein expression from the lac operon occurs 
with a 0.1-1.0 mM IPTG concentration (Tolia and Joshua-Tor, 2006). GST-tagged protein 
expression from 50 ml bacterial cultures was therefore optimised by varying IPTG 
concentrations at 0.5 mM and 1.0 mM concentrations once O.D600 had reached~0.7. 
Proteins were then purified under native conditions on a GS4B column. IPTG 
concentration had no effect on the overall levels of C9.2 expression (Fig 3.5 A and B), 
however, it appeared to increase soluble expression (seen in the flowthrough fractions) at 
1.0 mM concentration in comparison to 0.5 mM. No protein was observed in the eluted 
fractions. 
 Low expression levels were observed for C10.2 following induction with either 0.5 mM or 
1.0 mM IPTG, with protein seen in the flowthrough fractions, but not eluted (Fig. 3.5 C 
and D). Since protein levels appeared unaffected by the concentration of IPTG, the 
induction temperature was varied for both proteins. C9.2 and C10.2 were induced with 0.5 
mM IPTG and incubated for 15 hours at either 18°C or 37°C, followed by lysate clearing 
and purification on a glutathione agarose matrix as before. C9.2 incubated at 18°C was 
expressed at low levels as inclusion bodies; protein was visible in the crude lysate (Fig. 3.6 
A, sample ‘T’),  but not in the flowthrough (FT), wash (W) or any of the eluted fractions 
(E1-E2). Several contaminating proteins were observed in the FT; similar observations 
were made when the protein was purified from cultures incubated at 37°C (Fig. 3.6 B). 
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C10.2 was mostly expressed as insoluble protein, present in the Total (T) fraction, with 
little protein remaining in the flowthrough (FT) fraction, after incubation at both 18°C and 
37°C (Fig 3.6 C and D). Interestingly, a ~28 kDa protein co-purified in the FT fractions of 
both C9.2 and C10.2 from 18°C (Fig. 3.6 A and C), but a slightly smaller protein (~24 
kDa) was evident in the same fractions from 37°C culture purifications (Fig. 3.6 B and D). 
No proteins were eluted successfully from the glutathione sepharose matrix under any of 





 Optimization of GST-tagged C9.2 and C10.2 protein expression following induction with 0.5 mM and 1.0 mM IPTG. Figure 3.5
Proteins were purified from 50ml cultures by affinity chromatography over a GS4B column and analysed on a 12% w/v SDS-PAGE gel. 
A. GST-C9.2, induction with 0.5 mM IPTG, B. GST-C9.2; 1.0 mM IPTG, C. GST-C10.2; 0.5 mM IPTG, D. GST-C10.2; 1.0 mM IPTG. 
Expected molecular weight (MW), 49.8 kDa. I, Induced fraction; T, Total (crude) lysate; FT, Flowthrough (soluble) fraction; W, Wash; E1-E2, 









 Optimization of GST-tagged C9.2 and C10.2 protein expression following induction incubation at 18°C or 37°C. Proteins Figure 3.6
were purified from 50ml cultures by affinity chromatography over a glutathione sepharose (GS4B) matrix and analysed on a 12% w/v SDS-
PAGE gel. A. GST-C9.2 incubated at 18°C; B. GST-C9.2 incubated at 37°C; C. GST-C10.2 incubated at 18°C; D. GST-C10.2 incubated at 
37°C. Expected molecular weight (MW), 49.8 kDa. T, Total (crude) lysate; FT, Flowthrough (soluble) fraction; W, Wash; E1-E3, Eluates 1-3. 







3.2.4 Large scale purifications of C7.2 and C8.2 under denaturing conditions 
The expression of C7.2 and C8.2 necessitated purification under denaturing conditions and 
subsequent refolding. In order to obtain C7.2 and C8.2 in sufficient amounts for in vitro 
assays, proteins were purified from 1L BL21(DE3)pRARE cultures induced with 0.5 mM 
IPTG at 37°C for 15 hours. Proteins were eluted from the Co-NTA column in His-elution 
buffer (pH 7.4) containing 6 M Guanidine-HCl (Gu-HCl) and high imidazole (300 mM) 
and salt concentrations (500mM NaCl). Eluates were then pooled and refolded into 5L 
refolding buffer (with a lower imidazole concentration, 20 mM) and buffer-exchanged into 
5L His-storage buffer. The stability of dialysate fractions at each step of the 
refolding/buffer exchange process was assessed by centrifugation at 16,100 x g and 4°C 
and SDS-PAGE. Proteins were successfully eluted from the Co-NTA column, and refolded 
(Fig. 3.7 A and B; (a)). However, excessive precipitation of C8.2 was observed after 
centrifugation, with little loss of C7.2 (Fig. 3.7 A and B; (b)). A second dialysis step was 
included to buffer exchange proteins into His-storage buffer. Visible precipitation within 
the dialysis tubing prompted the increase of NaCl concentration from 50 mM to 150 mM 
and the addition of 10% (v/v) glycerol as a stabilizing excipient, which prevented further 
aggregation (Fig. 3.7 A and B; (c)). Upon centrifugation, there was complete aggregation 
of C7.2, while C8.2 remained stable (Fig. 3.7 A and B; (d); however upon final analysis of 
collected samples, C8.2 appeared to have precipitated, as it did not yield any bands on the 
gel at the expected molecular weight (Fig. 3.7 A and B; (e)). Final yields for C7.2 and C8.2 





 Analysis of purified C7.2 and C8.2 by SDS-PAGE at various stages Figure 3.7
during refolding and buffer exchange. Fractions from 1L cultures were analysed by 
12% w/v SDS-PAGE. A. C7.2; B. C8.2. Lanes (a) purified protein in His-refolding buffer; 
(b) purified protein in refolding buffer following centrifugation at 16,100 x g; (c) refolded 
protein following buffer exchange into His-storage buffer/150 mM NaCl/10% (v/v) 
glycerol; (d) refolded protein in His-storage buffer/150mM NaCl/10% (v/v) glycerol 







Experimental evidence from a number of studies support the hypothesis that cell-
penetrating peptide uptake mechanisms vary between direct translocation and endocytosis 
depending on protein cargo and the size of complexes (Morris et al., 2001, Simeoni et al., 
2003, van Asbeck et al., 2013). Due to the complexity of factors involved in uptake 
pathways, there is no direct correlation between complex formation ability and intracellular 
delivery of bioactive siRNA cargo. Endosomal escape is therefore a rate-limiting step for 
the delivery of macromolecules into cells; the inclusion of a fusogenic moiety has been 
greatly investigated. Previous studies by Wadia et al. (2004), for example, had coupled a 
fusogenic HA2 tag to a Tat-Cre peptide, which exhibited increased transduction efficiency 
compared to Tat-Cre alone. A non-covalent strategy utilising a Penetratin analogue with 
histidine modifications (EB1), managed to deliver siRNA with higher efficiency than 
Penetratin-HA2 and Penetratin alone (Lundberg et al., 2007). C5.1, comprised of the 
Antennapedia homeodomain, lacks the ability to escape from endosomes by virtue of its 
primary structure. In light of Lundberg’s findings, we wanted to investigate whether the 
Penetratin analogue EB1, expressed as recombinant protein with the entire DRBD 
(DRBMx2) from human PKR, would show enhanced siRNA binding and transduction 
efficiencies. Moreover, we aimed to compare its theoretical properties to those of C5.1, 
which bound siRNA with low affinity, and co-purified with endogenous nucleic acids. This 
chapter aimed to clone, purify and characterize two novel proteins comprised of EB1 as a 
fusion protein with DRBM1 and 2 from human PKR (DRBMx2), or its counterpart in 
tandem (DRBMx2-EB1) as a non-covalent vector for siRNA delivery. Since protein 
stability is a critical parameter that may only be determined empirically, purification of 
EB1-based proteins was attempted under both native and denaturing conditions. Two 
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parameters, IPTG concentration and incubation temperature, were considered. Since the 
tac promoter in pGEX-6P-2 and the T7 promoter in pET32-a are under the control of 
IPTG, varying its concentration can affect both the rate of expression and their solubility, 
by displacing the lac repressor encoded by the lacIq gene and inducing the overexpression 
of protein (Amersham, 2013). Purifications of GST-tagged C9.2 and C10.2 under native 
conditions from BL21(DE3)pRARE cultures transformed with the pGEX-6P-2-insert 
plasmids, revealed that both proteins were expressed at low levels, which were unaffected 
by the concentration of IPTG used to induce heterologous protein production through the 
lacIq system. C9.2 was expressed at marginally higher levels with 1.0 mM IPTG, rather 
than with 0.5 mM. Since a lower IPTG concentration could increase soluble protein 
production albeit with decreased yield (by allowing the host to fold the protein properly) 
(Sorensen and Mortensen, 2005), the lower concentration was chosen for induction 
temperature optimization. Transformed host cells were allowed to grow at 37°C until an 
optical density (OD600) ∼0.6-0.7 was attained, which represents the logarithmic growth 
phase of bacteria in batch cultures, and 0.5 mM IPTG was added to the inoculum. The 
temperature was either kept constant or decreased to 18°C for 15 hours, inducing protein 
production through the tac promoter. It has been demonstrated previously that temperature 
is a critical factor affecting soluble protein production (Wang, 2005), with lower 
temperatures favouring expression into the cytoplasm. The often, direct correlation 
between aggregation and temperature has been attributed to the partial elimination of heat-
shock proteins produced at lower temperatures (Chesshyre and Hipkiss, 1989, Schein, 
1989). It was therefore expected that the expression levels of C9.2 and C10.2 would be 
increased by incubation at 18°C, rather than at 37°C. Observations from 50 ml-scale 
purifications, did not support this notion; low levels of insoluble protein were observed at 
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both temperatures assessed for both proteins. This may be attributed to the large molecular 
weight of both proteins (49.8 kDa); a large scale examination by Dyson et al. (2004) of 95 
recombinant proteins identified molecular weight as a critical parameter for soluble 
expression, with larger proteins (∼40 kDa) needing a solubility enhancing tag, such as 
thioredoxin, for soluble expression. A 31.5 kDa co-purifying protein in the FT fraction 
may correspond to β-lactamase co-purifying, a by-product of expression via IPTG 
induction (Amersham, 2013). 
In summary, since purifications of GST-tagged constructs were unsuccessful, His6-tagged 
C7.2 and C8.2 were purified, first under native conditions and then in the presence of 6 M 
Guanidinium hydrochloride (Gu-HCl) as a chaotrope.  
The addition of Gu-HCl in purification formulations for insoluble proteins, is beneficial in 
order to solubilize the protein. Gu-HCl must then be removed by dialysis or rapid dilution 
to allow the protein to return it to its native state (Maxwell et al., 2003). To increase the 
binding selectivity while decreasing the amount of co-purifying contaminants, 
nitrilotriacetic agarose was precharged with Co2+ ions as 0.1 M CoCl2, rather than Ni2+. 
Temperature optimization assays at 18°C and 37°C on a 50 ml scale, indicated that both 
proteins were expressed at higher levels at 37°C, rather than 18°C. Protein was mostly 
present in the crude lysate (total fraction) with some protein seen in the cleared lysate 
(flowthrough), signifying that protein must be solubilized prior to purification. Vertical 
streaking in the SDS-PAGE gel for C7.2 fractions indicated co-purification of nucleic acid 
or partial degradation, as these preliminary screening tests did not involve DNase treatment 
or protease inhibitors. Since no protein was eluted from the column under native 
conditions, purifications were attempted under denaturing conditions. The addition of 
lysozyme, MgCl2, benzonase and protease inhibitor cocktail in the His-resuspension and 
136 
 
His-binding buffers was necessary to prevent nucleic acid contamination and proteolytic 
degradation. Resuspension of the pellet in 1.1x His-binding buffer with a high ionic 
strength (0.55M NaCl) with 6.66M Gu-HCl, and 2mM β-mercaptoethanol (a potent 
disulfide bond and RNase denaturant) and subsequent purification by gravity flow affinity 
chromatography allowed the successful isolation of C7.2 and C8.2 in elution buffer. 
Sequential dialysis was done to remove any β-mercaptoethanol and Gu-HCl ions from the 
eluted proteins upon refolding. Proteins were dialysed into His-refolding buffer of high 
ionic strength (500 mM NaCl) in order to prevent aggregation and 20 mM imidazole, 
which resulted in C10.2 precipitating. This could be attributed to improper folding, whilst 
C9.2 remained stable, indicating a greater proportion of properly folded protein.  
Both proteins were lost during a second dialysis step into storage buffer. Aggregation at 
this point could be explained by the decrease of ionic strength (150 mM NaCl), which 
causes non-specific aggregation and subsequent precipitation of proteins even in the 
presence of 10% glycerol as a stabilising excipient. 
In theory, these novel constructs have great potential as non-covalent vectors of siRNA 
delivery vectors. The EB1 proteins had exhibited effective siRNA complex formation via 
EMSA assays at 5:1 molar excess to siRNA, compared to Penetratin, which shifted siRNA 
at 10:1 molar ratios, using the non-covalent co-incubation strategy as used by Geoghegan 
et al. (2012), Eguchi et al. (2009) and Lundberg et al. (2007) Moreover, EB1 proteins at 
25:1 molar ratios to siRNA in vitro showed effective luciferase knockdown following a 36 
hour treatment in a transiently transfected HeLa-pGL3 cell line, even in the absence of a 
dsRNA binding moiety (Lundberg et al., 2007). The siRNA binding properties of EB1 
could have been further potentiated by incorporating the DRBMx2.  This in turn may have 
resulted in an effective, non-covalent siRNA carrier with endosomolytic abilities.  
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The unsuccessful purification of recombinant proteins however, did not allow for 
downstream analysis; this chapter shows that the purification strategy adopted in this 
instance, under both native and denaturing conditions, allowed the purification of protein, 
which was however lost upon dialysis. 
Obtaining functional, pure and native-state protein from bacterial expression systems has 
been found to depend on solubilisation and refolding (Tsumoto et al., 2003). According to 
Maxwell et al. (2003). With one-step dialysis, as was done in this chapter, the 
concentration of the denaturant is decreased as the rate of refolding into the native step 
increases; this sometimes results in nonspecific aggregation, even if the protein 
concentration remains near-constant within the dialysis tubing. The exchange of a buffer 
containing 6 M Gu-HCl to one with none (0 M Gu-HCl), then, may have forced proteins 
into a rigid structures, which, if improperly folded, cannot revert back to the native state. It 
may have been beneficial to adopt a step-wise dialysis process, which would sequentially 
refold proteins by manual exchange of buffer from one of high denaturant concentration to 
one of medium and finally to one of low concentration, thereby controlling the equilibrium 
at each stage (Tsumoto et al., 1998).  
The possibility of buffer contamination despite one’s best intentions during dialysis is also 
another factor that affects refolded protein yields, as reported by Maachupalli-Reddy et al. 
(1997); these include nucleic acid and contaminating proteins that may have co-purified 
along with the target protein. This is consistent with our observations with C7.2 and C8.2 
proteins in refolding buffer (Fig. 3.7, lane (a)). Purification optimization to isolate the 




Finally, buffer exchange via a size-exclusion chromatography approach that incorporates a 
flow rate suitable for protein folding kinetics may be a suitable alternative to dialysis. The 
column matrix (such as a G25 column), equilibrated in an intermediate denaturant 
concentration buffer, may prevent the formation aggregated species, via hydrogen or 
hydrophobic interactions between the column and the refolded protein. This approach has 
been successfully used for the purification of interleukin-6 (IL-6), and is primarily 
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The sequence-independent, efficient dsRNA binding properties of human PKR are 
conferred by its regulatory binding domain (DRBD). The domain is comprised of two 
tandem motifs, DRBM1(amino acids 6-79) and DRBM2 (amino acids 96-169), which 
adopt a dumb-bell shape upon  interaction with dsRNA; this allows DRBM2 to ‘release’ 
the kinase domain, shifting  the entire PKR to an open conformation and  inducing  PKR 
autophosphorylation and activation (Nanduri et al., 1998, Nanduri et al., 2000). 
 Although both DRBMs bind dsRNA, DRBM1 (Kd = 2.8x10-7 M) has a higher affinity 
compared to DRBM2, potentiated by the cooperative action of both tandem motifs (Kd= 
4x10-9 M) (Patel and Sen, 1992, Schmedt et al., 1995, Tian and Mathews, 2001).  
In 2012, Geoghegan et al.,  reported that cell penetrating protein fusions with the dsRNA 
binding motif 1 (DRBM1) from human PKR bind siRNA with low affinity, requiring a 20-
60-fold molar excess for in vitro knockdown as opposed to the 4:1 ratio as previously 
reported with PTD-DRBD (Tat-Tat-HA-Tat-DRBM1) (Eguchi et al., 2009). The 4:1 ratio 
reported was the result of non-specific interactions of Tat with siRNA. The group purified 
several constructs comprised of a cell penetrating moiety and both dsRNA binding 
domains (DRBMx2) and used them to assess siRNA binding via electrophoretic mobility 
shift assays (EMSA) and gene knockdown. 
Although the utilization of the DRBMx2 yielded stable and specific siRNA binding 
compared to DRBM1 alone, these fusion proteins (Tat-DRBMx2 and Pen-DRBMx2) 
failed to mediate gene-specific knockdown when targeting the endogenous gene 
hypoxanthine-guanine phosphoribosyl transferase (HPRT) in HeLa cells. This lack of gene 
expression knockdown was attributed to the endosomal entrapment of the protein-siRNA 
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cargo, even though efficient complex formation and transduction in vitro was observed. 
Pen-DRBMx2, yielded 60% HPRT knockdown in the presence of chloroquine, an 
endosomolytic agent (El-Sayed et al., 2009, Xiao and Samulski, 2012).  
Considering that the binding efficiency of Pen-DRBMx2 had not been investigated by the 
group via EMSA assays, we set out to investigate the molar ratio necessary to induce a gel 
shift. Moreover, the transduction efficiency and cytotoxicity of Penetratin and Tat have 
been reported to be cell-line specific (Sugita et al., 2008). Although Penetratin exhibits 
enhanced cellular transduction in the HeLa cell line compared to Tat (Mueller et al., 2008), 
it has also been reported to induce cytotoxicity (Sugita et al., 2008). With these findings in 
mind, we set out to investigate whether Pen-DRBMx2 and Tat-DRBMx2 may be more 
effective in a HepG2 cell line, targeting the endogenous expression of PTP1B, and in a 
HEK293-dEGFP reporter cell line. Previous electrophoretic mobility shift assay 
experiments with C5.1, comprised of the Antennapedia homeodomain (AntpHD) and the 
dsRNA binding motif 1 from human PKR, revealed that C5.1 co-purified with endogenous 
nucleic acid, and that at the molar ratios tested, dsRNA was not complexed by the protein 
as previously reported  (Eguchi et al., 2009). These observations were in good accordance 
with those made by Geoghegan et al. with DRBM1.  
Plasmids encoding for His6-Tat-dsRNA binding motifs 1 and 2 (DRBMx2) (C11.2), His6-
Penetratin-DRBMx2 (C12.2) and His6-DRBMx2 (C13.2) were obtained (a kind gift from 
Professor Davidson, University of Iowa) (Fig 4.1). The siRNA oligos used in this study 




 Plasmids were used for protein expression studies from BL21(DE3)pRARE cultures and 
purifications under denaturing conditions, followed by refolding by dialysis. Purified 
proteins were used to assess cytotoxicity in HEK293 and HepG2 cells. In order to 
quantitatively assess uptake and gene knockdown by flow cytometry analysis, a HEK293 
reporter cell line stably expressing destabilised enhanced green fluorescent protein 
(dEGFP) was created. The pd1EGFP-N1 plasmid (Clontech, Saint-Germain-en-Laye, 
France), used to transfect HEK293 cells, encodes the destabilised variant of the wild-type 
GFP protein from Aequorea victoria fused to a mouse ornithine decarboxylase (MODC422-
461) with a PEST amino acid sequence which destabilises the protein, with a half-life of ~2 
hours, allowing knockdown analysis at 24 or 48 hours after treatment. It also encodes for a 
neomycin resistance gene, allowing the specific selection of dEGFP-expressing cells from 







 Schematic of fusion proteins comprised of the HIV Tat; Penetratin; Figure 4.1
DRBM1 and DRBM2; His6 affinity tag. C11.2, Tat-DRBMx2-His6; C12.2, Pen-









4.2.1 Purification and Refolding of C11.2, C12.2 and C13.2 
Recombinant C11.2, C12.2 and C13.2 were purified under denaturing conditions, as 
purified by Geoghegan et al. (2012) with some modifications with regards to the refolding 
strategy. C11.2 (Fig. 4.2 A) was successfully eluted in the E1-E2 fractions, while C12.2 
and C13.2 were present in the first eluate only (E1), with little protein loss in the FT 
fractions (Fig 4.2 B-C). Eluates were sequentially dialysed first into 5L His-refolding 
buffer to eliminate Gu+ ions and then into 5L His-storage buffer in order to refold the 
proteins into their native state. Stability was assessed by centrifugation (Fig 4.2). All three 
proteins were isolated with ~90% purities (Fig. 4.2 A, C) except C12.2 (Penetratin-
DRBM2), which showed some degradation or contamination with a smaller co-purifying 
protein (Fig. 4.2 B). Concentrations of final fractions in storage buffer were analysed by 
Nanodrop at A280 using the expected molecular weights (MW, kDa) and extinction 
coefficients (ε) (Appendix I). The final yields for C11.2 (expected molecular weight 
(MW): 21.7 kDa), C12.2 (expected MW: 24.3kDa) and 10.2 (expected MW: 20.4 kDa) 
were isolated with yields of 0.9 mg, 4.3 mg and 1.5 mg, respectively (Table 4.1). 
Table 4.1 Final yields for purified proteins C11.2-C13.2 from 0.5 L cultures. 
Yields were calculated following purification under denaturing conditions and refolding by 
sequential dialysis. 
Protein Protein concentration (mg/ml) Final yield of refolded proteins  
from 0.5L purifications (mg) 
C11.2 0.2 0.9 
C12.2 0.7 4.3 







 Purification of C11.2, C12.2 and C13.2 from 0.5L bacterial cultures Figure 4.2
under denaturing conditions. Left panels, purification fractions under denaturing 
conditions; right panels, eluted fractions at various stages of the refolding process. A. 
C11.2; B. C12.2; C. C13.2. Samples were analysed on a 12% w/v SDS-PAGE gel. 
Purification fractions analysed; T, Total; FT, Flowthrough; W1-W2, Washes 1-2; E1-E3, 
Eluates 1-3 and dialysate fractions; (a) pre-spin, in refolding buffer; (b) post-spin at 16,100 
x g, in refolding buffer; (c) pre-spin, in storage buffer; (d) pre-spin, in storage buffer /10% 
(v/v) glycerol and (e) post-spin at 16,100 x g, in storage buffer /10% (v/v) glycerol. Arrows 






4.2.2 Functional analysis of purified C11.2, C12.2 and C13.2 
4.2.2.1  Assessment of siRNA binding abilities by EMSA 
The molar concentrations required by C12.2 and C13.2 for effective siRNA complex 
formation, were assessed by EMSA and compared to the molar ratios tested with C5.1 and 
dsRNA. Prior analysis by Geoghegan et al. (2012) had revealed that Tat-DRBMx2 (C11.2) 
bound siRNA with lower affinity that PTD-DRBD. In our case, these results could not be 
replicated due to the low molar concentration of purified C11.2 (3.65 µM). 
Excess C12.2, upon complex formation with siRNA at 5:1, 10:1, 20:1 and 40:1, produced a 
gel shift at the 5:1 molar ratio, with some free siRNA remaining. At a 10:1 molar ratio, a 
complete gel shift was observed, followed by protein aggregation and minimal migration at 
the 20:1 and 40:1 molar ratios (Fig 4.3 A). 
C5.1, C12.2 and C13.2 in molar excess were allowed to complex with 1.0 µM siRNA at 
various molar ratios. C13.2 showed a partial gel shift at a 3:1 molar ratio, indicating 
incomplete binding by the C13.2 protein. At a 6:1 molar ratio, further complex formation 
was observed, as indicated by the increased ‘shift’ intensity on the gel. A third shift, or 
‘supershift’ was also observed at this molar ratio. Unexpectedly, a ‘supershift’ band was 
also evident at a 12:1 molar ratio; free siRNA was not observed on the gel. C13.2 was 
therefore able to bind dsRNA with high specificity and avidity at both 6:1 and 12:1 molar 




            
 
 Electrophoretic mobility shift assays with C12.2 (A) or C5.1 and C13.2 Figure 4.3
(B) complexed with siRNA at various molar ratios. A. C12.2-siRNA. B. Comparison of 
the DRBM1 (C5.1) and DRBMx2 (C13.2). Proteins and siRNA were incubated at 4°C for 
30 minutes in PBS and analysed by polyacrylamide gel electrophoresis on a 6% (w/v) 
native PAGE gel in 0.5x TBE buffer. The third ‘supershift’ band seen with C13.2 indicates 





4.2.2.2  Viability assays with purified C5.1, C11.2, C12.2 and C13.2 in HEK293 
and HepG2 cells. 
Having investigated  the siRNA-binding capacities of C5.1, C12.2 and C13.2 by EMSA, 
the potential for cytotoxicity or other effects on cell viability were investigated via the 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in HEK293 
and HepG2 cells (Mosmann, 1983).  
Tetrazolium salts are composed of a positively charged tetrazole ring core with four 
nitrogen atoms, surrounded by three aromatic phenyl groups and counterbalanced with one 
negatively charged sulfonate group (Fig. 4.4) (Berridge et al., 2005). The tetrazole ring is 
reduced by NAD(P)H-dependent oxidoreductases in the mitochondria of metabolically 
active (and therefore viable) cells following uptake via changes in the plasma membrane 
potential (Bernas and Dobrucki, 2002, Bernas and Dobrucki, 2000), forming brightly 
coloured formazan crystals. Cell viability, can thus be directly assessed by dissolving 
formazan crystals in an organic solvent such as DMSO, and measuring the absorbance at 
540-570nm (Mo et al., 2012).  
Since the reduction of MTT to formazan correlates with metabolic activity in actively 
dividing cells, decreased A570 is expected in non-dividing, or quiescent cells. HEK293 cells 
were seeded in 96-well microplates and allowed to adhere prior to treatment with 0.1, 0.3, 
1.0 or 3.3 µM C5.1, C11.2, C12.2, C13.2 or mock-treated control for 24 hours in low 
serum media (Optimem). Since most knockdown assays in vitro are performed with siRNA 
at a final concentration of 50 nM and a protein:siRNA ratio of 50:1, this concentration 
range provided some insight as to any potential cytotoxicity effects prior to loading with 
siRNA. Cytotoxicity was assessed by adding MTT to a final concentration of 0.45 mg/ml 
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and measuring absorbance at A570. Background signal was measured A640, and values were 
subtracted from  their respective A570 values to remove background fluorescence caused by 
non-specific interactions between the dye and  media (Riss TL, 2013). Results shown 
represent average % viability compared to mock-treated control (Optimem). 
 
 Schematic of the chemical reaction of MTT reduction to formazan, Figure 4.4
catalyzed by mitochondrial NADH oxidoreductase. MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; NADH, NADH dehydrogenase; NAD+, oxidised 
dehydrogenase. Br-, Bromide ions. 
 
In HEK293 (Fig. 4.5 A), C5.1, C11.2, C12.2 and C13.2 increased cell viability, or at least 
mitochondrial activity at  0.1, 0.3 and 1.0 µM concentrations, compared to the mock-
treated control. At 3.3 µM, C11.2 exhibited dose-dependent cytotoxicity, with only ~60% 
cell viability following a 24 hour treatment. However, pairwise comparisons between the 
0.1, 0.3 and 1 µM concentrations against the 3.3 µM concentration of C12.2 were not 
significant (P>0.05), indicating that C12.2 does not elicit dose-dependent cytotoxicity at 
the concentrations tested. For C11.2, similar pairwise comparisons between concentrations 
were significant (P<0.02), indicating that changes in cell viability are dose-dependent. 
Similarly, C13.3 showed dose-dependent changes between the 0.1, 0.3 and 3.3 µM 
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concentrations, but not between the 1.0 and 3.3 µM concentrations. Differences in cell 
viability due to protein concentration were not significant for C5.1 (Appendix II). Taken 
together, these results indicate that at the concentration range tested, cytotoxicity increases 
in the order of C12.2≤C5.1<C13.2<C11.2 in HEK293 cells (*p<0.05) (Fig 4.5 A). Results 
represent three independent experiments (n=3). Since no cytotoxicity was evident in 
HEK293 cells at the lowest molar concentration, it was omitted from HepG2 viability 
assays.  
Similar effects on cell viability were observed in HepG2 cells treated with 0.1-3.3 M 
protein, with C11.2 eliciting the highest cytotoxicity at all three concentrations when 
compared to C12.2 (Fig. 4.5 B, +p<0.05 ). The increase in cell viability observed with 1.0 
µM treatment with C11.2, C12.2 and C13.2 was not significant at P≤0.05. 
Pairwise comparisons between the different concentrations for each protein, were not 
significant. Differences between each protein at each concentration were not significant in 
HepG2 assays, either (P>0.05).  
Overall, effects on cell viability were cell-type dependent; however protein-specific results 
were significant between C11.2 and C12.2, indicating that overall, C12.2 is less cytotoxic 
than C11.2, at least in HepG2 cells. Results for HepG2 cells represent three independent 
experiments with biological replicates in triplicate (n=9).  
Mean values were calculated for each treatment, normalised against the untreated control 
cells and expressed as %. Error bars reflect ± standard deviation values (± SD) for 
HEK293 cells (n=3), and ± standard error of the mean (± SEM) for HepG2 cells (n=9).  
Statistical analysis was done with a 2-way Anova, and statistical significance was 
established with p-values set at 0.05 for pairwise comparisons, followed by Dunnet’s post-
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hoc test. In conclusion, statistically significant, dose-dependent cytotoxicity was observed 
in HEK293 cells, but not HepG2 cells, which signifies that cell-type specific effects on 




 Cell viability in HEK293 and HepG2 cells following a 24 hour Figure 4.5
incubation with increasing concentrations of C5.1, C11.2, C12.2 and C13.2 is cell-line 
dependent. Cells were incubated with increasing molar concentrations of proteins for 24 
hours and viability was assessed by the MTT reduction assay. A. HEK293 cell viability 
with 0.1, 0.3, 1.0 and 3.3 µM proteins. n=3; error bars ±SD. B. HepG2 cell viability with 
0.3, 1.0 and 3.3 µM proteins. n=9; error bars ±SEM. Statistical analysis was done by 2-way 
Anova followed by Dunnet’s post-hoc test of each protein concentration against the highest 






4.2.2.3  Qualitative assessment of protein-siRNA complex uptake in live 
HepG2 cells with C5.1, C12.2 and fluorescent siRNA 
Electrophoretic mobility shift assays with C5.1, C12.2 and C13.2 complexed with siRNA 
showed that DRBMx2 binds siRNA at lower molar ratios that DRBM1 alone (Fig. 4.3 B).  
In order to compare siRNA transduction efficacy between C5.1 and C12.2, proteins were 
co-incubated with 60 pmol siRNA-fluorescein at a 50:1 molar ratio (to give a final siRNA 
concentration =100 nM) and applied to adhered HepG2 cells for 2 hours. WGA-dsRed was 
used as a counterstain, localising primarily in the membrane and the nucleus at a 
concentration of 2.5 mg/ml (Fig. 4.6 D). 
Assuming that ~98 % siRNA is complexed with protein at this molar ratio (van Asbeck et 
al., 2013), C12.2 delivered siRNA to the cytoplasm of adherent HepG2 cells (Fig. 4.6 A), 
with comparable efficiency to the lipofectamine-transfected control (Fig. 4.6 C).  
The punctate distribution points towards an endocytic mechanism of uptake, consistent 
with results by Geoghegan et al. (2012). C5.1-siRNA, on the other hand, exhibited poor 
intracellular localization with a diffuse distribution interspersed by distinct punctae, which 





 Intracellular localisation of C5.1 and C12.2 complexed with 100 nM Figure 4.6
siRNA-fluorescein in live HepG2 cells. Protein-siRNA complexes were allowed to form 
at a 50:1 molar ratio and incubated with cells for two hours at 37°C. WGA-dsRed was used 
as a counterstain, translocating to the nucleus. A. C12.2-siRNA-fluorescein; B. C5.1-
siRNA-fluorescein; C. Lipofectamine RNAiMax-siRNA-fluorescein and D. Mock-treated 
control. Arrows indicate endosome-entrapped siRNA. Cells were visualized with a TCS 
SP2 Leica confocal microscope. Scale bar: 47.6 µm. 
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4.2.2.4 Generation of a HEK293 reporter cell line  
A HEK293 reporter cell line stably expressing destabilized enhanced green fluorescent 
protein (dEGFP) was created in order to assess whether fusion protein-mediated siRNA 
transduction could effectively induce transient knockdown of protein expression by RNAi. 
Cells were transfected with pd1EGFP-N1 plasmid DNA. To determine the optimal 
antibiotic selection concentration a kill curve was generated following a dose-response 
assay with 0.4-2 mg/ml G418 for 10 days. Lethal dose (LD) was observed at 2 mg/ml, with 
decreased viability (≤15%) observed at doses ≥0.8mg/ml (Fig. 4.7). A sub-lethal dosage of 
1 mg/ml G418 was therefore used as the effective antibiotic concentration for a further two 
weeks. Fluorescence activated cell sorting analysis (FACS) indicated that a range of 
dEGFP levels (measured on a FITC log10 scale) was stably expressed after auto-
fluorescence levels were normalised with untransfected HEK293 cells. Event limits were 
set at 1x104 cells. First, a population gate was set to encompass the majority of live, 
healthy cells based on the forward scatter (FSC, indicating cell size) and side scatter (SSC, 
indicating granularity) axes. Then, cell populations at GFP log height ~102 and ~103 were 
considered to be ‘Medium’ and ‘Highly’ – expressing populations and gated (R6 and R3 
regions, respectively). Highly-expressing cells (R3) represented only 2.75% of the total 
viable cell population, whereas the ‘medium’ expressing cells (R6) made up 12.19% of the 
population (Fig. 4.8 A). The cell population (gated as R5) represented cells that expressed 
the protein at high (103) levels. This subpopulation equated to only 4.35% of cells (Fig. 4.8 
B). Cells were analysed by Fluorescence-activated cell sorting (FACS) following stable 
selection with 1.0 mg/ml G418 into a ‘Medium’-expressing and a ‘Highly’-expressing 
population with specific expression profiles (Fig 4.9) Following sorting into distinct 
populations on the basis of their dEGFP expression, the maintenance dosage was decreased 
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to 0.5 mg/ml, which shifted both population expression levels to a lower expression profile 
(Fig. 4.10). FACS analysis was done at the Institute of Child Health, University College 
London (ICH, UCL). 
 
 Cell viability of HEK293-dEGFP cells treated for 10 days with Figure 4.7
increasing concentrations of G418 following transformation with pdEGFP-N1. Stable 
clones were counted as a % of untransfected cells by the trypan-blue assay.  
 
 
 FACS analysis of stable HEK293-dEGFP clones. A. 2-D dot plot of Figure 4.8
1x104 HEK293 cells stably transfected with pd1-EGFP-N1. R6, ‘medium’ expressing cells 
(GFP log ~102); R3, highly expressing cells (GFP log ≥103); R6, medium-expressing 
viable HEK293-dEGFP cells. B. Histogram of gated cell populations. R5, highly 





 FACS histogram analysis of stably transfected HEK293-dEGFP cell populations selected with 1.0 mg/ml G418. A. Figure 4.9
Untransfected HEK293 cells. B. Medium-expressing HEK293-dEGFP cell population (FITC log 102). C. Highly-expressing HEK293-dEGFP 




 FACS histogram analysis of stably transfected HEK293-dEGFP cell populations maintained with 0.5 mg/ml G418 shows a Figure 4.10
shift to a lower dEGFP phenotype. A. Untransfected HEK293 cells. B. Medium-expressing HEK293-dEGFP cell population (FITC log≥102). 
C. Highly-expressing HEK293-dEGFP cell population (FITC ≥log 103). R5, highly expressing gated population.Total cell count in histogram 
analysis, 7x104 cells. 




4.2.2.5 Transient knockdown assays in a HEK293-dEGFP reporter cell line 
In order to establish whether cell penetrating fusion proteins could effectively deliver 
siRNA into living cells and induce potent and specific gene knockdown, C5.1 and C12.2 
were complexed with either 10 nM or 100 nM final siRNA concentrations in low-serum 
media (Optimem). 2.5 x105 HEK293-dEGFP cells were seeded and adherent cells were 
transduced with complexes for 5 hours. Gene knockdown was observed by flow cytometry 
after either 24 or 48 hours treatment, with propidium iodide (PI) as a dead cell 
counterstain. 10 nM siRNA as a final concentration is the minimum concentration that is 
able to induce knockdown in vitro, and therefore served as a starting point for knockdown 
assays (Invitrogen, 2007). Since C5.1 and C12.2 lack the capability to escape from 
endosomes upon internalisation, they become sequestered into vesicles following uptake, 
thereby limiting the amount of siRNA cargo that is loaded onto the RNAi machinery 
(Geoghegan et al., 2012). To enhance endosomal escape, cells were treated with 50 µM 
chloroquine in complete growth media following transduction, according to the method 
from Geoghegan et al. (2012). Lipofectamine RNAiMax was used as a positive control in 
order to assess the efficiency of knockdown using this siRNA concentration.  Flow 
cytometry analysis on 1x104 HEK293-dEGFP cells in the presence of PI, showed that 
C5.1-siRNA failed to induce GFP expression knockdown actually increasing dEGFP 
expression levels (%). No knockdown was observed with RNAiMax-transfected siRNA 
(Fig. 4.11). Interestingly, C12.2-siRNA produced a modest GFP expression knockdown, 
whereas siRNA only treatment decreased the levels of dEGFP expression by ∼20%. 
Although live cells, that have taken up PI at a log10≥102, were gated, the cytotoxic or non-




 dEGFP expression analysis following treatment with 10 nM siRNA Figure 4.11
complexed with C5.1 or C12.2 for 48 hours. Cells were treated with either C5.1 or C12.2 
complexed with 10 nM GFP-specific siRNA at 50:1 molar ratios. 1x104 HEK293-dEGFP 
cells were analysed for GFP fluorescence by flow cytometry in the presence of propidium 
iodide. Mean values for each treatment were normalised against the mock-treated 
HEK293-dEGFP control and expressed as a %. Error bars represent ±SD, n=3. Statistical 
analysis was done by 1-way Anova, followed by Dunnet’s post-hoc test against the siRNA 
control. *P<0.05, **P<0.01. 
 
None of the Lipofectamine-siRNA or protein-siRNA treatments, mediated any statistically 
significant knockdown. This indicated that the siRNA concentration was insufficient for 
the number of cells seeded.  The assay was therefore repeated with 100 nM siRNA. To 
limit potential cytotoxicity elicited by a high siRNA concentration, protein-siRNA 
transductions were assessed 24 hours following treatment, rather than after 48.  
A population sample of 1x104 cells was analysed by flow cytometry with a FITC/PI filter. 
Untreated HEK293 cells were used to normalise against autofluorescence (FITC log10 
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≤103); this cell population was excluded from further analysis. Cells were stained with 0.5 
mg/ml PI with a log10 value of ≥103 were also gated and excluded from analysis (R1), 
therefore only live, highly expressing (FITC log10≥103) were considered when assessing 
for knockdown efficiency (R3) (Fig. 4.13). Mock-treated HEK293-dEGFP cells were used 
as the normalisation control (i.e set to 100%). All sample % histogram values were 
averaged and normalised against the untreated control. Two distinct subpopulations exist 
within the HEK293-dEGFP reporter cell line analysed, although the selection marker G418 
was used at very high concentrations (1.8mg/ml) to ensure high stable plasmid expression 
(FITC log10≥103). This is a normal distribution of fluorescence within a polyclonal stable 
cell line; a subpopulation has lost the dEGFP plasmid but is still resistant to G418 and 
another is expressing the pd1-EGFP-N1 plasmid at high levels. 
As expected, mock-treated HEK293 cells showed minimal fluorescence, whilst the cell 
population transfected with Lipofectamine RNAiMax showed a 40% decrease in dEGFP 
expression after 24 hours. C5.1-siRNA and C5.1-scrambled siRNA control failed to induce 
any dEGFP knockdown. Interestingly, C12.2-siRNA treatment showed a marked decrease 
(≈ 60%) in dEGFP expression – although treatment with scrambled, non-specific siRNA 
also showed a comparable decrease. siRNA-only treatment in the absence of protein or 
transfection agent elicited a modest, yet significant (20%) decrease in dEGFP expression, 
which was unexpected, as negatively charged siRNA molecules are usually excluded from 
cells by virtue of the negatively charged membrane bilayer (Fig.4.13). This observation 
cannot be attributed to cytotoxic effects since cells expressing PI at ≥ log 103 values  (and 
were therefore considered dead), were omitted from further analysis. 
Live (Fig. 4.12 A, R1), highly expressing cells were gated (Fig. 4.12 A, R3) and used to 
normalize cell populations prior to univariate analysis of overlaid treatment averages (Fig. 
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4.12 B). A decrease in dEGFP expression is shows as a shift in fluorescence, and was 
observed for cells treated with C12.2-siRNA (yellow), C12.2-scrambled siRNA control 
(pink) and lipofectamine-siRNA (green), in comparison to expression profiles observed 
with the mock-treated control (red), C5.1-siRNA (blue) and siRNA only (black). 
...  
....    
 FACS analysis of a HEK293-dEGFP cell line following treatment with Figure 4.12
protein-siRNA complexes for 24 hours. A. Histogram analysis of HEK293-dEGFP cells 
showing the gated subpopulations of the cells prior to dEGFP knockdown analysis. R1 
(left panel): Live cell subpopulation of untreated HEK293-dEGFP cells (PI log10≤103). R3 
(right panel): Highly expressing, live, untreated HEK293-dEGFP subpopulation after 
superimposition of the R1 gate. B. Univariate analysis showing overlaid histograms 





showing a decrease in dEGFP expression are shown shifted to the left; the highly 
expressing HEK293-dEGFP population is shown on the right of the FL1 channel axis. 
 
 dEGFP expression analysis following treatment with 100 nM siRNA Figure 4.13
complexed with C5.1 or C12.2 for 24 hours. Cells were treated with either C5.1 or C12.2 
complexed with 100 nM GFP-specific siRNA at 50:1 molar ratios. 1x104 HEK293-dEGFP 
cells were analysed by flow cytometry in the presence of propidium iodide. Mean values 
for each treatment were normalised against the mock-treated HEK293-dEGFP control and 
expressed as a %. Error bars represent ±SD, n=3. Statistical analysis was done by 1-way 




4.2.2.6 Protein –induced morphology changes in HepG2 cells 
Potential effects on the morphology of HepG2 cells were briefly assessed prior to proof-of-
principle experiments with protein-siRNA PTP1B knockdown. One of the intracellular 
targets for siRNA-induced knockdown in this study was the protein tyrosine phosphatase 
1B (PTP1B) protein, which is endogenously expressed in HepG2 cells and is a therapeutic 
target for type 2 diabetes (T2D).  
Lipofectamine RNAiMax and mock-treated HepG2 cells were used as controls. The 
siRNA duplex used corresponded to a 21-23nt sequence in the PTPN1 gene, which 
encodes for PTP1B (Life Technologies). Protein-siRNA complexes were formed with 25 
nM siRNA at a 1:50 molar ratio to proteins (Fig. 4.14). Cells were treated for 5 hours at 
37°C in low-serum media and incubated for 72 hours (Johnson et al., 2010, Lu et al., 
2008). Cell morphology was assessed by phase-contrast microscopy, following treatment 
Interestingly, C11.2-siRNA and C12.2-siRNA induced marked morphological changes in 
HepG2 cells, causing a shift from the typical epithelial phenotype associated with 
hepatocellular carcinoma cell lines, to a fibroblastic one, generally associated with 
connective tissue. Morphological changes were visible as elongated, bipolar apices, rather 
than the regular polygonal structures that HepG2 cells adopt. 
C5.1-siRNA, C13.2-siRNA and Lipofectamine RNAiMAX-siRNA complexes did not 
cause any morphological or colony structure changes, compared to the mock-treated 
control. None of the proteins appeared to induce cytotoxicity at the molar concentration 
tested with the siRNA (1.25 µM). These preliminary, qualitative results did not include 
siRNA-only and protein-only treatments, which would need to be included in subsequent 
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assays in order to assess whether morphological changes were induced by the protein-











 Phase-contrast microscopy of HepG2 cells transduced with 25 nM PTPN1 siRNA complexed with proteins at a 50:1 molar Figure 4.14
ratio for 72 hours. Cells were incubated with protein-siRNA complexes for 5 hours before media were changes and incubated at 37°C for 72 
hours before analysis by phase-contrast microscopy Arrows represent apical structure formation induced by protein treatment. Mock-treated 
control, Optimem only. 
C11.2-siRNA C5.1-siRNA C12.2-siRNA 
C13.2-siRNA Lipofectamine-siRNA Mock-treated control 
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4.2.2.7 Protein-siRNA assessment of PTP1B knockdown  
 C5.1, C11.2, C12.2 and C13.2 fusion proteins had been previously complexed with 25 nM 
PTPN1 siRNA and incubated HepG2 cells, with C11.2-siRNA and C12.2-siRNA had 
induced morphological changes in HepG2 cells. It was still unknown, though, whether a) 
these complexes had indeed transduced the cells and b) whether complexed PTPN1-
specific siRNA had induced a transient knockdown in the expression levels of protein 
tyrosine phosphatase 1B (PTP1B). Since HepG2 endogenously expresses PTP1B, 
knockdown assays were performed, and protein levels were assessed by immunoblotting 
with a PTPN1-specific antibody (Fig. 4.15 A and B). Western blotting with an anti-PTP1B 
antibody (BD Biosciences, Oxford, UK) established antibody specificity at a 1:2500 
dilution and 10 µg as the minimum amount of crude lysate protein resolved (Fig. 4.15 A). 
Preliminary transfections using lipofectamine and two siRNA oligonucleotide sequences 
(VHS204190 and VHS204191) (Methods), corresponding to the PTPN1 gene, showed a 
dose-dependent PTP1B  knockdown effect with 10, 25 and 50 nM siRNA at 72 hours post-
transfection (Fig 4.15 B). The minimum effective concentration required to induce 
complete PTP1B expression knockdown for both siRNA sequences was 25 nM. 
Lipofectamine-transfected siRNA induced a complete knockdown of PTP1B expression 
(Fig. 4.16, lane A) By contrast, none of the fusion proteins complexed with 25 nM siRNA 
induced any detectable protein expression knockdown at 50:1 molar ratios 72 hours post-





 HepG2 cell lysate immunoblot analysis with an α-PTP1B antibody. A. Figure 4.15
Lysate amount optimization from untreated HepG2 cells for detection by immunoblotting. 
B. PTP1B knockdown efficiency analysis following transfection with lipofectamine 
RNAiMax and two anti-PTPN1 siRNAs at various molar concentrations. Top panel, 
siRNA oligo 1 (VHS204190); lower panel, siRNA oligo 2 (VHS204191). β-Actin was 
used as a loading control. 15 µg protein loaded. PTP1B, 50 kDa; β-Actin, 42 kDa.  
 
 
 Immunoblot analysis on HepG2 cell lysates following PTP1B Figure 4.16
knockdown for 72 hours. A. Lipofectamine RNAiMax-siRNA; B. Lipofectamine 
RNAiMax-scrambled control siRNA; C. C5.1-siRNA; D. C12.2-siRNA; E. C11.2-siRNA; 
F. C13.2-siRNA; G. C9.2-siRNA; H. C10.2-siRNA and I. Untransfected control. β-Actin 




  Discussion  4.3
In this chapter, we aimed to purify and characterise recombinant proteins that contain the 
entire dsRNA binding domain (DRBMx2) from human PKR (Fig. 4.1), with the aim of 
assessing their siRNA binding efficiency by electrophoretic mobility shift assays; their 
ability to deliver GFP-specific siRNA to a dEGFP-expressing HEK293 reporter cell line; 
potential cytotoxicity by the MTT assay, and finally, the proteins’ potential to induce 
PTP1B expression knockdown, evident at the protein level, by immunoblotting.  
Previous research from Geoghegan et al, had purified Tat-DRBMx2 (C11.2), Penetratin-
DRBMx2 (C12.2) and DRBMx2 (C13.2) under denaturing conditions from bacterial 
cultures by low pressure chromatography. Purification and refolding were done on-column, 
and proteins were eluted, concentrated and buffer exchanged into PBS/10% glycerol 
(Geoghegan et al., 2012).  The approach used in this project, involved purification under 
denaturing conditions and sequential dialysis to refold proteins into their native state. 
Buffer-exchange to remove Gu+ ions and imidazole, resulted to the near-complete loss of 
C11.2 (final molar concentration = 3.65 µM). This protein was thereby excluded from 
these analyses. To eliminate the possibility that incorrectly folded protein had been 
purified, each step of the dialysis process was followed by a centrifugation step that 
eliminated aggregated protein as a precipitate. Increased precipitation with each dialysis 
step was observed for all proteins, even with the addition of 10% glycerol as an excipient, 
(Arakawa and Timasheff, 1983, Arakawa and Timasheff, 1984b, Arakawa and Timasheff, 
1984a, Arakawa et al., 2007, Frokjaer and Otzen, 2005, Gerlsma, 1968, Jorgensen et al., 
2009, Taneja and Ahmad, 1994). Although the process of dialysis is effective in the 
elimination of unwanted ions from the final buffer formulation, it appears to leave innately 
unstable proteins, such as C11.2 susceptible to degradation due to exogenous factors, such 
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as variations in temperature during handling, and slow buffer exchange kinetics. An 
alternative purification strategy, such as an ion exchange column, may have eliminated 
stability-dependent aggregation.  
EMSA assays with C12.2 and C13.2 yielded effective siRNA complex formation at low 
molar ratios with little or no aggregation, in comparison to C5.1.  Initial EMSA assays with 
fluorescent siRNA and no EtBr staining were unsuccessful, subsequent experiments 
utilised an unconjugated siRNA oligonucleotide (n=2). It would be expected that both 
C12.2 and C13.2, since they contain the same dsRNA binding domains, would bind siRNA 
with the same efficiency. SiRNA binding by C12.2 yielded a complete shift at a 10:1 molar 
ratio, whereas C13.2 showed a complete shift at a 6:1. This finding contradicts the 2:1 
molar ratio observed by Geoghegan et al. (2012). Since the methodology adopted was the 
same, this discrepancy could be attributed to structural differences between the siRNA 
molecules used due to the different stabilising modifications; in our case, a 25-mer siRNA 
with no overhangs was used, with other proprietary sense strand modifications, whereas 
the study by Geoghegan et al utilised 21-mer siRNAs. Although the sequence length is not 
expected to affect binding efficiency (Bycroft et al., 1995, Kharrat et al., 1995, Ryter and 
Schultz, 1998), (Dzananovic et al., 2013), these discrepancies may be attributed to the lack 
of 2’-OH overhangs, or other proprietary modifications in the siRNA used. Indeed, crystal 
structure studies on the highly conserved DRBD from Xenopus laevis, showed that RNA-
protein interactions occur through hydrogen bonding with 2’-OH groups present in the 
minor groove, in A-form dsRNA (Ryter and Schultz, 1998). A non-equivalence of dsRNA 
binding by the DRBMx2 occurs with nucleoside modifications or the incorporation of 
stabilising G-U wobble pairs (Nallagatla et al., 2008, Nallagatla and Bevilacqua, 2008), 
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that ultimately change the overall structure of the A-form helix (Masquida and Westhof, 
2000, Weeks and Crothers, 1993).  
MTT assay results pointed towards dose-dependent as well as cell-line specific effects of 
unconjugated proteins on cell viability. In HEK293 cells, relative cytotoxicities at 3.3 µM 
were highest for C11.2 and C13.2, with C5.1 and C12.2 eliciting the lowest (n=3). 
Alhough C11.2 also showed the greatest effects on cell viability at the 3.3 µM 
concentration in HepG2 cells, statistical analysis of these assays (n=9) showed no 
significance at p-values≤0.05 (Appendix II.2), indicating that there is no correlation 
between our concentration range and mitochondrial activity in this cell line.  
By comparison, pair-wise comparisons between C11.2 and C13.2, or between proteins and 
concentrations in HEK293 cells were significant at p≤0.05, indicating that cytotoxicity is 
indeed dose-dependent, at least for these two proteins. Cell viability differences between 
C5.1 and C12.2, were not statistically significant (Appendix II.2). The observation of cell 
line-specific effects on cell viability is consistent with previous research with Penetratin by 
Sugita et al, 2008. Their group had observed Penetratin-induced cytotoxicity in HeLa, but 
not HaCat and A431 cells at concentrations ≥100 µM, with negligible cytotoxicities below 
that concentration (Sugita et al., 2008), with negligible cytotoxicity at 50 µM was observed 
in CHO cells (El-Andaloussi et al., 2007a). Our results obtained from HEK293 cell assays 
point towards dose-dependent cytotoxicity at a much lower concentration range than 
previously tested (El-Andaloussi et al., 2007a, Mueller et al., 2008, Sugita et al., 2008). It 
is still unknown why mitochondrial activity is affected by various concentrations of 
proteins, although overestimations of mitochondrial activity (and by extension, cell 
numbers), are a common limitation of this assay (Wang et al., 2010). Also unknown are 
the causes behind cell line susceptibilities. It would be interesting to replicate these 
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findings using another colorimetric assay, such as the WST-8 assay. The WST-8 assay 
involves the extracellular, rather than intracellular reduction of water-soluble tetrazolium 
salts, and thus does not require the solubilisation step with DMSO, minimizes cytotoxicity, 
can be colorimetrically assayed and provides better accuracy with regards to cell viability 
(Berridge et al., 2005). Moreover, our observations reinforce the notion that cell-type 
specific effects should be considered when preparing protein-based therapeutic 
formulations.  
Morphology-specific effects, especially with non-covalently conjugated siRNA cargo, 
have not been previously reported for HepG2 cells. Here, we have shown that a 72-hour 
incubation of HepG2 cells with C11.2 and C12.2 complexed with 25 nM siRNA elicit 
distinct morphological changes in HepG2 cells, which were not observed by similar 
treatment with Lipofectamine-siRNA, C13.3-siRNA or C5.1-siRNA. Again, it is unclear as 
to why Tat-DRBMx2 (C11.2) and Pen-DRBMx2 (C12.2), but not DRBMx2 (C13.2) or 
AntpHD-DRBMx2 (C5.1), have caused these changes. Both proteins appear to shift the 
morphology of epithelial HepG2 cells from a well-defined, cubical morphology, to a more 
fibroblastic one with apical structures extending in a bipolar manner. Assuming that 
complexes are indeed taken up by the cells, it would be interesting to assess potential 
changes on the actin cytoskeleton by phalloidin staining. Holm et al (2011) investigated 
the effects of 20 µM fluorescently labelled Penetratin and its retro-inverso (RI) enantiomer 
with the same amino acid sequence in an epithelial mammary gland adenocarcinoma cell 
line (MDA-MB-231) (Holm et al., 2011). Although Penetratin did not elicit any changes to 
the arrangement of the actin cytoskeleton, RI-Penetratin caused drastic changes in the 
adhesive actin bundles, producing a similar phenotype to the HepG2 cells treated with 
C11.2 and C12.2. Absence of morphological changes with Lipofectamine-siRNA treatment 
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signify that siRNA is not the causative agent, however, in the absence of a siRNA-only and 
protein-only controls, these qualitative results can only be construed as preliminary and in 
need of further investigation. 
Localisation assays in live HepG2 cells with a WGA-dsRed counterstain showed enhanced 
intracellular localisation of C12.2-fluorescent siRNA complexes, compared to C5.1-
fluorescent siRNA and lipofectamine-transfected cells. The punctate distribution observed 
is consistent with previous work with unconjugated Penetratin in HEK293, HeLa, MDCK 
and Cos-7 cells (Mueller et al., 2008), presumably by associating with heparan sulfate 
proteoglycans on the cell surface (Console et al., 2003, Marty et al., 2004, Tyagi et al., 
2001). Since these are qualitative results, the transduction efficiency cannot be quantified, 
and may be attributed to an enhanced complex formation efficiency of the DRBMx2 in 
C12.2 compared to the DRBM1 in C5.1, consistent with observations by Geoghegan et al. 
(2012). An alternative explanation would be due to the lack of co-purified nucleic acids.  
Since C5.1 was able to transduce siRNA intracellularly, this indicates that the protein is 
still able to bind siRNA, and transduce it into cells, consistent with observation by Eguchi 
et al, albeit with lower affinity than intact DRBMx2 (C13.2). This observation could be 
explained by the mode of dsRNA binding by PKR; although DRBM1 can effectively bind 
dsRNA, DRBM2 is required to stabilise the overall complex (Dabo and Meurs, 2012).  
To quantify C5.1 and C12.2-mediated siRNA transduction, a dEGFP-expressing HEK293 
reporter cell line was developed from a polyclonal culture transformed with the 
destabilised variant of GFP from Aquirea  victoria. Stable clones were selected with a high 
dose of geneticin (G418), due to the generation of the kill-curve after plasmid transfection, 
and not before. However, fluorescence-activated cell sorting (FACS) of stable clones 
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revealed two distinct sub-populations, with the majority of cells showing stable plasmid 
integration, suitable for further assays. The actual percentage of cells expressing dEGFP at 
high levels (FITC log10≤103) may be attributed to the expression of many plasmid copies 
within each cell. Decreasing the maintenance dose shifted GFP expression levels and 
decreased the number of highly expressing clones. Further attempts to increase the 
proportion of highly expressing cells by increasing the antibiotic concentration did not 
change the expression profile, with a large number of cells (67%) still showing stable 
plasmid integration.  
Eguchi et al (2009) had reported robust dGFP expression knockdown in a lung 
adenocarcinoma reporter cell line (H1299-dGFP/dsRed) with PTD-DRBD following 
treatment for 24 hours, that was sustained after 48 hours. Treatment of HEK293-dEGFP 
cells with either C5.1 or C12.2-siRNA at a final siRNA concentration of 10 nM did not 
elicit any effects on dEGFP expression; neither did lipofectamine-transfected siRNA, 
which indicated that the siRNA concentration was insufficient to induce knockdown. 
Considering previous observations of C5.1 aggregating, (i.e. associating with, but not 
entering the cell) at the plasma membrane of fixed HepG2 cells, and the work of Mueller et 
al, (2008), who reported that fewer than 10% of CPPs in general are effectively 
internalised, the possibility that an insufficient number of protein-siRNA complexes were 
successfully internalised remains. Since C12.2 (Geoghegan et al, 2012) and C5.1 lack the 
ability escape from endosomes upon internalisation, an incubation step for 24 hours in 
complete GM supplemented with 50 µM chloroquine, a known endosomolytic agent, was 
performed (Geoghegan et al., 2012). In following assays (n=3), the final concentration of 
siRNA was subsequently increased to 100 nM and knockdown was assessed after 24, 
rather than 48 hours. Non-covalent complexes with C12.2-siRNA were able to decrease 
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dEGFP expression significantly, which indicated that complexes were transduced into cells 
and siRNA was able to induce RNAi. However, the same observations occurred with the 
non-specific scrambled control, which was unexpected. The possibility that a non-specific 
decrease in dEGFP expression is caused by a decrease in viable cell numbers was taken 
into consideration by staining cells with PI (0.5 mg/ml) prior to analysis and gating cells 
that had appeared to be alive. However, further work in needed to assess any non-specific 
knockdown effects that may be caused by the scrambled control siRNA. 
 C5.1-siRNA on the other hand, failed to mediate any dEGFP knockdown, indicating that 
the DRBM1 does not bind the siRNA sufficiently, consistent with previous observations 
from EMSA assays. In contrast, Eguchi et al, had reported robust and specific reporter 
gene knockdown with the PTD-DRBM1 protein non-covalently loaded with siRNA; their 
results however, were obtained with 400 nM siRNA. Moreover, their observations were 
attributed to non-specific interactions with the Tat moieties within the protein, which aided 
siRNA complex formation (Calnan et al., 1991, Geoghegan et al., 2012, Mujeeb et al., 
1994).  
As a proof-of-concept experiment aimed to validate whether any of the recombinant 
proteins were able to knockdown the expression of PTP1B in HepG2 cells, all purified 
proteins were complexed with 25 nM siRNA and used to treat cells for 72 hours. This 
RNA concentration was optimised with lipofectamine transfections (n=2), with evidence at 
the protein level assessed by western blot. Other optimisation assays on untreated whole 
cell lysates with an anti-PTP1B antibody identified 10 µg as the minimum amount of crude 
lysate protein resolved by immunoblotting. Whole cell lysate analysis following 
knockdown was therefore done with 15µg crude protein. Apart from the lipofectamine-
treated control, none of the recombinant protein-siRNA complexes induced knockdown. It 
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would be interesting to investigate potential changes in putative primary mRNA transcript 
levels instead, by RT-PCR (Reverse Transcription Polymerase Chain Reaction), which 










RNAi-based therapies have the potential to revolutionize personal medicine by specifically 
targeting aberrant gene expression - the cause of a cornucopia of chronic, debilitating and 
fatal diseases.  In theory, RNAi based therapies target primary mRNA transcripts before 
they are translated into aberrant or misfolded protein, in a potent, specific, universal and 
non-cytotoxic manner, as opposed to small molecule inhibitors (SMocs) that target the 
protein product from affected DNA following transcription and translation from its 
putative mRNA (Fig. 5.1).   
 
 Modes of action of the attenuation of protein activity. A. Translation Figure 5.1
inhibition by siRNA-mediated RNAi; B. Inhibition of protein activity by small molecule 
inhibitors (SMocs). Adapted from Weiss et al. (2007). 
 
An important issue for the development of these therapies lies in their delivery; as Meade 
and Dowdy wrote, ‘delivery of nucleic acid therapies is the 800-pound gorilla in the room’ 
(Meade and Dowdy, 2009). Current nanoparticle-based strategies that include cationic 
motifs, whether these are polymers, peptides or liposomal formulations, aim to increase in 
vivo circulation time, reduce renal clearance and avoid the stimulation of the interferon 
response (de Fougerolles et al., 2007, Vaishnaw et al., 2010). The most commonly used 




large anionic charge of the siRNA backbone is amenable to non-covalent approaches 
which may be able to release cargo intracellularly upon internalisation.  
In light of recent developments in the non-covalent delivery of siRNA by incorporating a 
dsRNA binding domain sequence with a cell-penetrating peptide (CPP, in this instance the 
HIV-Tat protein) (Eguchi et al., 2009), that exhibited potent and specific gene knockdown 
in a number of cell lines, we set out to investigate whether the Antennapedia 
homeodomain, a transduction domain part of a much larger protein complex from D. 
melanogaster, could potentially be an efficacious siRNA delivery vector.  To aid complex 
formation with siRNA, we recombinantly expressed the AntpHD, as well as Penetratin, 
with a dsRNA binding domain from human PKR – a strategy which has proved highly 
effective in inducing potent and specific gene knockdown in recent studies by Eguchi et al. 
(2009) and Geoghegan et al. (2012). 
The development of peptide-based delivery vectors, may seem ideal in theory – after all, 
cell penetrating peptides, or transduction domains, have been well documented in the last 
20 years and indeed pose a beautiful alternative to viral vectors and toxic liposomal 
formulations. They are small (15-30 kDa) in size, are able to traverse the cell membrane 
with generally negligent cytotoxicity, and their generally cationic charge allows for the 
attachment of anionic cargo. In practice, their Achilles’ heel lies in a formulation that 
keeps the protein both stable and active following purification from a heterologous system. 
Other potential issues include endosomal entrapment following internalisation, serum 




In the context of siRNA delivery, proteins to be used as vectors ought to be devoid of any 
nucleic acid contamination during purification, to be properly folded and retain their 
biological activity; thus purified through an optimised strategy, and finally be stable in a 
formulation that will allow complex formation with siRNA. Lastly, they should be able to 
bind their cargo with high affinity, transduce it intracellularly and release it into the 
cytoplasm upon protein-cargo-induced release from endosomal vesicles.  
We have designed various DRBM1 or DRBMx2-based fusion proteins with various cell 
penetrating moieties, cloned them, and by studying biochemical parameters such as their 
molecular weight, pI and primary structure, we have purified them under both native and 
denaturing conditions from a bacterial cell system in suitable buffers for their isolation. 
Although similar with respect to their lengths, pIs and overall charge, there was no 
universality in the purification process. Indeed, from our observations using two well-
characterised affinity tags (the poly(His) and GST tags), differences in levels of 
expression, solubility, stability and final yields were immense. Aggregation was by far the 
most common problem encountered, with yield losses that prevented some proteins, such 
as the Pen-DRBMx1 (C6.1 and C6.1-myc), EB1-DRBMx2 (C7.2, C9.2), DRBMx2-EB1 
(C8.2, C10.2) and Tat-DRBM1 (C11.2), from being isolated for further analysis. Indeed, 
the optimisation of critical parameters (such as culture temperature, IPTG concentration for 
induction, expression time, media choice and the choice of purification strategy) is 
necessary for streamlined protein production. Solid-phase synthesis is at the moment, 
prohibitive to large-scale protein production, due to costs. Time and money permitting, the 
purification strategies adopted in this project would have been further optimised to include 
a wider variety of purification methods, such as ion exchange chromatography, the use of 
DNA-binding protein affinity chromatography, a wider choice of buffer pH and the 
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development of an efficient refolding strategy that minimized aggregation and allowed for 
the isolation of increased yields of properly folded protein. Although care was taken to 
address the innate instability of our proteins with buffers of high ionic strength and 
stabilising excipients (Frokjaer and Otzen, 2005, Jorgensen et al., 2009, Wang, 2005), 
further work is needed in order to successfully generate a comprehensive purification 
strategy, as critical parameters need to be addressed on a case-by-case basis (Arakawa et 
al., 2007). Further purification steps may include ion exchange chromatography via fast 
protein exclusion chromatography (HPLC) to remove any bound nucleic acid, as well as 
size exclusion chromatography to remove smaller contaminating protein species from the 
final purified product.  
Results obtained with the Antennapedia homeodomain as an siRNA carrier in this thesis 
highlighted the biological activity of the AntpHD as a DNA binding protein by nature 
(Muller et al., 1988). This conclusion was drawn upon evaluation of the C5.1 construct 
binding with siRNA yet co-purifying with endogenous DNA. This was an important 
observation that limited its use as a siRNA carrier in this project and one which should be 
addressed with DNAse digestion during  future purifications.  Immunofluorescence and 
live cell localization assays did confirm  its transducing abilities in both cell lines tested, 
however, its inefficient siRNA complex formation as demonstrated by EMSA assays, and 
the failure to induce any RNAi-induced knockdown in our reporter cell line, signified that 
this particular fusion protein is not an effective delivery vector. It would have been 
interesting to investigate the outcomes of these assays following DNA-free purification of 
these constructs. Endosomal entrapment upon cell entry could be attributed to the lack of 
endosomolytic histidines within primary amino acid sequence of C5.1 and C5.1-myc. This 
could be addressed by incorporating a pH-sensitive linker that improves the chances of 
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successful release of the protein and its cargo from endosomes upon internalisation, as 
demonstrated by June et al. (2010) and Chen et al. (2010). Fusion proteins containing the 
EB1 peptide sequence were designed to address the issue of endosomolytic entrapment; 
although these proteins were successfully isolated, they were subsequently lost during 
refolding by dialysis.  With respect to these  constructs, an optimised refolding strategy 
that limits yield losses during the last stages of refolding and storage may be beneficial; 
alternatives to sequential dialysis, as outlined in Chapter 3, may have allowed further 
evaluation of these fusion proteins.  
It would have been interesting to compare the siRNA binding efficiency of these proteins 
in comparison to the EB1 construct by Lundberg et al. (2007); the incorporation of the 
entire DRBD may have increased the siRNA-binding capabilities, while the EB1 moiety 
would have addressed the issue of endosomal sequestration.  
Our results with fusion proteins C5.1 (AntpHD-DRBM1), C11.2 (Tat-DRBMx2), C12.2 
(Penetratin-DRBMx2) and C13.2 (DRBMx2) further reinforced the notion of cell-type 
specific cytotoxicity for all the proteins tested, although C12.2 elicited significantly less 
cytotoxicity than C11.2 in both cell lines. Moreover, the successful delivery of siRNA and 
the induction of statistically significant GFP expression knockdown by C12.2 in a reporter 
cell line, leaving the prospect of further developing Penetratin-based, rather than Tat-based 
recombinant proteins, open to further investigation.  
C11.2-siRNA and C12.2-siRNA induced morphological changes in HepG2 cells, an 
observation previously unreported. Further work is necessary to understand the molecular 
mechanisms behind the morphological changes observed in HepG2 cells following 
treatment with C11.2 and C12.2, as our results were only preliminary and addressed only 
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phenotypic changes. Are they signs of toxicity? Is the cellular phenotype associated with 
pre-apoptotic or pro-proliferative pathways? It has been shown that the AntpHD induces 
neuronal differentiation (Cosgaya et al., 1998, Joliot et al., 1991a), but its effects in 
adherent cell lines are still unknown. Does uptake by mammalian cells induce any changes 
in endogenous gene expression? These are interesting questions that need to be answered if 








6.1.1 Bacterial Strains 
 E.coli strains and associated genotypes Table 6.1
Strain Genotype Source 
XL1-Blue recA1, endA1, gyrA96, thi-1, hsdR17 
supE44, relA1, lac [F ́ proAB lacIqZ∆M15 
Tn10 (Tetr)] 
Stratagene (A. 
Markiv, U. of 
Westminster) 




6.1.2 Plasmids  
 Plasmid vectors and inserts Table 6.2







C1.1 pET32-a AntpHD-DRBM1 His10 NcoI/XhoI Factor Xα 
C2.1 pET32-a Pen-DRBM1 His10 NcoI/XhoI Factor Xα 
C3.1 pET32-a AntpHD-DRBM1 His6 NdeI/XhoI TEV 
C4.1 pET32-a Pen-DRBM1 His6 NdeI/XhoI TEV 
C5.1 pGEX-6P-2 AntpHD-DRBM1 GST BamHI/XhoI Prescission 
protease 












GST BamHI/XhoI Prescission 
protease 
C7.2 pGEX-6P-2 EB1-DRBMx2 GST BamHI/XhoI Prescission 
protease 
C8.2 pGEX-6P-2 DRBMx2-EB1 GST BamHI/XhoI Prescission 
protease 
C9.2 pET32-a EB1-DRBMx2 His6 NdeI/XhoI - 
C10.2 pET32-a DRBMx2-EB1 His6 NdeI/XhoI - 
C11.2 pET11-d Tat-DRBMx2 His6 - - 
C12.2 pET11-d Pen-DRBMx2 His6 - - 




6.1.3 Cloning primers 
 Primer list for PCR amplification of constructs C1.1-C6.1 Table 6.3






































































 Primer list for PCR amplification of constructs C7.2-C10.2 Table 6.4
Construct Forward primer sequence  
(5’→3’) 




















6.1.4 Sequencing primers 
 Sequencing primer list Table 6.5
Construct Primer  Primer sequence (5’→ 3’) 
C1.1 T7minus1 AATACGACTCACTATAGGG 
C2.1 T7minus1 AATACGACTCACTATAGGG 
C3.1 T7minus1 AATACGACTCACTATAGGG 
C4.1 T7minus1 AATACGACTCACTATAGGG 
C5.1 pGEX5-FP AACGTATTGAAGCTATCCC 













C7.2 T7minus1 AATACGACTCACTATAGGG 
C8.2 T7minus1 AATACGACTCACTATAGGG 
C9.2 pGEX5-FP AACGTATTGAAGCTATCCC 
C10.2 pGEX5-FP AACGTATTGAAGCTATCCC 
C11.2 pUC-FP GCCAGTGAATTCGAGCTCGG 
C12.2 pUC-FP GCCAGTGAATTCGAGCTCGG 





6.1.5 Protein purification buffers, media, solutions 
6.1.5.1 General Media and Antibiotics 
XL1-Blue and BL21(DE3)pRare cells were grown in Luria Bertani broth: 1% (w/v) 
Tryptone, 0.5% (w/v) NaCl, 0.5% (w/v) yeast extract. 
 Antibiotics used in bacterial cell cultures or in cell culture Table 6.6
Name Stock concentration 
(w/v) 
Working concentration Source 
Ampicillin 100 mg/ml 100µg/ml Sigma 
Chloramphenicol 34 mg/ml in 80% EtOH 34 µg/ml Sigma 
Kanamycin 10 mg/ml 10 µg/ml Sigma 
Geneticin (G418) 50 mg/ml 0.4-2 mg/ml Sigma 
 
 General buffers and solutions2 Table 6.7
Name Composition 
10x SDS running buffer 250 mM Tris-base, 2.5 M glycine, 1% (w/v) SDS, in 
ddH2O,  pH 8.3 
Coomassie total protein stain 0.05% -0.1% (w/v) Coomassie Brilliant blue, 50% (v/v) 
Methanol, 10% (v/v) Acetic acid in ddH2O 
Destaining solution 7% (v/v) Acetic acid in ddH2O 
5x Transfer buffer 960 mM Glycine, 120 mM Tris-base in ddH2O 
1x Transfer buffer 20% (v/v) 5x Transfer buffer, 10% (v/v) Methanol 
10x TBS 200 mM Tris-base 1.5 M NaCl, (pH 7.6) in ddH2O  
TBS-T 10% (v/v) 10x TBS, 0.05% (v/v) Tween-20 in ddH2O 
 
  
                                                 
2




 Reagents used in Polyacrylamide gel electrophoresis (SDS-PAGE) Table 6.8
Reagent 12 % Resolving 
gel(x2) (ml) 
15 % Resolving 
gel (x2) (ml) 
4% Stacking gel 
(x2) (ml) 
ddH2O 4.9 4.15 3.6 
1.5 M Tris-base pH 8.8 2.6 2.6 - 
0.5 M Tris-base, pH 6.8 - - 0.625 
10% (w/v) sodium dodecyl 
sulfate 
0.1 0.1 0.05 
40% (w/v) Bis-Acrylamide 3.0 3.75 0.5 
10% (v/v) ammonium 
persulfate 
0.1 0.1 0.05 
TEMED 0.02 0.02 0.01 
 
6.1.5.2 Protein purification buffers 
 Protein purification buffers used in IMAC under native conditions  Table 6.9
Name Composition 
His-Binding buffer 50 mM HEPES, 500 mM NaCl, 5 mM Imidazole, 5% (v/v) 
Glycerol 
His-Wash buffer 50 mM HEPES, 500 mM NaCl, 30 mM Imidazole, 5% (v/v) 
Glycerol 
His-Elution buffer 50 mM HEPES, 500 mM NaCl, 250 mM Imidazole, 5% (v/v) 
Glycerol 
 




50mM Tris-HCl, 500 mM NaCl, 10 mM DTT, 5% (v/v) Glycerol, 
pH 7.5 




50mM Tris-HCl, 500 mM NaCl, 10 mM DTT, 5% (v/v) Glycerol, 
10 mM reduced glutathione pH 8.0, 
GST-Equilibration 
(cleavage) buffer 









 Protein purification buffers used in IMAC under denaturing conditions  Table 6.11
Name Composition 
His-Resuspension buffer 50 mM sodium phosphate (pH 7.4) 
Additives (per 0.5L)  1 tablet complete mini protease inhibitor (without EDTA), 
1200 U benzonase, 30,000 U lysozyme, 2 mM MgCl2 
1.1x His-Guanidine 
binding buffer 
50 mM sodium phosphate, 550 mM NaCl, 22.2 mM 
imidazole, 6.66 M Guanidine-HCl, 2 mM β-mercaptoethanol  
(pH 7.4) 
His-Wash buffer 50 mM sodium phosphate, 550 mM NaCl, 22.2 mM 
imidazole, 6.66 M Guanidine-HCl, 2 mM β-mercaptoethanol 
(pH 7.4) 
His-Elution buffer 50 mM sodium phosphate, 500 mM NaCl, 150 mM 
imidazole (pH 7.4) 
His-Refolding buffer 50 mM sodium phosphate (pH 7.4), 500 mM NaCl, 20 mM 
imidazole (pH 7.4) 








6.2.1 Plasmids  
The AntpHD-DRBM1 plasmid was obtained from Epoch Biosciences (Missouri City, TX, 
USA). The pd1-deGFP-N1 plasmid was kindly provided by Drs Chang and Moore 
(University of Pittsburgh). Modified pET32-a lacking the thioredoxin (trx) tag was a kind 
gift from Dr Markiv (University of Westminster). EB1-DRBMx2 and DRBMx2-EB1 were 
from Genscript (Piscataway, NJ, USA). The Tat-DRBMx2, Pen-DRBMx2 and DRBMx2 
plasmids were a kind gift from Prof. Beverly (University of Iowa). 
6.2.2 Competent E. coli strain preparation 
XL1-Blue and BL21(DE3)pRARE cells were grown  in 200 ml fresh LB broth inoculated 
with 10 ml starter cultures in the absence of antibiotics at 37°C and 250 rpm in a shaking 
incubator, until an O.D595 ~0.4 was reached. The flask was then chilled on ice for 30 
minutes and 50 ml were aliquoted into pre-chilled sterile centrifuge tubes. Cells were 
harvested by centrifugation for 10 minutes at 4,500 rpm at 4°C. Supernatants were 
discarded and each pellet was resuspended in 12.5 ml 0.1 M MgCl2. Resuspended cells 
were centrifuged again as before and the pellets were resuspended in 25 ml 0.1 M CaCl2. 
Cells were incubated on ice for 30 minutes, centrifuged again and the supernatant was 
discarded. Pellets were resuspended in 700 µl 0.1 M CaCl2 and 300 µl 50% glycerol, 
before being stored as 50 µl aliquots at -80°C. 
6.2.3 cDNA Cloning by PCR 
For C1.1-C6.1, a synthetic cDNA template encoding for the entire Antennapedia 
homeodomain (AntpHD) linked to the dsRNA binding domain 1 (DRBM1) from human 
PKR by a small fexible linker ((G4S)2), was  obtained as an EcoRV fragment  inserted into 
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a modified pBSK plasmid lacking its MCS (Epoch Biosciences, (Missouri City, TX, 
USA)and used as the template for the construction of 8 new constructs, encoding for either 
the AntpHD-DRBM1 or Penetratin-DRBM1.  AntpHD-DRBM1 and Pen-DRBM1 were 
cloned by PCR using Platinum Pfx DNA Polymerase (Invitrogen, Paisley, UK) as 
NcoI/XhoI fragments with an N-terminus His10 tag and a Factor-Xα cleavage site for the 
tag’s subsequent removal following purification (His10-HQEA-AntpHD/Pen-DRBM1, 
where –HQEA- corresponds to the Factor Xα protease cleavage site). Similarly, they were 
also cloned as NdeI/XhoI fragments with a C-terminus His6 tag separated from the fusion 
peptide by a TEV protease cleavage site (AntpHD/Pen-DRBM1-ENLYFQ(G/S)-His6, 
where ENLYFQ(G/S)- corresponds to the TEV cleavage site).  An N-terminally GST 
tagged construct was generated by inserting the PCR product into a vector pGEX-6P-2 
(GE Healthcare, Uppsala, Sweden).  Both AntpHD-DRBM1 and Pen-DRBM1 were cloned 
as BamHI/XhoI fragments with an N-terminus Prescission protease (PP) cleavage site (-
LEVLFQGP-). The c-myc epitope tag (-EQKLISEEDLN-) was added to the C-terminus of 
GST-AntpHD-DRBM1 and GST-Pen-DRBM1 using the amplified GST-AntpHD-DRBM1 
sequence as a template.  10 µM of custom-designed oligonucleotide primers  were used for 
this purpose on an MJ Mini Thermal Cycler (Biorad, Hertfordshire, UK). The cDNA 
templates for EB1-DRBMx2 and DRBMx2-EB1 were obtained as synthetic plasmids with 
a pUC57 backbone from Genscript (Piscataway, NJ, USA) and sequenced with a universal 
pUC57 forward and reverse primer. NdeI/XhoI or BamHI/XhoI cleavage sites inserted by 
PCR and amplified fragments were cloned into a modified pET32-a and pGEX-6P-2, 
respectively. Thermocycler reaction conditions were optimised for each construct by 




6.2.4 Cloning into plasmid vectors 
Purified target sequences with PCR-inserted restriction sites were double-digested with 1-2 
units of appropriate restriction endonucleases (REs) (New England Biolabs, Herts, UK) in 
a final volume of 50 µl prior to ligation with plasmid vectors. N-terminus His10-tagged 
AntpHD-DRBM1 and Pen-DRBM1 were double-digested with NcoI/XhoI for 60 minutes 
at 37°C while constructs cloned with a C-terminus His6-tag were digested with NdeI/XhoI. 
A modified pET32-a vector plasmid, was also digested with either NcoI/XhoI or NdeI/XhoI 
enzymes to create appropriate sticky ends for ligation. Constructs to be inserted into 
pGEX-6P-2 (GE Healthcare, Uppsala, Sweden) were digested with BamHI/XhoI under the 
same conditions are before. 2 µg of each plasmid vector were also digested with the same 
REs. Ligations were done with a T4 DNA ligase as part of a Rapid Ligation kit (Roche, 
Sussex, UK) at insert-to-vector molar ratios of 3:1 and 5:1, respectively, for 2 hours at 
25°C, using a linearised plasmid vector (minimum 50 ng) and digested insert. Their 
concentration and purities assessed by a Nanodrop 1000 micro-volume spectrophotometer 
(Thermo Scientific, DE, USA) at 260 nm and 280 nm.  
6.2.5 Gel extraction and ligation into plasmid vectors 
For gels bands to be blind-excised and purified, samples were run in duplicate on the same 
gel, and the gel was halved prior to visualization under UV light, to avoid inserting 
mutations.  
Digested vector plasmids were isolated by gel blind-excision, solubilised and eluted in 50 
µl EB buffer using a QiaQuick Gel Extraction kit (Qiagen, Crawley, UK) according to the 
manufacturer’s specifications. Digested PCR fragments were ligated into either a modified 
pET32-a vector or a pGEX-6P-2 vector using T4 DNA ligase, respectively, as before, for 
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5-30 minutes at 25°C. The resulting ligation mixes were used to transform competent XL1-
Blue E. coli, which were then aseptically plated on amp+ (100 µg/ml) plates overnight at 
37°C. Similarly, Tat-DRBMx2-His6, Pen-DRBMx2-His6 and DRBMx2-His6 plasmids 
ligated with pET11-d were used to transform competent XL1-Blue cells as before.  
6.2.6 Transformation of competent cells 
50 µl competent E. coli cells were thawed on ice for 5 minutes. 1-2 µl plasmid DNA (1-2 
µg/µl) was added, and cells were incubated on ice for 5 minutes. For transformation, cells 
were heat-shocked for 60 seconds at 42°C and allowed to recuperate on ice for 5 minutes. 
250 µl SOC buffer was added and cells were incubated in a shaking incubator at 37°C and 
250 rpm for 60 minutes. Transformed cells were plated on agar plates containing the 
antibiotic corresponding to the plasmid’s resistance marker, and allowed to grow at 37°C 
for 16 hours. For plasmid propagation, the E. coli propagation strain XL1-Blue was used. 
For protein expression, the BL21(DE3)pRARE strain was used, which is chloramphenicol 
resistant. It contains plasmids with genes encoding for rare codon tRNAs (argU, argW, 
glyT, ileX, leuW, metT, proL, thrT, thrU and tyrU) for the rare codons AGA and AGG 
(Arginine), GGA (Glycine), AUA (Isoleucine), CUA (Leucine), AUG (Methionine), CCC 
(Proline), ACA and ACC (Threonine) and UAC (Tyrosine), as well as reduced mRNA 
degradation. The DE3 lysogen encodes for the T7 polymerase, which is used to induce 
transcription and protein expression from the T7 promoter in E. coli.  
6.2.7 Plasmid propagation  
To obtain stock DNA, 1-1.5 µl sequenced DNA (≥50 ng/µl) was used to transform 50 µl of 
competent XL1-Blue E. coli, which were then plated on ampicillin-containing agar plates 
(100 µg/ml) and incubated overnight at 37ºC. 10 ml LB broth starter cultures supplemented 
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with 100 µg/ml ampicillin were inoculated with 1 colony from each plate and incubated 
overnight at 37ºC and 250 rpm on a shaking incubator. DNA was purified from the 
centrifuged cell pellet using a QiaPrep Spin Miniprep kit into 50.0 µl Elution buffer (EB), 
according to the manufacturer’s specifications (Qiagen, Crawley, UK). 
6.2.8 Agarose gel electrophoresis 
The correct size of amplicons was confirmed by agarose gel electrophoresis on 2% gels in 
1xTAE Buffer. PCR-amplified sequence bands corresponding to the correct size of insert  
were pooled together, and treated with DpnI endonuclease (recognition site 5’-Gm6ATC-
3’) to remove methylated/hemimethylated bases on the template DNA strand (as DNA 
isolated from most E.coli strains is dam methylated). PCR fragments were recovered with a 
QiaQuick PCR purification kit (Qiagen, Crawley, UK) in 50.0 µl EB buffer (10 mM Tris-
Cl, pH 8.5) according to the manufacturer’s specifications. Their concentration and purity 
were assessed at 260 nm and 280 nm.  
2% Agarose gels were prepared by dissolving 1.2 g of Agarose (Fisher Scientific, 
Loughborough, UK) in 60 ml 1x TAE buffer (40 mM Tris, 20 mM Acetic acid, 1 mM 
EDTA) diluted from 50x stock (2 M Tris-base, 0.5 M Disodium EDTA (pH 8.0), 1M 
acetic acid) and heating in a microwave until all solid had dissolved . Prior to pouring, 0.6 
µl SYBR Safe DNA staining dye (Life Technologies, CA, US) was added and the gel was 
allowed to solidify in its gel tank. 20-25 µl samples with 6x loading dye and 5 µl marker 
(0.4 µl of 1 kb PLUS Marker (Invitrogen, Paisley, UK) diluted into 4.0 µl 1xTAE buffer 
and 1.0 µl 6x loading dye) were loaded. Gels were run at 100V for 60 minutes.  
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6.2.9 DNA purifications 
Following transformation of XL1-Blue cells and plating on agar plates containing the 
appropriate antibiotic, one colony was used to inoculate 10 ml Luria-Bertani (LB) broth 
(Fisher Scientific, Loughborough, UK) supplemented with ampicillin. Cells were allowed 
to grow overnight at 37°C and 250 rpm on a shaking incubator for a maximum of 16 hours. 
Cells were then pelleted by centrifugation at 4,500 rpm for 10 minutes, and purified from 
silica membrane columns as per the manufacturer’s instructions using a QiaPrep spin 
Minipep kit (Qiagen, Crawley, UK). DNA was eluted in 50 µl EB buffer. Concentrations 
and purity were assessed using a Nanodrop 1000 (Thermo Scientific, DE, USA) at 260 nm 
and 280 nm.  
6.2.10 Validation of target sequence amplification by colony PCR 
To confirm that transformed XL1-Blue cells contained the gene of interest, and not empty 
vector plasmids, three colonies from each plate were used to inoculate 3 x 10 µl ddH2O, 
and colony PCR was performed on 1.0 µl template DNA from a diluted colony using 
Biotaq Red DNA polymerase (Bioline, London, UK) with 10 µM gene-specific forward 
and reverse primers. Amplified fragments were analysed on a 2% agarose gel 
electrophoresis at 100V for 35 minutes and visualized under UV light for correct size. 
Colony mixes with amplicons showing correct insert sizes were then used to inoculate 10 
ml Luria-Bertani (LB) broth starter cultures supplemented with 100 µg/ml ampicillin 
overnight at 37°C and 250 rpm for a maximum of 16 hours. The next day, cells were 
pelleted by centrifugation at 4,500 rpm on a bench-top centrifuge for 10 minutes at 25°C. 
Plasmid DNA was extracted and purified from the harvested pellet via alkaline lysis using 
a Qiaprep Spin Miniprep kit on a bench-top centrifuge (Qiagen, Crawley, UK), according 
to the manufacturer’s specifications and eluted into 50 µl EB buffer. Sample concentration 
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was assessed with a Nanodrop, before storing at -20°C for future use. To confirm that 
transformed cells contained the fusion gene of interest and not template DNA, 1.0 µg 
miniprepped DNA from each construct was digested with NdeI/XhoI, NcoI/XhoI or 
BamHI/XhoI, according to its amplified restriction sites, and analysed by agarose gel 
electrophoresis. Finally, 100 ng/µl purified DNA from each sample cloned into pET32-a 
was sequenced using 5 µM T7-minus1 primer corresponding to the T7 promoter. In the 
case of pGEX-6P-2-ligated inserts, a pGEX5’ universal forward primer was used (GATC 
Biotech, London, UK). Chromatogram files were analysed on Finch TV software (v.1.4.0, 
Geospiza Inc, US). 
6.2.11 Small scale purifications of C1.1-C4.1 by immobilized metal ion 
chromatography (IMAC) under native conditions 
Purified plasmids from XL1-Blue containing constructs of interest were used to transform 
the expression strain BL21(DE3)pRARE. Cells were plated on LB Miller agar plates 
(Fisher, Loughborough, UK) containing 34 µg/ml chloramphenicol and 100 µg/ml 
ampicillin and incubated overnight at 37°C. The next day, 10 ml LB Lennox broth (Fisher 
Scientific, Loughborough, UK) supplemented with Chl/Amp were aseptically inoculated 
with one colony from each plate and incubated at 37°C on a rotating shaker (250 rpm) for a 
maximum of 16 hours. To assess soluble protein expression on a 50 ml scale, 1 ml from 10 
ml starter cultures was used to inoculate 50 ml LB broth supplemented with Chl/Amp and 
incubated on a Innova 43 rotating shaker (New Brunswick Biosciences, CT, USA) at 37°C 
and 250 rpm to an O.D600 ~0.3, after which temperature was decreased to 18°C until 
O.D600~0.7. Protein production was induced with 0.5 mM IPTG at 18°C overnight. 
Cultures were pelleted by centrifugation at 4,500 rpm, re-suspended in 5 ml His-Binding 
buffer on ice and mechanically lysed by sonication for 5 minutes at 10 second intervals 
196 
 
followed by a 30 second rest period. 100 µl supernatant was collected as the ‘Total’ 
fraction (in 2x v/v 6 M Urea). Lysate was cleared by centrifugation at 13,000 rpm and 4°C, 
and His-tagged constructs were purified under native conditions by IMAC over a nickel-
nitrilotriacetic acid (Nickel-NTA) matrix. Proteins were then purified by gravity filtration 
through a 0.2 ml b.v of IMAC Sepharose 6 Fast Flow resin (GE Healthcare, Uppsala, 
Sweden) that had been primed with 5x column volumes (c.v) of 0.2 M NiSO4•6H2O and 
equilibrated with 5 ml His-Binding buffer at 4°C. The soluble fraction was collected 
(‘Flowthrough’). The resin was then washed with 5 ml His-Wash buffer and the 
flowthrough was collected as ‘Wash’. Finally, the proteins were eluted from the metal ion 
matrix with 2x 200 µl Elution buffer as ‘Eluates 1 and 2’.  Samples were analysed by the 
method of Laemmli (1970) on 12% running and 4% stacking 0.75 mm polyacrylamide gels 
at 160-200 V for 45 minutes using a Mini-Protean Tetra Cell (BioRad, Herfordshire, UK) 
and stained with 0.5% (v/v) Coomassie Blue and destained with 7% (v/v) acetic acid.  
6.2.12 Small scale purifications of GST-tagged proteins by affinity chromatography  
GST-tagged peptides from 50 ml bacterial cultures were purified over glutathione-
sepharose columns using a 0.4 ml b.v. of Glutathione Sepharose 4B (GS4B) resin (GE 
Healthcare, Uppsala, Sweden) pre-equilibrated with 5 ml GST-Binding buffer. The cell 
pellet was lysed by sonication (73mm probe, power 40%, 10 second cycles) and the lysate 
was cleared by centrifugation at 16,000 x g and 4°C. Cleared lysate was applied to the 
columns and collected as ‘Flowthrough’ by gravity flow. Columns were washed with 5 ml 
GST-binding buffer and the flowthrough was collected as ‘Wash’. Peptides were eluted 2x 
with 200 µl GST-elution buffer . All samples were analysed by SDS-PAGE as before. 
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6.2.13 Large scale purifications of GST-tagged C5.1, C6.1, C5.1-myc and C6.1-myc 
Glycerol stocks from BL21(DE3)pRare were used to inoculate 10 ml Chl+/Amp+ LB 
starter cultures overnight, which were then transferred to 1L LB broth in 3L Erlenmeyer 
flasks (Chl+/Amp+). Cultures were grown to an O.D600 ~ 0.3 at 37°C and then at 18°C until 
O.D600 ~ 0.7 before induction with 0.5 mM IPTG overnight on a rotating shaker at 18°C  
(180 rpm).  The next day, cultures were transferred to 800 ml rotor flasks and spun for 30 
minutes at 4,500 rpm. The supernatant was discarded, and the pellet was again spun in 50 
ml centrifuge tubes (Fisherbrand, Loughborough, UK) for 20 minutes at 4°C. Pellets were 
resuspended in a total volume of 25 ml GST-Binding buffer and sonicated for 10 minutes 
on ice (73 mm probe, power 40%, 10 second cycles). A 100 µl aliquot in 200 µl 6 M Urea 
was collected as the ‘Total’ fraction. Lysates were cleared in 80 ml round-bottom flasks by 
centrifugation at 24,000 x g at 4°C for 30 minutes.    
For a bed volume (b.v) of 4 ml, 5 ml Glutathione Sepharose 4B (GS4B) resin in 20 % (v/v) 
ethanol (GE Healthcare, Uppsala, Sweden) was centrifuged at 500 x g and resuspended in 
5x b.v GST-binding buffer and spun again. The resin was resuspended in 4 ml (1x b.v) 
GST-binding buffer and kept on ice.  
For batch-binding, cleared lysate was applied to the resin and incubated on a rotating mixer 
for at 2 hours at 4°C and centrifuged at 500 x g for 15 minutes or until the supernatant was 
clear. The supernatant was discarded, while the resin was resuspended in 40 ml GST-
binding buffer, and sequentially transferred as 10 ml aliquots to a 20 ml glass column and 
collected as ‘Flowthrough 1’. The column was then washed 1x with 40 ml GST-binding 
buffer (‘Wash 1’), and 3x with 10 ml, which were then pooled (‘Wash 2’). For on-column 
cleavage of the GST tag, Prescission protease in GST binding buffer was applied to the 
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resin at a 1:5 enzyme:protein ratio in a sealed column overnight on a rotating mixer at 4°C. 
The next day, the column was mounted and the flowthrough (‘Flowthrough 2’) was 
collected. Cleaved protein was eluted from the column sequentially with 4x 8 ml GST-
binding buffer (‘Eluate 1-4’). A final elution step with 10 ml GST-Elution buffer released 
cleaved GST, Prescission protease and any uncleaved protein. All samples were assessed 
for purity and concentration by Nanodrop, and analysed on either 12% or 15% 
polyacrylamide gels at 180V for 45 minutes. Samples containing the cleaved protein of 
interest were pooled together (FT2, E1-E4, or a combination of the above) and 
concentrated over an Amicon Ultra-15 Centrifugal Filter device (3K MWCO) (Millipore, 
MA, USA) and a fixed-angle rotor at 5,000 x g, according to the manufacturer’s 
specifications. Concentrations were assessed by Nanodrop and concentrated samples were 
buffer exchanged into either 10% (v/v) Glycerol/PBS or 1xPBS in 5 ml Zeba Desalt Spin 
columns (Thermo Scientific, DE, USA) and analysed by Nanodrop using the expected 
molecular weight (MW) and extinction coefficient (ε) and SDS-PAGE followed by 
Coomassie staining or Western blotting. Proteins were aliquoted into 1 ml and 200 µl 
stocks and stored at -80°C for future use. 
6.2.14  Denaturing cobalt IMAC purification of His-tagged proteins 
1L bacterial cultures for EB1-DRBMx2-His6 (C7.2) and DRBMx2-EB1-His6 (C8.2) and 
0.5L cultures for Tat-DRBMx2-His6 (C11.2), Pen-DRBMx2-His6 (C12.2) and DRBMx2-
His6 (C13.2) were grown at either 18°C or 37°C. C7.2 and C8.2 were grown for 8 hours, 
whereas C11.2-C13.2 for 4 hours on a shaking incubator. The following reagents were 
used on 0.5L cultures, and were doubled for 1L cultures. Cells were pelleted by 
centrifugation as before. For 0.5 L cultures, pellets were resuspended in 5 ml His-
resuspension buffer and quick-frozen at -80°C for 15 minutes. Cells were then thawed and 
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incubated with 1 Complete Mini Protease Inhibitor tablet (Roche, Manheim, Germany), 
1200 U benzonase, 30,000 U rLysozyme, 2 mM MgCl2 on ice for 30 minutes. 10 ml of 
1.1x binding buffer was added and cells were lysed by sonication for 7 minutes over ice 
(73 mm probe, power 40%, 20 second cycles, with 60 seconds rest). 35 ml chilled 1.1x 
binding buffer was subsequently added with 3 mM β-Mercaptoethanol for a final volume 
of 50 ml. Lysates were cleared by centrifugation at 16,000 x g for 40 minutes at 4°C.  The 
supernatant was filtered through a 0.45 µM Millex PVDF filter (Millipore, MA, USA) and 
protein was purified on nitriloacetic acid columns pre-charged with 0.1 M CoCl2 and pre-
equilibrated with 5 b.v of elution. Following elution, proteins were sequentially dialysed in 
a SnakeSkin Dialysis tubing (Thermo Scientific, DE, US) into 5 L refolding buffer and 
then into 5 L storage buffer. Dialysed protein was briefly centrifuged at 13,000 x g for 2 
minutes to remove any precipitated protein, aliquoted and stored at -80°C.  
6.2.15 Trichloroacetic Acid – Ethanol (TCA-EtOH) Protein Purification  
Samples from large-scale (0.5L) purifications under denaturing conditions were isolated in 
buffers containing 6-6.66 M Gu-HCl and 2 mM ß-mercaptoethanol. Gu-HCl, unlike Urea, 
is not soluble in SDS and cannot be resolved by SDS-PAGE. To remove guanidinium ions, 
25 µl samples were diluted to 100 µl in ddH2O and 100 µl 20% (v/v) TCA was added to 
samples on ice for 20 minutes. Samples were centrifuged at 13,000 rpm at 4ºC for 15 
minutes in a bench-top centrifuge and the supernatant was discarded. The protein pellet 
was washed with 100 µl ice-cold EtOH, air-dried for 30 minutes at room temperature and 
resuspended in 6x Laemmli sample buffer supplemented with 5% (w/v) SDS. A yellow 
color signified acidification by TCA and therefore samples were titrated with 1 N NaOH 
until the blue color was restored. Samples were then boiled at 95ºC on a heat block for 5 
minutes prior to analysis by SDS-PAGE. 
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6.2.16  Polyacrylamide Gel Electrophoresis, protein transfer and Western Blotting 
For all experiments, proteins were resolved using the method of Laemmli (1970). Briefly, 
10-40 µg protein were diluted into 6x loading Dye supplemented with 150 mM 
Dithiothreitol (DTT) and heated to 95°C for 3 minutes in a Biorad PCR block prior to 
loading (except in the case of whole cell lysate samples, which were destined for blotting 
with an anti-PTP1B antibody). Samples were then loaded on either a 12% or 15% 
polyacrylamide gels with 4% stacking gels with an EZ-Run Pre-stained marker (Fisher 
Scientific).  Gels were run for 60 minutes at 120-160V at 25°C (RT) in a BioRad Mini 
Electrophoresis tank in 1x gel running buffer (from 10x Stock; 250 mM Glycine pH 8.3, 
2.5 M Tris-Base, 1% (w/v) SDS, pH 8.3) and were either stained with 0.5% (w/v) 
Coomassie blue total protein stain, or transferred to a PVDF membrane for Western 
blotting.  
For electroblotting (protein transfer), the assembly cassette was setup in chilled 1x 
Transfer buffer  while the membrane was activated in 100% (v/v) methanol for 5 minutes 
at RT followed by a brief wash with ddH2O and a 5 minute incubation in 1x Transfer 
buffer.  Proteins were transferred overnight at 30V and 4°C in a Criterion Blotter tank 
(BioRad, Herts, UK). Once the proteins had transferred, the cassette was disassembled and 
the membranes were washed with ddH2O and blocked for 1 hour at 25°C in 5% (w/v) 
Milk/TBS (diluted to 10% (v/v) from 10x Stock TBS) with gentle shaking or 4% (v/v) 
BSA/TBS for 45 minutes at RT on a shaking platform, and incubated overnight at 4°C 
with primary antibody at a 1:1,000 dilution in 5% (w/v) Milk/TBS or 5% (v/v) BSA/TBS.  
The primary antibody was then removed, and the membrane was washed 2x with TBS 
buffer for 5 minutes each, before incubation with an HRP-conjugated secondary antibody 
in 5% (w/v) milk/TBS for 60 minutes at RT on a shaking platform. The secondary 
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antibody was then washed away with 3x-6x washes with TBST buffer (TBS buffer 
supplemented with 0.05% (v/v) Tween-20) for 5 minutes each. Finally, membranes were 
visualized by chemilluminescence using Labworks 4.1 software (Perkin-Elmer, 
Cambridge, UK) after a 3 minute incubation with 0.8 ml ECL reagent (SuperSignal West 
Femto Chemiluminescent Substrate, Thermo Scientific, DE, USA) prepared at a 1:1 (v/v) 
ratio of luminol:peroxidase. For PTP1B, an α-PTP1B IgG2a primary antibody from mouse 
(Cat. 610140, BD Biosciences, Oxford, UK) was used in 5% (w/v) milk/TBS at a 1:1,000 
dilution with an anti-mouse HRP conjugated IgG whole molecule peroxidase at a 1:5,000 
dilution (Cat. A4416, Sigma, Dorset, UK). For the myc-epitope tag, a mouse anti-myc 
antibody (Clone 4A6, Millipore, MA, USA) was used in 5% (w/v) Milk/TBS at a 1:1,000 
dilution. For the His6 tag, an α-His IgG1 antibody from mouse was used (Cat. 34660, 
Qiagen, Crawley, UK) at a 1:1,000 dilution in 5% (w/v) Milk/TBS and an anti-mouse 
HRP-conjugated (IgG whole molecule peroxidase) secondary antibody (Cat. A4416, 
Sigma, Dorset, UK), at a 1:1,500 dilution in 5% (w/v) Milk/TBS. For the actin loading 
control, an α-Actin affinity purified primary antibody from rabbit (Cat. 2066, Sigma, 
Dorset, UK) was used in 5% BSA-TBS and developed with an HRP-conjugated whole IgG 
peroxidase secondary antibody at a 1:10,000 dilution in 5% BSA-TBS.  Detection by 
chemilluminescence was done as before. 
6.2.17 Electromobility shift assay (EMSA) with C5.1, C12.2 and C13.2 
The potential of fusion proteins to bind dsRNA was assessed by electrophoretic mobility 
shift assay on a 6% Native PAGE gels (1.5 ml 40% (w/w) Bis-Acrylamide, 0.5 ml 10x 
Tris-Borate EDTA buffer, 7.89 ml ddH2O, 100.0 µl 10% (w/v) APS, 10 µl TEMED).  
Glassware was thoroughly cleaned with 70% (v/v) Ethanol followed by RNAse-free water. 
The gel was prepared, poured, and allowed to solidify for 3 hours at 4°C. For the protein-
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dsRNA coupling reaction in a 10 µl final volume, 10 pmol of 10 µM dsRNA (Stealth 
RNAi GFP reporter control, Life Technologies, CA, US) was diluted in complexation 
buffer (1xPBS for C5.1 and 25 mM HEPES (pH 7.4) for C12.2 and C13.2.  Various 
amounts of protein were added to the dsRNA mix at molar concentrations calculated from 
values obtained by the BCA assay. The final dsRNA concentration was therefore 1 µM. 
Protein-siRNA complex formation was allowed to proceed for 20 minutes on ice. 2µl 
sterilized 40% (w/v) sucrose was added. Gels were run at 4°C in 0.5x TBE buffer for 60-90 
minutes at 90V. Gels were then stained with 1% (w/v) EtBr for 10 minutes, washed in 
ddH2O for 5 minutes and visualized under UV light.  
6.2.18 Cell culture 
Human Embryonic Kidney (HEK) 293 (ATCC #CRL-1573) were a kind gift from 
Professor Tinker (QMUL, London, UK). Human hepatocellular carcinoma (HepG2) cells 
(ATCC # HB-8065) were obtained from the American Type Culture Collection (LGC 
Standards, Middlesex, UK). HEK293 cells were routinely grown in Dulbecco’s Modified 
Eagle Medium (DMEM) GlutaMax (Gibco, Paisley, UK), supplemented with 10% (w/v) 
fetal bovine serum (FBS) (Sigma, Dorset, UK).  For the generation of the HEK293 reporter 
cell line stably expressing dEGFP, HEK293 cells were cultured in DMEM-AQ media 
(4,500 mg/L glucose, L-alanyl-glutamine, and sodium bicarbonate) (D0819, Sigma, 
Dorset, UK) supplemented with 1 mM Sodium Pyruvate, 10% FBS and penicillin-
streptomycin at a final concentration of 100 U/ml and 100 µg/ml, respectively (1x) (P4333, 
Sigma, Dorset, UK) in a humidified atmosphere with 5% CO2, to 80% confluency. 
Selection was done with 0.4-2 mg/ml G418 (Sigma, Dorset, UK). Stably expressing 
HEK293-dEGFP clones were maintained with 1.8 mg/ml G418. HepG2 cells and grown in 
DMEM (1.5 mg/L glucose, Lonza, Slough, UK), supplemented with 10% (w/v) FBS and 
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2mM L-glutamine. For passaging, cells were seeded in 10 ml complete growth media 
(GM) in 75 cm3 Nunc plates (Nunc, NY, USA) with 100 U/ml penicillin and 100 µg/ml 
streptomycin (Sigma, Dorset, UK), incubated at 37ºC and 5% CO2 in a humidified 
atmosphere and passaged bi-weekly or when 80-90% confluence was reached.  For 
experimental purposes, only cells of passage ≤ 20 were used.  
For passaging, HEK293 cells were briefly trypsinised in 0.25x Trypsin/EDTA from 10x 
stock (Sigma, Dorset, UK) at room temperature, whereas HepG2 cells were trypsinised for 
5 minutes at 37°C. Trypsin was neutralised with 5 ml complete growth media. Cells were 
centrifuged at 1,000 rpm for 3 minutes and media was removed. The cell pellet was 
resuspended in fresh media and plated at a 1:10 dilution with antibiotics. 
6.2.19 Trypan Blue exclusion assay and hemocytometry 
For experimental purposes, it was important that only adherent (live) cells were seeded.  
The trypan blue dye exclusion assay is based on the premise that healthy cells, with an 
impervious cell membrane, cannot take up the dye. Live cells therefore remain unstained, 
and can be counted by hemocytometry in an improved Neubauer haemacytometer. Cells 
were trypsinised, pelleted for 3 minutes at 1000 rpm and resuspended into 10 ml complete 
growth media without antibiotics. 100 µl cell culture was diluted into 150 µl sterile DPBS 
and 250 µl Trypan Blue dye (Sigma, Dorset, UK), were added at RT for 5 minutes. 10 µl 
of the cell suspension in PBS/Trypan Blue were added to the chambers and counted under 
phase-contrast microscopy. The number of live cells/ml were established using the 
formula: 
 Average cell number x n x 104 = number of cells/ml 
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where n = dilution factor (5) and the average cell number is derived from the number of 
cells within each counting chamber square (4), and where 104 is the multiplication factor to 
convert the chamber depth (0.1 mm3) to cm3.  
 
6.2.20 Generation of a polyclonal HEK293 Reporter cell line 
A. Antibiotic Titration Curve  
HEK293 cells were seeded at a density of 3x104 cells/ml in a 6-well plate, in 2 ml 
complete growth media without antibiotics. 24 hours after seeding, cells in each well were 
forward-transfected with 2.5 µg pd1-EGFP-N1 vector DNA (Clontech, Saint-Germain-en-
Laye, France). Plasmid DNA was diluted in 250 µl Optimem with 2.5 µl PLUS reagent. 5 
µl Lipofectamine LTX (Life Technologies, Paisley, UK) were diluted in 250 µl Optimem. 
Plasmid DNA was then added to the Lipofectamine solution and Lipofectamine-DNA 
complexes were allowed to form at RT for 20 minutes according to the manufacturer’s 
recommendations. 16 hours post-transfection, media were replaced with 2 ml fresh media, 
supplemented with G418 to the following final concentrations; 0 mg/ml, 0.4 mg/ml, 0.8 
mg/ml, 1.2 mg/ml, 1.6 mg/ml and 2 mg/ml. Antibiotic-containing media were replaced 
every 24-48 hours for a period of 10 days, and cell viability was monitored daily under a 
microscope. To establish a titration curve, media were transferred to a 15 ml centrifugation 
tube. Adherent cells were washed 1x with 1 ml Dulbecco’s Phosphate buffered saline 
(DPBS) (D8537, Sigma, Dorset, UK), trypsinised with 1 ml of 0.25x Trypsin-EDTA 
(T4174, Sigma, Dorset, UK), neutralised with 1 ml complete growth medium and 
centrifuged at 1,000 rpm for 3 minutes in a bench-top centrifuge. Live cells were then 
counted by hemocytometry and counts were standardized to the G418-untreated control. 
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B. Generation of stable HEK293-dEGFP cells 
For the generation of the pd1EGFP-N1- expressing HEK293 cell line, cells were seeded at 
a density of 3x104 cells/ml in a 6-well plate and transfected with 2.5 µg pd1EGFP-N1 
DNA by Lipofectamine LTX (Invitrogen, Paisley, UK). The next day, G418 was added at 
a final concentration of 1 mg/ml, and replaced with fresh complete growth media every 48 
hours for 12 days until cells became ∼80% confluent. Cell viability was monitored daily by 
phase-contrast microscopy. Once confluent, cells were trypsinised and seeded in a T75 
Nunc plate in 10 ml complete growth medium supplemented with 1 mg/ml G418 from 50 
mg/ml stock solution prepared in DPBS.  HEK293-dEGFP cells in a T75 Nunc plate were 
prepared for FACS by removing media, washing 1x with 5 ml DPBS, trypsinised with 4 ml 
0.25x Trypsin-EDTA at room temperature for 2 minutes, followed by trypsin neutralisation 
with 4 ml complete growth media. Cells were then transferred to a 15 ml Eppendorf tube 
and centrifuged for 3 minutes at 1,000 rpm at room temperature. Media were removed 
without disturbing the cell pellet, and cells were resuspended in 10 ml FACS Analysis 
buffer (1% (v/v) FBS/DPBS supplemented with 2 mM EDTA). Live cells were counted by 
hemocytometry following the Trypan Blue Exclusion assay and diluted in FACS cell 
buffer to a final density of 1x106 cells/ml into 2ml aliquots. Cells were kept on ice 
throughout. For fluorescence-activated cell sorting, confluent cells were washed 1x with 
PBS, trypsinised and viable cells were counted. 1x107 cells were resuspended in 10 ml 1% 
(v/v) FBS/PBS to encourage monodispersion and kept on ice. 3x105 untransfected cells in 
1% (v/v) FBS/PBS were used as controls to ‘normalize’ auto-fluorescence levels. Cells 
were filtered through a 0.7 m filter, resuspended thoroughly by pipetting and analysed for 
fluorescence (dEGFP expression) on a MoFlo XDP Cell Sorter (Dako, Cambridgeshire 
UK) and viewed as histograms with Summit software (Beckman Coulter, High Wycombe, 
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UK) at the Wolfson Institute for Biomedical Research (UCL, London) at a rate of 1,300 
events/sec into either medium or highly expressing populations. 1x105 cells from each 
population were collected into tubes containing 3 ml 100% FBS supplemented with 100 
g/ml penicillin/streptomycin on ice, and replated into 75 cm3 Nunc plates in complete 
growth media supplemented with the appropriate G418 concentration as a maintenance 
dose and 100 g/ml Penicillin/Streptomycin. 
6.2.21 Cell viability assay 
The MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used 
in order to assess potential cytotoxicity elicited on HEK293 and HepG2 by protein 
treatments at various concentrations for 24 hours. 5x103 HEK293 cells were seeded in a 
96-well plate in 100 µl complete growth media without antibiotics and incubated at 37ºC 
and 5% CO2 in a humidified atmosphere 16 hours before treatment.  C11.2-C13.2 and C5.1 
were thawed on ice and forward-transfect cells at a final molar concentration of 0.1, 0.3, 1 
and 3.3 µM in triplicate, in 100 µl Optimem (Gibco, Paisley, UK). Optimem was used as a 
mock control. All treatments were done in triplicate (n=3). For HepG2 cells, complexes 
were prepared within wells at final siRNA concentrations of 0.3, 1 and 3.3 µM in triplicate, 
and overlaid with 7.5x103 cells in Optimem for 5 hours, at a final volume of 100 µl. Media 
were then aspirated and replaced with complete growth media supplemented with 
penicillin-streptomycin for 24 hours at 37ºC and 5% CO2 in a humidified atmosphere. 
Results for HepG2 cells represent 3 independent experiments done in triplicate with 
biological replicates (n=9). MTT (M5655, Sigma Dorset, UK) was dissolved in DPBS at a 
concentration of 5 mg/ml and 10 µl were added to the cells in Optimem, to a final 
concentration of 0.45 mg/ml for 60 minutes at 37ºC in a light-sealed environment. Media 
was carefully aspirated and 100 µl dimethyl sulfoxide (DMSO) (Sigma, Dorset, UK) were 
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added to dissolve the formazan crystals. Cell viability was assessed at A570 in a Versamax 
microplate spectrophotometer (Molecular Devices, Oslo, Norway) and A640 to adjust for 
background fluorescence. Data acquisition was done using the SoftMax Pro Data 
Acquisition and Analysis software. For analysis, A640 values were subtracted from A570 
values and values were normalized against the average, normalized mock-treated controls 
and mean cell viability was expressed as a % of mock-treated control. SD± was calculated 
based on each sample’s deviation from the mean. Statistical analysis was done by two-way 
Anova followed by post-hoc analysis with Dunnett’s 2-sided test (SPSS, IBM UK).  
6.2.22 Protein-siRNA complex formation 
For GFP knockdown assays in the HEK reporter line, Stealth GFP RNAi Reporter control 
siRNA (Cat. # 12935-145, Ambion, Life Technologies, CA, US) in 1x RNA Annealing 
buffer (10 mM Tris-HCl, 20mM NaCl, 1 mM EDTA, pH 8) was used. For 100 nM final 
concentration, 60 pmoles were diluted into 50 µl Optimem. For 10 nM final concentration, 
6 pmoles were diluted as before.  Previous studies have shown that 98% encapsulation of 
siRNA can be achieved with a molar excess of CPP at a ratio of 50:1 (Von Asbeck et al,  
2013). CPPs were thus diluted at the appropriate molar concentration in 50 µl Optimem 
(Life Technologies, Paisley, UK) on ice. Complex formation was allowed to proceed for 
30 minutes on ice once the protein had been added to the siRNA.  
6.2.23 Transient knockdown assays in a HEK293 reporter cell line 
For knockdown assays, highly expressing HEK293-dEGFP cells (6x104 cells/well) were 
seeded in a 24-well plate in a final volume of 1 ml complete growth media supplemented 
with 1.8 mg/ml G418 only. HEK293 cells were also seeded to correct for auto-
fluorescence during analysis (in triplicate). At 80% confluency, protein-siRNA complexes 
with various proteins and Stealth GFP RNAi Reporter control siRNA were prepared as 
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described previously. Cells were briefly incubated in 500 µl Optimem (Life Technologies, 
Paisley, UK) and 100 µl of protein-siRNA complexes at a 50:1 molar ratio were directly 
added to the cells, to a final volume of 600 µl and siRNA concentration of 10 nM or 100 
nM. All treatments were done in triplicate (n=3).  Complexes were incubated with the cells 
for 5 hours at 37°C and 5% CO2 in a humidified atmosphere in Optimem (Life 
Technologies, Paisley, UK). Then, media were gently aspirated and replaced with 
complete growth media supplemented with 1.8 mg/ml G418, 50 mM chloroquine (Sigma, 
Dorset, UK) and 1x penicillin/streptomycin for 24 or 48 hours. Lipofectamine-transfected 
siRNA was used as a positive control. Scrambled siRNA (Stealth RNAi siRNA Negative 
control (LoGC) (Cat. #12935-200), Ambion, Life Technologies, Paisley, UK) and siRNA 
only treatments were used as a negative control. Following knockdown, plates were 
centrifuged at 1,000 rpm for 3 minutes at 4°C. Media were aspirated to minimize cell loss 
and cells prepared for flow cytometry analysis.   
6.2.24 Analysis of dEGFP knockdown by flow cytometry 
Following dEGFP knockdown, HEK293-dEGFP cells were gently resuspended by 
pipetting and transferred to pre-chilled sterile 1.5 ml Eppendorf tubes. They were then 
centrifuged at 1000 rpm for 3 minutes at RT and the supernatant was discarded. The cell 
pellet was resuspended in chilled 1 ml FACS sample buffer (1% (v/v) FBS/DPBS, 2 mM 
EDTA), transferred to flow cytometry tubes and kept on ice. 1 mg/ml of propidium iodide 
(PI) were added to cells as a live/dead counterstain and analysed by flow cytometry on a 
Dako Cyan ADP cytometer. 
6.2.25 PTP1B knockdown assays in HepG2 cells. 
In order to optimise the minimum amount of cells needed for PTP1B detection by 
immunoblotting, a titration was done with varying cell numbers followed by the BCA 
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assay on whole cell lysates. In short, either 5x106, 2.5x106, 5x105, 2.5x105 and 5x104 cells 
were seeded in either a T75 Nunc flask, a T25 Nunc flask or a 6-well plate in complete 
growth media and allowed to adhere overnight. The next day, media were removed, and 
cells were washed 1x with DPBS before treatment with each of 2 ml, 1 ml or 0.25 ml Lysis 
buffer, respectively. The total amount of protein present in the sample was determined by 
the BCA assay, and 10 µg protein were analysed by WB with an α-Actin primary antibody 
at a 1:200 dilution in 5% non-fat dry Milk-TBS and an anti-rabbit HRP conjugated 
secondary antibody and visualized by chemilluminescence. 
Then, in order to optimise PTP1B transfection efficiency by Lipofectamine RNAiMax, two 
siRNA duplexes corresponding to different regions of the PTPN1 gene (VHS41290- 5’-
CCAUAGUCGGAUUAAACUACAU-3’ and VHS41291- 5’-GGAAAGACCCUUCU- 
UCCGUUGAUAU-3’) were assessed. 6, 15 or 30 pmol were complexes with 5 µl 
Lipofectamine RNAiMAX in 500 µl Optimem (Life Technologies, Paisley, UK). Cells 
were reverse-transfected inside wells by allowing complex formation inside wells and 
overlaying with 2.5x105 HepG2 cells/well in 2 ml Optimem (Life Technologies, Paisley, 
UK) to yield final concentrations of siRNA of 10 nM, 25 nM and 50 nM, respectively. 
Cells were transfected for 4 hours to allow adherence at 37°C and 5% CO2 in a humidified 
atmosphere. Adherence was monitored hourly by phase-contrast microscopy. Once 
adherence reached ~ 100%, media were removed and replaced with complete growth 
media and antibiotics. The cells were incubated for 72 hours at 37°C to allow efficient time 
for protein expression knockdown. Then, whole cell lysates were prepared and knockdown 
was analysed by western blotting 15 µg crude protein with an anti-PTP1B antibody at a 
1:1,000 dilution in 5% (w/v) Milk/TBS and a secondary HRP-conjugated anti-mouse 
secondary antibody at a 1:10,000 dilution in 5% (w/v) Milk-TBS.  
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6.2.26 Whole cell lysate preparation 
Whole cell lysates were prepared in Lysis buffer (150mM NaCl, 20mM Tris-HCl pH 7.5, 
1mM EGTA, 1% Triton-X, 1% Nonidet-P40 (Igepal) supplemented with Protease 
Inhibitors at a 1:1,000 dilution, 100 mM NaF, 10 mM Na4P2O7 (sodium pyrophosphate 
tetrabasic) and 2 mM Na3VO4 (sodium orthovanadate)). First, plates were centrifuged at 
4ºC and 1,000 rpm for 3 minutes, and media were carefully removed. Cells were lysed 
with 250 µl chilled lysis buffer for 15 minutes at RT. Lysed cells were then carefully 
scraped and transferred to chilled 1.5 ml eppendorf tubes and centrifuged at 13,000 rpm at 
4ºC for 15 minutes. The supernatant was transferred to clean, chilled 1.5 ml eppendorf 
tubes and stored at -80ºC for future use.  
6.2.27 Localisation studies in fixed HepG2 and HEK293 cells 
Confluent (∼80%) HEK293 and HepG2 cells were trypsinised, counted by the Trypan Blue 
exclusion test on a haemocytometer and seeded at a density of 6x105 cells in 2ml 10% 
(v/v) FBS/DMEM supplemented with 2 mM L-Glutamine on uncoated glass coverslips in 
6-well plates. Cells were allowed to adhere overnight in a humidified atmosphere and 5% 
CO2 until confluency was reached (∼60-80%; approximately 18 hours). Media were 
replaced following a wash with 2ml filter-sterilized 1xPBS (Ca2+/Mg2+). Cells were treated 
with either a low (0.1µM), medium (1 µM) or high (10 µM) dosage of C5.1-myc (from 
290 µM stock in 1xPBS) in 500 µl PBS or Optimem for 2 or 24 hours at 37°C in a 
humidified atmosphere and 5% CO2. 500µl sterile Dulbecco’s PBS (Ca2+/Mg2+-free) was 
also used as a control.  
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Protein concentration was measured by Nanodrop at A280 using 1xPBS as a blank. Protein 
concentrations and MW were used with following conversion formula to calculate its 
molar concentration: 
Molar concentration of protein (mmol/L)  
= Concentration at A280 (mg/ml) x MW (mMol/mg) x Volume (1,000ml/L) 
∴
 [(mg/ml) / MW (Da)] x 1,000 
 
C5.1-myc to be used for either 10 µM, 1 µM or 0.1 µM final molarities were calculated 
using the following dilution formula: 
 Ci (µM) x Vi (µl) = Cf (µM) x Vf (µl) 
Cell viability and confluence were assessed by phase-contrast microscopy prior to 
treatment whilst the protein was thawed on ice. Cells were incubated in a humidified 
atmosphere and 5% CO2 for either 2 or 24 hours. Following treatment, cells were 
aspirated, gently washed with 2 ml filter-sterilized 1xPBS (Ca2+/Mg2+). Cells were fixed 
and permeabilized with fresh filter-sterilized 0.2% (v/v) Triton-X / 4% (v/v) 
paraformaldehyde (from 36% (v/v) formalin stock, in 1xPBS (Ca2+/Mg2)) for 15 minutes at 
25°C. Cells were then gently washed again 3x with 2.5 ml/well filter-sterilized PBS and 
coverslips (VWR, Leicestershire, UK) were transferred to a 12-well plate to minimize 
antibody volumes. Fixed cells were then blocked with 300µl 10% (v/v) goat serum/PBS 
(from 10x stock) supplemented with 1.5µl RNase A and incubated with an anti-myc tag 
antibody (Clone 4A6, Millipore, MA, USA) in 10% (v/v) goat serum/PBS at a 1:1,000 
dilution for 1.5 hours at 25°C. Cells were then washed 3x with 300 µl 1xPBS (Ca2+/Mg2+) 
for 15 minutes each and incubated with a secondary anti-mouse FITC-labeled antibody 
(Sigma, Dorset, UK) at 1:500 dilution in 300 µl 10% (v/v) goat serum/PBS for another 
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hour. Nuclei were stained with 300 µl ToPro3 (Life Technologies, Paisley, UK) in 
Dulbecco’s PBS at a 1:750 dilution, for 30 minutes at 25°C in a light-sealed container.  
Coverslips were mounted on glass slides using Vectashield H1000 and visualized with a 
Leica TCS-SP2 spectral confocal microscope and Leica LCS imaging software (described 
in Section 6.2.30). 
6.2.28 Localisation studies in live HepG2 cells 
HepG2 cells were seeded in a 6-well plate at a density of 2.5x105 cells/well in 2.5ml 
complete growth media without antibiotics, 16 hours before transfection with protein-
siRNA complexes. Protein-siRNA-FITC (Block-iT fluorescent oligo, Life Technologies, 
Paisley, UK) complexes were allowed to form at 4°C at 50:1 molar ratios and applied to 
cells in Optimem for 60 minutes at 37°C at a final volume of 2.5 ml. Complexes were 
removed and replaced with fresh complete growth media without antibiotics. Wheat germ 
agglutinin-dsRed (WGA-dsRed) was added at a final concentration of 1 mg/ml for 10 or 30 
minutes at RT. Media were removed and cells were gently washed 2x with PBS. 
Visualisation in 2.5ml PBS was done by confocal microscopy with a Leica SP2 laser 
scanning microscope. 
6.2.29 Confocal microscopy 
Fixed cells were mounted on slides and visualized on a Leica SP2 DM-RXE confocal 
microscope under a 63x oil immersion lens, whereas live cells were analysed in 1x PBS. 
Images were taken using the proprietary Leica confocal software (Leica Microsystems, 
Heidelberg, Germany). To-Pro3 nuclear staining was acquired with Ar/HeNe lasers at an 
excitation wavelength (Exmax) of 633nM and an emission wavelength (Emmax) of 650-720 
nm. FITC was detected at 488 nM (Exmax = 490 nm, Emmax = 525 nm). WGA-dsRed 
213 
 
(Exmax = 557 nm and Emmax= 572 nm) was detected at 563 nM. Laser intensities were 35-
60%. To minimize noise-to-signal ratios, the pinhole diameter was set to 1 Airy unit and 
the speed of image lines/second when taking horizontal xy-sections in scan mode was set 







I.1 Bioinformatic analysis on constructs C1.1-C6.1  





























116 13.4 9.8 15.5 
                                                 
3
 Continued overleaf 
 Amino acid sequences of constructs C1.1-C6.13. ε, extinction coefficient at 280 nm measured in water. Important sequences are Table I.1
highlighted; AntpHD, green; Penetratin, yellow; DRBM1, light blue; histidine tags, dark grey (His10 or His6); GST tag, light grey; Factor Xα 
cleavage site, red (C1.1, C2.1); TEV protease cleavage site, purple (C3.1, C4.1); Prescission protease cleavage site, dark purple (C5.1, C6.1). 


























I.2 Bioinformatic analysis on myc-tagged constructs 





























344 39.8 8.6 57.1 
 
                                                 
4
 Continued overleaf 
 Amino acid sequences for constructs C5.1-myc and C6.1-myc4. Important sequences are highlighted as in Table I.1. The myc Table I.2














150 17.4 10.7 18.45 
C6.1 Pen-DRBM1 GPLGSRQIKIWFQTRRMKWKKENGGGGSGGGGSFFMEELNTYRQKQGVVLKYQELP
NSGPPHDRRFTFQVIIDGREFPEGEGRSKKEAKNAAAKLAVEILKEKKGVS- 










118 13.3 9.9 14 
 Amino acid sequences of GST-tagged constructs following  purification and tag cleavage by Prescission protease. Important Table I.3















































438 49.8 8.8 70.2 
 Amino acid sequences of concstructs C7-C10.2. Important features are highlighted as in Table I.1. Amino acid sequences for Table I.4
constructs C7.2-C10.2. These are comprised of the Penetratin analogue EB1 fused to the DRBMx2, or the inverted sequence, DRBMx2-
EB1. A His6 tag (dark grey) was conferred by cloning into a modified pET32-a vector, and a GST tag (light grey), from the pGEX-6P-2 
vector. EB1 is highlighted in yellow; DRBMx2 is shown in light blue. ε, extinction coefficient  
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I.3 Bioinformatic analysis on constructs C11.2- C13.  
 

























184 20.4 9.1 10.6 
 Amino acid sequences for constructs C11.2-C13.2. These are comprised of Tat-DRBMx2, Penetratin-DRBMx2 or DRBMx2 Table I.5
only, respectively. A His6 tag (dark grey) was conferred by cloning into a pET11-d vector. Important features are highlighted; Tat, dark blue; 
Penetratin, yellow; DRBMx2, light blue. 
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I.4 Figure 2.19, Enlarged 
   
   






 Plasmid Vector Maps II.1
Figure II.1.1 Restriction map and multiple cloning site (MCS) of the pBSK-50518 
plasmid vector.  
 
The AntpHD-DRBM1 synthetic gene (GS50518) was cloned into the EcoRV-digested 




Figure II.1.2 Restriction map and multiple cloning site (MCS) of the pGEX-6P-2 
plasmid vector 
 
Inserts cloned into pGEX-6P-2 downstream of the glutathione-S-transferase (GST) tag 
were purified by affinity chromatography. A Prescission protease cleavage site allows for 




Figure II.1.3 Restriction map and multiple cloning site (MCS) of modified pET32-a 
plasmid vector.  
 
 
The vector lacks part of its MCS (highlighted in pink) by restriction digestion with 
XbaI/NcoI. Unique restriction sites are in bold. Inserts cloned into the pET32-a vector 
plasmid were conferred with an  N-terminus His10 (primer-inserted) or a C-terminus His6 








Unique restriction sites are in bold. The Not I site follows the d1EGFP stop codon. The 
Xba I site is methylated in the DNA provided by BD Biosciences Clontech. This plasmid 
was used to generate the dEGFP expressing HEK293-dEGFP reporter cell line. 
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 Statistical Analysis of MTT assays in HEK293 and HepG2 cells by II.2
2-way Anova (SPSS). 
 MTT assay in HEK293 cells (n=3). P-value limits were set at ≤0.05. II.2.1
Source Type III Sum 
of Squares 
df Mean  
Square 
F Significance Partial R 
Squared 
Corrected Model 11.747 19 .618 2.094 .024 .499 
Intercept 236.013 1 236.013 799.476 .000 .952 
Protein Level 3.085 4 .771 2.612 .050 .207 
Concentration Level 5.327 3 1.776 6.015 .002 .311 
Protein-Concentration 
combined 3.335 12 .278 .941 .517 .220 
Error 11.808 40 .295    
Total 259.568 60     
Corrected Total 23.555 59     
 
R Squared = 0 .499 (Adjusted R2 = 0.261) 
Table II.2.1.1 Tests of Between-Subjects Effects. Important entries are in bold. 
228 
 








Significance.b 95% Confidence Interval for 
Differenceb 




.30 .079 .279 .778 -.484 .642 
1.00 .237 .279 .401 -.327 .800 
3.30 .432 .279 .128 -.131 .996 
.30 
.10 -.079 .279 .778 -.642 .484 
1.00 .157 .279 .575 -.406 .720 
3.30 .353 .279 .212 -.210 .916 
1.00 
.10 -.237 .279 .401 -.800 .327 
.30 -.157 .279 .575 -.720 .406 
3.30 .196 .279 .486 -.367 .759 
 3.30 
.10 -.432 .279 .128 -.996 .131 
.30 -.353 .279 .212 -.916 .210 
1.00 -.196 .279 .486 -.759 .367 
C13.2 
.10 
.30 .033 .279 .906 -.530 .596 
1.00 .146 .279 .602 -.417 .709 
3.30 .701* .279 .016* .138 1.264 
.30 
.10 -.033 .279 .906 -.596 .530 
1.00 .113 .279 .687 -.450 .676 
3.30 .668* .279 .021* .105 1.231 
 1.00 
.10 -.146 .279 .602 -.709 .417 
.30 -.113 .279 .687 -.676 .450 
3.30 .555 .279 .053 -.008 1.118 
                                                 
5
 Continued overleaf  
Table II.2.1.2 Pairwise comparisons between proteins by 2-way Anova. After mean viability at each concentration is normalised against the 




.10 -.701* .279 .016* -1.264 -.138 
.30 -.668* .279 .021* -1.231 -.105 
1.00 -.555 .279 .053 -1.118 .008 
Mock control 
.10 
.30 .000 .279 1.000 -.563 .563 
1.00 1.110E-016 .279 1.000 -.563 .563 
3.30 1.110E-016 .279 1.000 -.563 .563 
.30 
.10 .000 .279 1.000 -.563 .563 
1.00 1.110E-016 .279 1.000 -.563 .563 
3.30 1.110E-016 .279 1.000 -.563 .563 
1.00 
.10 -1.110E-016 .279 1.000 -.563 .563 
.30 -1.110E-016 .279 1.000 -.563 .563 
3.30 .000 .279 1.000 -.563 .563 
3.30 
.10 -1.110E-016 .279 1.000 -.563 .563 
.30 -1.110E-016 .279 1.000 -.563 .563 
1.00 .000 .279 1.000 -.563 .563 
C12.2 
.10 
.30 -.267 .279 .344 -.830 .296 
1.00 -.168 .279 .550 -.731 .395 
3.30 .098 .279 .726 -.465 .661 
.30 
.10 .267 .279 .344 -.296 .830 
1.00 .099 .279 .725 -.464 .662 
3.30 .365 .279 .198 -.198 .928 
1.00 
.10 .168 .279 .550 -.395 .731 
.30 -.099 .279 .725 -.662 .464 
3.30 .266 .279 .345 -.297 .829 
 3.30 
.10 -.098 .279 .726 -.661 .465 
.30 -.365 .279 .198 -.928 .198 
1.00 -.266 .279 .345 -.829 .297 
C11.2 .10 
.30 -.001 .279 .996 -.565 .562 
1.00 .275 .279 .330 -.288 .838 




.10 .001 .279 .996 -.562 .565 
1.00 .276 .279 .328 -.287 .839 
3.30 .970* .279 .001* .407 1.533 
1.00 
.10 -.275 .279 .330 -.838 .288 
.30 -.276 .279 .328 -.839 .287 
3.30 .694* .279 .017* .131 1.257 
3.30 
.10 -.969* .279 .001* -1.532 -.406 
.30 -.970* .279 .001* -1.533 -.407 
1.00 -.694* .279 .017* -1.257 -.131 
 
Based on estimated marginal means. 
*. The mean difference is significant at the .05 level.  


















.10 3.30 .44019* .124595 .003 .13600 .74439 
.30 3.30 .47134* .124595 .001 .16715 .77554 
1.00 3.30 .34227* .124595 .024 .03807 .64646 
 
Based on observed means. 
 The error term is Mean Square (Error) = .116. 
*. The mean difference is significant at the .05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
 MTT assay in HepG2 cells (n=9) II.2.2





F Significance Partial R 
Squared 
Corrected Model .158a 14 .011 .657 .811 .071 
Intercept 6.338 1 6.338 368.519 .000 .754 
Protein Level .117 4 .029 1.704 .153 .054 
Concentration Level .001 2 .000 .020 .980 .000 
Protein Level * 
Concentration Level .040 8 .005 .293 .967 .019 
Error 2.064 120 .017    
Total 8.560 135     
Corrected Total 2.222 134     
a. R Squared = .071 (Adjusted R Squared = -.037) 
Table II.2.1.3 Dunett’s post-hoc test based on observed means following MTT assays 
in HEK293 cells. This test compares each concentration against the highest concentration 
tested, regardless of which protein is being tested to indicate dose-dependent effects. 
Significance values are highlighted. 




Protein Concentration Level 1 
Concentration  
Level 2 




95% Confidence Interval for 
Differencea 
 Lower Bound Upper Bound 
C12.2 .33 1.00 -.022 .062 .728 -.144 .101 
3.33 .013 .062 .840 -.110 .135 
1.00 .33 .022 .062 .728 -.101 .144 
3.33 .034 .062 .582 -.088 .157 
3.33 .33 -.013 .062 .840 -.135 .110 
1.00 -.034 .062 .582 -.157 .088 
C11.2 .33 1.00 -.019 .062 .763 -.141 .104 
3.33 .025 .062 .681 -.097 .148 
1.00 .33 .019 .062 .763 -.104 .141 
3.33 .044 .062 .476 -.078 .167 
3.33 .33 -.025 .062 .681 -.148 .097 
1.00 -.044 .062 .476 -.167 .078 
C5.1 
.33 1.00 .048 .062 .437 -.074 .171 3.33 -.019 .062 .761 -.141 .104 
1.00 .33 -.048 .062 .437 -.171 .074 3.33 -.067 .062 .280 -.189 .055 
3.33 .33 1.00 
.019 
.067 
.062 .761 -.104 .141 
.062 .280 -.055 .189 
C13.2 .33 1.00 -.002 .062 .974 -.124 .120 
                                                 
6
 Continued overleaf 
Table II.2.1.5 Pairwise comparisons between proteins by 2-way Anova. After mean viability at each concentration is normalised against the 
mean mock-treated value, Anova was used to compare each concentration for each protein with the rest6. 
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3.33 -.012 .062 .849 -.134 .111 
1.00 .33 .002 .062 .974 -.120 .124 3.33 -.010 .062 .875 -.132 .113 
3.33 .33 .012 .062 .849 -.111 .134 1.00 .010 .062 .875 -.113 .132 
Mock control 
.33 1.00 .003 .062 .961 -.119 .125 3.33 -.026 .062 .677 -.148 .097 
1.00 .33 -.003 .062 .961 -.125 .119 3.33 -.029 .062 .641 -.151 .094 
3.33 .33 .026 .062 .677 -.097 .148 1.00 .029 .062 .641 -.094 .151 
 
Based on estimated marginal means 





Table II.2.1.6 Dunett’s post-hoc analysis for each protein against C11.2 to indicate 
protein-specific effects in HepG2 cells . This test compares each protein against C11.2, 
regardless of which protein concentration is being tested. Significance values are 
highlighted. 
(I) Drug_type (J) Drug_type Mean 
Difference (I-
J) 





C5.1 C11.2 .02247 .035693 .923 -.06586 .11080 
C13.2 C11.2 .05210 .035693 .396 -.03623 .14043 
Mock control C11.2 .02810 .035693 .847 -.06023 .11643 
C12.2 C11.2 .08659 .035693 .050 -.00174 .17492 
 
Table II.2.1.7 Dunett’s post-hoc test based for each concentration against the highest 
concentration used to indicate dose-dependent effects in HepG2 cells. This test compares 
each concentration against the highest concentration tested, regardless of which protein is 
















.33 3.33 -.00368 .027647 .987 -.06557 .05820 
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